CA2812132C - Natural igm antibodies and inhibitors thereof - Google Patents

Abstract

The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases of disorders.

Description

CA 02812132 2013-10-11 =

Natural IgM Antibodies and Inhibitors Thereof This application is a division of application 2,560,066 filed March 1, 2005.
1. Government support This invention was made with government support under grant No. GM52585, GM2489I, and 0M07560 from the National Institutes of Health. The government has certain rights in the invention. =

2. Cross-reference to related applications This application claims the benefit of U.S. Provisional Application No.
60/588,648, filed on July 16, 2004 and U.S. Provisional Application No. 60/549,123 filed on March 1, 2004.

- 3. Background of the Invention Nucleated cells are highly sensitive to hypoxia and even short periods of ischemia in multi-cellular organisms can have dramatic effects on cellular morphology, gene .
transcription, and enzymatic processes. Mitochondria, as the major site of oxygen metabolism, are particularly sensitive to changes in oxygen levels and during hypoxia release reactive oxygen species that chemically modify intracellular constituents such as lipids and proteins. Clinically these effects manifest as an inflammatory response in the patient. Despite intensive investigations of cellular responses to hypoxia little is known regarding the initiation of acute inflammation.
Acute inflammatory responses can result from a wide range of diseases and naturally occurring events such as stroke and myocardial infarction. Common medical procedures can also lead to localized and systemic inflammation. Left untreated inflammation can result in Significant tissue loss and may ultimately lead to multi-system failure and death. Interfering with the inflammatory response after injury may be one method to reduce tissue loss.
Inflammatory diseases and acute inflammatory responses resulting from tissue injury, however, cannot be explained by cellular events alone. Accumulating evidence .supports a major role for the serum innate response or complement system in inflammation.
Studies to date have looked at tissue injury resulting from ischemia and reperfusion as one type of inflammatory disorder that is complement dependent. For example, in the rat =

= 60412-4434D1 myocardial model of reperfusion injury, pretreatment of the rats with the soluble form of the complement type 1 receptor dramatically reduced injury. Understanding how complement activation contributes to an inflammatory response is an area of active investigation.
Inflammatory diseases or disorders are potentially life-threatening, costly, and affect a large number of people every year. Thus, effective treatments of inflammatory diseases or disorders are needed.

4. Summary of the Invention In one aspect, the invention features isolated natural immunoglobulins (IgMs).
In one embodiment, the antibody is produced by ATCC Accession Number PTA-3507. In another embodiment, the antibody has a light chain variable region comprising the amino acid sequence shown as SEQ ID NO: 8. In yet another embodiment, the antibody has a heavy chain variable region comprising the amino acid sequence shown as SEQ ID NO: 2.
In another aspect, the invention features IgM inhibitors and pharmaceutical preparations thereof. In one embodiment, the IgM inhibitor is a peptide that specifically binds to a natural IgM and thereby blocks binding to the antigen and/or complement activation. In one embodiment, the peptide includes the following consensus sequence:
xNNNxNNxNNNN (SEQ
ID NO: 14). Certain inhibitory peptides are provided as SEQ ID NOs: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, and 38. Inhibitory peptides may be modified, for example to increase in vivo half-life or bioavailability. Inhibitory peptides may also be labeled to facilitate detection.
In another aspect, the invention features nucleic acids encoding peptides that specifically bind to natural IgM antibodies, as well as vectors and host cells for expressing the peptides. Certain nucleic acids are provided as SEQ NOs: 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35 and 37.
In a further aspect, the invention features methods of treating an inflammatory disease in a subject by administering to the subject a pharmaceutical composition comprising an IgM inhibitor as disclosed herein.
In yet other aspects, the invention features method of detecting, diagnosing or monitoring inflammatory diseases in a subject using labeled inhibitory antibodies.

, The invention as claimed relates to:
- an inhibitor of natural IgM antibodies, wherein the inhibitor is an isolated antibody or antigen-binding fragment thereof that binds to a self-antigen, inhibits binding of a natural IgM antibody to the self-antigen, and blocks complement activation, wherein the amino acid sequence of the self-antigen is SEQ ID NO: 38;
- the use of an inhibitor as described herein for the preparation of a medicament for treating a complement-dependent inflammatory condition triggered by binding of natural IgM antibodies; and - a pharmaceutical composition comprising the inhibitor as described herein, and a pharmaceutically acceptable excipient.
Other features and advantages of the invention will be apparent based on the following Detailed Description and Claims.

=

5. Brief Description of the Drawings Figure 1 shows an IgM heavy chain sequence of I3-1 hybridoma 22A5. (A) shows = the IgMcm-22 (or 22A5 1gM) heavy chain nucleic acid sequence (SEQ ID NO:
1) and (B).
shows the amino acid sequence corresponding to the heavy chain sequence of SEQ
ID NO: 1 (SEQ JD NO: 2). Framework regions (FVWR) and complementarity-determining regions (CDR) are indicated above the nucleotides.
Figure 2 shows an IgM light chain sequence of B-1 hybridoma 22A5. (A) shows the IgMcm'22 (or 22A5 IgM) light chain nucleic acid sequence (SEQ ID NO: 7) and (B) shows the amino acid sequence corresponding to the light chain sequence of SEQ
ID NO: 7 (SEQ ID NO: 8), Framework- regions (FVWR) and complementarity-determining regions (CDR) are indicated above the nucleotides.
Figure 3 is a bar graph depicting changes in intestinal permeability of inbred mice after intestinal ischemia and reperfusion or no injury (sham). WT represents parent strain for Cr2-/- mice. Cr24- was reconstituted with pooled IgG or IgM or saline control. Pooled IgM or IgG (0.5 mg) was administered intravenously approximately 1 hour before treatment. Values are means + standard error, n equals the number of mice in experimental groups.
Figure 4 demonstrates reconstitution of I/R. injury in antibody deficient mice (RAG- .
1) by pooled IgM from a single B-1 cell hybridoma clone. IgM or saline was injected = intravenously 30 minutes before initial laparotomy. At the end of reperfusion, blood is obtained and permeability index is calculated as the ratio of 1251 counts of dried intestine versus that of blood. Values represent means* standard error, n equals the numbers of mice used in experimental groups. 1 = WT plus normal saline; 2 .= RAG plus normal saline; 3 =
RAG plus IgM hybridoma CM-22; 4 = WT sham control.
Figure 'S is a schematic diagram of the proposed role for complement and =
complement receptors in positive selection of peritoneal B-1 lymphocytes.
Figure 6A is a graph showing the ELISA screening of M-13 phage-display library for IgmCM-22-specific peptides. Symbols: a-P1 clone; X-P2 clone, o-P7 clone; 0-P8 clone.
=
- 3a -The plate was coated with a solution of IgMcm-22 before addition of varying concentrations of phage-clones. The results are representative of at least three independent experiments.
Figure 6B is a bar graph showing that the synthetic peptide P8 inhibits IgmCM-binding of phage clone P8. ELISA was performed with varying concentrations of the synthetic peptide P8 added to the Iguic¨ m-22-coated plate prior to the addition of 5x1On PFU
phage. The results are representative of at least three independent experiments.

Figure 6C is a bar graph showing specific binding of the P8 peptide to IgmCM.
The ELISA plates were coated with 50 ug/m1 solution of P8 peptide, followed by addition of Ig mCM-22 or IgMcm-75 at 1 or 10 ug/ml. IgM binding was detected with a biotinylated rat anti-mouse IgM followed by streptavidin-phosphatase and color reaction. The results are representative of at least three independent experiments.
Figure 7A is a series of photomicrographs showing that the P8 peptide blocked IgMcm-22 mediated injury in vivo. Two upper panels (i and ii) are representative sections (stained with Haematoxylin and Eosin) prepared following RI treatment in RAG-14- mice with IgMcm-22 alone or mixed with P8 peptide, respectively. Two lower panels (iii and iv) are representative sections prepared from wild type mice treated for intestinal reperfusion injury, which received either saline or peptide P8 5 minutes prior to reperfiision. Arrows indicate pathologic features of injury. Magnification 200x.
Figure 7B is a scatter plot indicating the mean pathology score of each group of treated animals. Each symbol represents the score from one animal. Control group is WT
mice pretreated with a control peptide (ACGMPYVRIPTA; SEQ ID NO: 61) at a similar dose as the peptide P8. * indicates statistical significance determined by Student t test of the P8-treated versus untreated groups (p<0.05).
Figure 7C is a series of photomicrographs showing the absence of IgM and complement C3 or C4 within the microvilli of P8-treated animals.
Representative cryosections of intestinal tissues were harvested following intestinal RI. Panels i-viii are IgMcm-22 reconstituted RAG-14"
mice without pretreatment with P8 (panels i-iv) or with P8 (panels v-viii).
Panels represent cryosections from the intestines of WT without P8 (panels ix-xii) or pretreated with P8 (panels xiii-xvi). Sections (i, v, vii, ix, xiii, xv) were stained with anti-IgM-biotin followed by Streptavidin-Alexa-568 (red) and counterstained with DAPI (violet). Panels (ii, x, xiv) were stained with anti-C4-Alexa 488/FITC (green) and panels (iv, viii, xii, xvi) were stained with anti-C3-FITC (green).
Magnification 400x.

=

Figure 8A is an immunoblot showing the immune precipitation of reperfusion injury (RI) specific antigens. Detection of a unique band (arrow) at approximately 250 kDa on a SDS-PAGE (10%). Size markers are indicated on the left. Intestinal lysates were prepared from RAG-14" mice reconstituted with IgMcm-22 and either sham control (no ischernia) or subjected to ischemia followed by reperfusion for 0 or 15 min.
Figure 8B is a series of graphs showing results of in vitro binding assays of IgMcm-22 to the isoforms of non-muscle myosin heavy chain-H (NMHC-H). ELISA plates were coated with monoclonal antibodies for 3 different isoforms of NMHC-II (upper left:
isoform A, upper right: isoforrn B, lower left: isoforrn C and lower right:
anti-pan myosin antibody). Bound myosin heavy chain from intestinal lysates was detected by Ig or mCM-22 IgMcm-31. The results represent mean standard error of OD 405 nm units and are representative of triplicate samples.
Figure 8C is a photomicrograph and a scatter plot showing the restoration of RI
injury by anti-pan:myosin antibody in RAG-14" mice. RAG-14- mice were reconstituted with affinity purified anti-pan myosin followed by RI surgery. The left panels represents morphologies of RAG-14- animals with saline control and with anti-pan myosin treatment.
The right panel is the pathology scores of intestinal injury. The scatter plot (right panel) represents the pathology scores where each symbol represents a single animal.
Figure 9A is a graph showing the surface plasmon resonance for the self-peptide N2. Binding isotherms for samples of the self-peptide N2 with concentration from 10.5 M
to 120 M injected over the tmcm-22-coupled surface.
Figure 9B is a graph showing the surface plasmon resonance for a control peptide.
Binding isotherm for a same-length, random-sequence control peptide (AGCMPYVRIPTA;
SEQ ID NO: 62), injected at a concentration of 117 p.I\.4 over the IglAcm-22-coupled surface.
Figure 9C is a graph showing the nonlinear curve fitting with a 1:1 Langmuir binding isotherm to the steady-state response levels for the injection showed in Figure 9A
(x2=10).
Figure 9D is a graph showing the binding isotherm for the injection of the self-peptide N2 at 120 M over a surface coupled with the control IgMcm-31.
Figure 10A is a series of photomicrographs showing that the N2 self-peptide blocking RI in RAG-14" mice. Two upper panels show representative sections prepared . .

following RI treatment in RAG-14" mice with IgMcm-22 alone or mixed with N2 self-peptide. Two lower panels are representative sections prepared from WT mice treated for intestinal RI, which received either saline or N2 peptide 5 minutes prior to reperfusion.
Figure 10B is a scatter plot indicating the mean pathology score of each group of 5 treated animals. Each symbol represents a single mouse. * indicates a statistical significance bases on a Student t test.
Figure 10C is a series of photomicrographs showing the prevention of the activation of classical pathway of complement in intestinal RI by the self-peptide N2.
Representative cryosections of intestinal tissues were harvested following intestinal RI and 10 treated with an antibody specific for the mouse IgM, C4 or C3 (400x magnification).
IgMcm-22-reconstituted RAG-14- mice without pretreatment with the self-peptide N2 are in panels i-iv or with the self-peptide N2 are in panels v-viii. Wild type mice without pretreatment with the self-peptide N2 are in panels ix-xii or with pretreatment with the self-peptide N2 are in panels xiii-xvi. The tissue in panels i, iii, v, vii, ix, xiii, xi, xv were 15 stained with anti-IgM-biotin followed by Streptavidin-Alexa-568 (red) and counterstained with DAPI (violet). Panels ii, vi, x, and xiv were stained with anti-C4-FITC
(green).
Panels iv, viii, xii, xvi were stained with anti-C3-FITC (green).
Figure 11 shows the (A) nucleic acid sequence (SEQ ID NO: 47; Genbank Accession no. NM 022410) and (B) amino acid sequence (SEQ ID NO: 48; Genbank 20 Accession no. NP_071855) of mouse non-muscle myosin heavy chain II-A
(mNMTIC-IIA).
Figure 12 shows the (A) nucleic acid sequence (SEQ ID NO: 49; Genbank Accession no. NM 002473) and (B) amino acid sequence (SEQ ID NO: 50; Genbank Accession no. NP 002464) of human non-muscle myosin heavy chain II-A (11NMHC-TIA).
Figure 13 shows the (A) nucleic acid sequence (SEQ ID NO: 51; Genbank 25 Accession no. NM_175260) and (B) amino acid sequence (SEQ ID NO: 52;
Genbank Accession no. NP 780469) of mouse non-muscle myosin heavy chain (inNMHC-JIB).
Figure 14 shows the (A) nucleic acid sequence (SEQ ID NO: 53; Genbank = Accession no. NM 005964) and (B) amino acid sequence (SEQ ID NO: 54;
Genbank Accession no. NP 005955) of human non-muscle myosin heavy chain II-B (hNMHC-ITB).
30 Figure 15 shows the (A) nucleic acid sequence (SEQ ID NO: 55; Genbank Accession no. AY363100) and (B) amino acid sequence (SEQ ID NO: 56; Genbank

- 6 -Accession no. AAQ24173) of mouse non-muscle myosin heavy chain II-C (mNMHC-IIC).
(C) shows the nucleic acid sequence (SEQ ID No: 57; Genbank Accession no.
NM_028021) and (D) shows the amino acid sequence (SEQ ID NO: 58; Genbank Accesion no. NP 079005) of another non-muscle myosin heavy chain II-C.
Figure 16 shows the (A) nucleic acid sequence (SEQ ID NO: 59; Genbank Accession no. NM 024729) and (B) amino acid sequence (SEQ ID NO: 60; Genbank Accession no. NP_079005) of human non-muscle myosin heavy chain IT-C (liNMHC-11C).
6. Detailed Description 6.1. Definitions:
For convenience, certain terms employed in the specification, examples, and appended claims are provided. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
"A" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element"
means one element or more than one element.
"Amino acid" is used herein to refer to either natural or synthetic amino acids, including glycine and D or L optical isomers, and amino acid analogs and peptidomimetics.
"Antibody" is used herein to refer to binding molecules including immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site. Immunoglobulin molecules useful in the invention can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass.
Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains.
Each heavy chain has at one end a variable domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end. Antibodies include, but are not limited to, polyclonal, monoclonal, bispecific, chimeric, partially or fully humanized antibodies, fully human antibodies (i.e., generated in a transgenic mouse expressing human immunoglobulin genes), camel antibodies, and anti-idiotypic antibodies. An antibody, or generally any molecule, "binds specifically" to an antigen (or other molecule) if the antibody binds preferentially to the antigen, and, e.g., has

- 7 -= CA 02812132 2013-04-04

8 PCT/US2005/006276 less than about 30%, preferably 20%, 10%, or 1% cross-reactivity with another molecule.
The terms "antibody" and "immunoglobulin" are used interchangeably.
"Antibody fragment" or "antibody portion" are used herein to refer to any derivative of an antibody which is less than full-length. In exemplary embodiments, the antibody fragment retains at least a significant portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(abI)2, scFv, Fv, dsFAr diabody, minibody, Fd fragments, and single chain antibodies.
The antibody fragment may be produced by any means. For instance, the antibody fragment may be enzymatically or chemically produced by fragmentation of an intact antibody, it may be recombinantly produced from a gene encoding the partial antibody sequence, or it may be wholly or partially synthetically produced. The antibody fragment may optionally be a single chain antibody fragment. Alternatively, the fragment may comprise multiple chains which are linked together, for instance, by disulfide linkages. The fragment may also optionally be a multimolecular complex. A functional antibody fragment will typically comprise at least about 50 amino acids and more typically will comprise at least about 200 amino acids.
"Antigen-binding site" is used herein to refer to the variable domain of a heavy chain associated with the variable domain of a light chain.
"Bind" or "binding" are used herein to refer to detectable relationships or associations (e.g. biochemical interactions) between molecules.
"Cells," "host cells" or "recombinant host cells" are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
"Comprise" and "comprising" are used in the inclusive, open sense, meaning that additional elements may be included.
"Consensus sequence" is used herein to refer to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See.
e.g., Winnaker, From Genes to Clones, 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that =

position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A "consensus framework" refers to the framework region in the consensus immunoglobulin sequence.
A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a natural immunoglobulin can be preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a natural immunoglobulin coding sequence, such as by saturation mutageriesis, and the resultant mutants can be screened for biological activity.
"Detectable label" is used herein to refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (e.g., biotin or haptens) and the like. "Fluorophore" refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range.
Particular examples of labels which may be used under the invention include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, NADPH, beta-galactosidase, and horseradish peroxidase.
"Inhibitor" or "IgM inhibitor" or "antagonist" as used herein refers to an agent that reduces or blocks (completely or partially) an interaction between a natural antibody and another molecule involved in an inflammatory cascade. An inhibitor may antagonize one or more of the following activities of a natural IgM: (i) inhibit or reduce an interaction (e.g., binding) between the IgM and an ischemia-specific antigen; (ii) inhibit or reduce an interaction (e.g., binding) between the natural IgM and a component of the complement pathway, e.g., Clq; (iii) neutralize the natural IgM by, e.g., sequestering the immunoglobulin and/or targeting its degradation; or (iv) inhibit or reduce production of the

- 9 -_ natural IgM e.g., blocks synthesis, assembly, and/or posttranslational modifications of the IgM. The inhibitor can bt. orotein or a peptide, an antibody or fragment thereof (e.g., an anti-idiotypic antibody), a modified antibody, a carbohydrate, a glycoprotein, or a small organic molecule.
"Interaction" refers to a physical association between two or more molecules, e.g., binding. The interaction may be direct or indirect.
"Inflammatory disease" is used herein to refer to a disease or disorder that is caused or contributed to by a complicated set of functional and cellular adjustments involving acute or chronic changes in microcirculation, movement of fluids, and influx and activation of inflammatory cells (e.g., leukocytes) and complement, and included autoimmune diseases. Examples of such diseases and conditions include, but are not limited to:
reperfusion injury, ischemia injury, stroke, autoimmune hemolytic anemia, idiopathic thrombocytopenic ptupura, rheumatoid arthritis, celiac disease, hyper-IgM
immunodeficiency, arteriosclerosis, coronary artery disease, sepsis, myocarditis, encephalitis, transplant rejection, hepatitis, thyroiditis (e.g. Hashimoto's thyroiditis, Graves disease), osteoporosis, polymyositis, dermatomyositis, Type I diabetes, gout, dermatitis, alopecia areata, systemic lupus erythematosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, pelvic inflammatory disease, periodontal disease, arthritis, juvenile chronic arthritis (e.g. chronic iridocyclitis), psoriasis, osteoporosis, nephropathy in diabetes mellitus, asthma, pelvic inflammatory disease, chronic inflammatory liver disease, chronic inflammatory lung disease, lung fibrosis, liver fibrosis, rheumatoid arthritis, chronic inflammatory liver disease, chronic inflammatory lung disease, lung fibrosis, liver fibrosis, Crohn's disease, ulcerative colitis, burns, and other acute and chronic inflammatory diseases of the Central Nervous System (CNS; e.g. multiple sclerosis), gastrointestinal system, the skin and associated structures, the immune system, the hepato-biliary system, or any site in the body where pathology can occur with an inflammatory component.
An "isolated" molecule, e.g., an isolated IgM, refers to a condition of being separate or purified from other molecules present in the natural environment.
"Natural IgM" is used herein to refer to an IgM antibody that is naturally produced in a mammal (e.g., a human). They have a pentameric ring structure wherein the individual monomers resemble IgGs thereby having two light (K or k) chains and two heavy (p) chains. Further, the heavy chains contain an additional CH4 domain. The monomers form a

- 10 -_ pentamer by disulfide bonds between adjacent heavy chains. The pentameric ring is closed by the disulfide bonding between a J chain and two heavy chains. Because of its high number of antigen binding sites, a natural IgM antibody is an effective agglutinator of antigen. Production of natural IgM antibodies in a subject are important in the initial activation of B-cells, macrophages, and the complement system. IgM is the first immunoglobulin synthesized in an antibody response.
"Nucleic acid" is used herein to refer to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.
"Operatively linked" is used herein to refer to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a coding sequence is "operably linked" to another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein. An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

- 11 -"Patient", "subject" or "host" are used herein to refer to either a human or a non-human mammal.
"Peptide" is used herein to refer to a polymer of amino acids of relatively short length (e.g. less than 50 amino acids). The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
The term also encompasses an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
"Promoter" is used herein to refer to a minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the of a polynucleotide sequence. Both constitutive and inducible promoters, are included in the invention (see e.g., Bitter et al., Methods in Enzymology 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the reh-ovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K
promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.
Tissue-specific regulatory elements may be used. Including, for example, regulatory elements from genes or viruses that are differentially expressed in different tissues.
"Specifically binds" is used herein to refer to the interaction between two molecules to form a complex that is relatively stable under physiologic conditions. The term is used herein in reference to various molecules, including, for example, the interaction of an antibody and an antigen (e.g. a peptide). Specific binding can be characterized by a dissociation constant of at least about 1x10-6 M, generally at least about 1x104 M, usually at least about 1x10-8 M, and particularly at least about 1x10-9 M or lx 1 0-1 M or greater.
Methods for determining whether two molecules specifically bind are well known and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.

- 12 -_ "Stringency hybridization" or "hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions" is used herein to describes conditions for hybridization and washing. Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y.
(1989), 6.3.1-6:3.6. Aqueous and non-aqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45 C, followed by two washes in 0.2X
SSC, 0.1%
SDS at least at 50 C (the temperature of the washes can 'be increased to 55 C
for low stringency conditions); 2) medium stringency hybridization conditions in 6X
SSC at about 45 C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60 C; 3) high stringency hybridization conditions in 6X SSC at about 45 C, followed by one or more washes in 0.2X
= SSC, 0.1% SDS at 65 C; and preferably 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65 C, followed by one or more washes at 0.2X
SSC, 1% SDS at 65 C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified. Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.
To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
The percent identity between the two sequences is a function of the number of identical positions shared by the sequences and the percent homology between two sequences is a function of the number of conserved positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be

- 13 -=

introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity and/or homology between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available on the world wide web with the extension gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available on the world wide web with the extension gcg.com), using a NWSgapdna CMP matrix and a gap weight of 40, 50, 60, 70; or 80 and a length weight of 1, 2, 3,4, 5, or 6. A
particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5.
The percent identity and/or homology between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
"Treating" is used herein to refer to any treatment of, or prevention of, or inhibition of a disorder or disease in a subject and includes by way of example: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the disease or disorder, i.e., arresting its progression; or (c) relieving or ameliorating the disease or disorder, i.e., causing regression. Thus, treating as used herein includes, for example, repair and regeneration of damaged or injured tissue or cells at the site of injury or prophylactic treatments to prevent damage, e.g., before surgery.
"Vector" as used herein refers to a nucleic acid molecule, which is capable of transporting another nucleic acid to which it has been operatively linked and can include a plasmid, cosmid, or viral vector. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked.
Vectors may be capable of directing the expression of genes to which they are operatively

- 14 -_ linked. A vector may also be capable of integrating into the host DNA.. In the present specification, "plasmid" and "vector" are used interchangeably as a plasmid (a circular arrangement of double stranded DNA) is the most commonly used form of a vector.
However, the invention is intended to include such other forms of vectors which serve equivalent functions and which become known in the art subsequently hereto.
Viral vectors include, e.g., replication defective retroviruses, adenoviru.ses and adeno-associated viruses.
6.2 Natural Ig111 antibodies The present invention is based, at least in part, on the identification of natural immuno globulins (Ig), in particular natural IgMs. Certain IgMs may be obtained from the hybridoma that has been deposited with the American Type Culture Collection and provided Accession Number PTA-3507.
The nucleotide sequence of the heavy chain variable region of the IgM produced from hybridoma PTA-3507, IgMcm-22 (also referred to as 22A5 IgM) is shown in Figure 1A (SEQ ID NO: 1), and the amino acid sequence is shown in Figure 1B (SEQ ID
NO: 2).
The CDR1 domain of the heavy chain variable region corresponds to amino acids 31 to 35 of SEQ ID NO: 2 (SEQ ID NO: 4), which is encoded by nucleotides 91-105 of SEQ ID
NO: 1 (SEQ ID NO: 3), and the CDR2 domain of the heavy chain variable region corresponds to amino acids 50 to 66 of SEQ ID NO: 2 (SEQ ID NO: 6), which is encoded by nucleotides 148-198 of SEQ ID NO: 1 (SEQ ID NO: 5).
The nucleotide sequence of the light chain variable region of IgMcm-22 is shown in Figure 2A (SEQ ID NO: 7), and the amino acid sequence is shown in Figure 2B
(SEQ ID
NO: 8). The CDR1 domain of the light chain variable region corresponds to amino acids 23 to 37 of SEQ ID NO: 8 (SEQ ID NO: 10), which is encoded by nucleotides 67-111 of SEQ ID NO: 7 (SEQ ID NO: 9), and the CDR2 domain of the light chain variable region corresponds to amino acids 53 to 59 of SEQ ID NO: 8 (SEQ ID NO: 12), which is encoded by nucleotides 157 to 177 of SEQ ID NO: 7 (SEQ ID NO: 11). Due to the degeneracy of the genetic code, other nucleotide sequences can encode the amino acid sequences listed herein.

-15-=
The nucleic acid compositions of the present invention, while often in a native sequence (except for modified restriction sites and the like), from either cDNA, genomic or mixtures may be mutated, in accordance with standard techniques. For coding sequences, these mutations, may affect the amino acid sequence as desired. In particular, nucleotide sequences substantially identical to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated.
For example, an isolated nucleic acid can comprise an IgMCM-22 (or 22A5 IgM) heavy chain variable region nucleotide sequence having a nucleotide sequence as shown in Figure lA (SEQ ID NO: 1), or a sequence, which is at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: I. A nucleic acid molecule may comprise the heavy chain CDR1 nucleotide sequence of SEQ ID NO: 3, or a portion thereof.
Further, the nucleic acid molecule may comprise the heavy chain CDR2 nucleotide sequence of SEQ ID
NO: 5, or a portion thereof. In an exemplary embodiment, the nucleic acid molecule comprises a heavy chain CDR1 nucleotide sequence of SEQ ID NO: 3, or portion thereof, and a heavy chain CDR2 nucleotide sequence of SEQ ID NO: 5, or portion thereof. The nucleic acid molecules of the present invention may comprise heavy chain sequences, e.g.
SEQ ID NO: I, SEQ ID NO: 3, SEQ ID NO: 5, or combinations thereof, or encompass nucleotides having at least 80%, 90%, 95%, 96%, 97 %, 98%, and 99% sequence identity to SEQ ID NOs: 1, 3 or 5. Further, the nucleic acid molecules of the present invention may comprise heavy chain sequences, which hybridize under stringent conditions, e.g. low, medium, high or very high stringency conditions, to SEQ ID NOs: 1, 3 or 5.
In another embodiment, the invention features nucleic acid molecules having at least 80%, 90%, 95%, 96%, 97 %, 98%, and 99% sequence identity with a nucleic acid molecule encoding a heavy chain polypeptide, e.g., a heavy chain polypeptide of SEQ ID
NOs: 2, 4 or 6. The invention also features nucleic acid molecules which hybridize to nucleic acid sequences encoding a heavy chain variable region of a natural antibody or portion thereof, e.g., a heavy chain variable region of SEQ ID NO: 2,4 or 6.
In another embodiment, the isolated nucleic acid encodes a IgMcm -22 (22A5 IgM) light chain variable region nucleotide sequence having a nucleotide sequence as shown in Figure 2A (SEQ ED NO: 7), or a sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99%
identical to SEQ ID NO: 7. The nucleic acid molecule may comprise the light chain CDR1 nucleotide sequence of SEQ ID NO: 9, or a portion thereof. In another preferred embodiment, the nucleic acid molecule may comprise the light chain CDR2 nucleotide

- 16 -=, =

sequence of SEQ ID NO: 11, or a portion thereof. In an exemplary embodiment, the nucleic acid molecule comprises a light chain CDR1 nucleotide sequence of SEQ
ID NO: 9, or portion thereof, and a light chain CDR2 nucleotide sequence of SEQ ID NO:
11, or portion thereof The nucleic acid molecules of the present invention may comprise light chain sequences, e.g. SEQ ID NOs: 7, 9 or 11, or combinations thereof, or encompass nucleotides having at least 80%, 90%, 95%, 96%, 97 %, 98%, and 99% sequence identity to SEQ ID NOs: 7, 9 or 11. Further nucleic acid molecules may comprise light chain sequences, which hybridize under stringent conditions, e.g. low, medium, high or very high stringency conditions, to SEQ ID NOs: 7, 9 or 11.
Nucleic acid molecules can have at least 80%, 90%, 95%, 96%, 97 %, 98% or 99%
sequence identity with a nucleic acid molecule encoding a light chain polypeptide, e.g., a light chain polypeptide of SEQ ID NOs: 8, 10, or 12. The invention also features nucleic acid molecules which hybridize to a nucleic acid sequence encoding a light chain variable region of a natural antibody or portion thereof, e.g., a light chain variable region of SEQ ID
NOs: 8, 10 or 12.
In another embodiment, the invention provides an isolated nucleic acid encoding a heavy chain cDR1 domain comprising the amino acid sequence of SEQ ID NO: 4, or a fragment or modified form thereof. This nucleic acid can encode only the CDR1 region or can encode an entire antibody heavy chain variable region or a fragment thereof. For example, the nucleic acid can encode a heavy chain variable region having a domain comprising the amino acid sequence of SEQ ID NO: 6. In yet another embodiment, the invention provides an isolated nucleic acid encoding a heavy chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, or a fragment or modified form thereof. This nucleic acid can encode only the CDR2 region or can encode an entire antibody heavy chain variable region or a fragment thereof. For example, the nucleic acid can encode a light chain variable region having a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4.
In still another embodiment, the invention provides an isolated nucleic acid encoding a light chain CDR1 domain comprising the amino acid sequence of SEQ
ID
NO: 10, or a fragment or modified form thereof. This nucleic acid can encode only the CDR1 region or can encode an entire antibody light chain variable region. For example, the nucleic acid can encode a light chain variable region having a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 12. The isolated nucleic acid can

- 17 -__ = WO 2005/085288 also encode a light chain CDR2 domain comprising the amino acid sequence of SEQ ID
NO: 12, or a fragment or modified foul), thereof This nucleic acid can encode only the CDR2 region or can encode an entire antibody light chain variable region. For example, the nucleic acid can encode a light chain variable region having a CDRI domain comprising the amino acid sequence of SEQ ID NO: 10.
The nucleic acid encoding the heavy or light chain variable region can be of murine or human origin, or can comprise a combination of murine and human amino acid sequences. For example, the nucleic acid can encode a heavy chain variable region comprising the CDR1 of SEQ ID NO: 2 (SEQ ID NO: 4) and/or the CDR2 of SEQ ID
NO: 2 (SEQ ID NO: 6), and a human framework sequence. In addition, the nucleic acid can encode a light chain variable region comprising the CDR1 of SEQ ID NO: 8 (SEQ ID
NO: 10) and/or the CDR2 of SEQ ID NO: 8 (SEQ ID NO: 12), and a human framework sequence. The invention further encompasses vectors containing the above-described nucleic acids and host cells containing the expression vectors.
The invention also features polypeptides and fragments of the Ig mCM-22 heavy chain variable regions and/or light chain variable regions. In exemplary embodiments, the isolated polypeptides comprise, for example, the amino acid sequences of SEQ
ID NOs: 8, 10, or 12, or fragments or combinations thereof; or SEQ ID NO: 2, 4, or 6, or fragments or combinations thereof. The polypeptides of the present invention include polypeptides having at least, but not more than 20, 10, 5, 4, 3, 2, or 1 amino acid that differs from SEQ
ID NOs: 8, 10, 12, 2, 4 or 6. Exemplary polypeptides are polypeptides that retain biological activity, e.g., the ability to bind an ischemia-specific antigen, and/or the ability to bind complement. In another embodiment, the polypeptides comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a light chain variable region, or portion thereof, e.g. a light chain variable region polypeptide of SEQ
ID NOs: 8, 10, or 12. In another embodiment, the polypeptides comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a heavy chain variable region, or portion thereof, e.g. a heavy chain variable region polypeptide of SEQ ID NOs: 2, 4, or 6. In another embodiment, the invention features a polypeptide comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 2, further comprising an IRES sequence.

- 18 --6.3 Inhibitors of Natural Igilf Antibodies 6.3.1 Peptide Inhibitors of Natural IgM Antibodies The invention further features IgM inhibitors. In one embodiment, the IgM
inhibitor is a peptide that specifically binds to a natural IgM and thereby blocks binding to the antigen. Such peptides can include, but are not limited to, the asparagine-rich peptides described in Table 1 below.
Table 1: Amino acid sequences of natural IgM antibody-binding peptides SEQ ID SEQUENCE Name NO:
14 xNNNxNNxNNNN Asparagine-rich Consensus 16 NrNNNNGNYTYRN P1 98 = = SN P7 The peptides can also include certain "self-peptides" as described in Table 2 below.
Table 2: Amino acid sequences of self-peptides SEQ ID SEQUENCE Name NO:
36 LMKNMDPLNDNI Self-1 38 LMICNMDPLNDNV Self-2 ("N-2") As described in more detail in the Exemplification, self peptides bind to the natural IgM antibody igmcm-22.

- 19-In addition to the peptides described above, the present invention encompasses modified peptides whose activity may be identified and/or assayed using a variety of methods well known to the skilled artisan. For example, binding of the peptide to the IgM
may be detected using biological assays, Western blotting, immunoprecipitation, or immonocytochernical techniques, such as those described below. In particular, the ' biological activity (e.g., the ability to a bind natural IgM antibody) of a modified peptide can be characterized relative to that of P8 (SEQ ID NO: 30) or N2 (SEQ ID NO:
38).
Such modified peptides, when designed to retain at least one activity of the naturally-occurring form of the protein, are considered "functional equivalents" of the peptides described in more detail herein. Such modified peptides may be produced, for instance, by amino acid substitution, deletion, or addition, which substitutions may consist in whole or part by conservative amino acid substitutions.
For instance, it is reasonable to expect that an isolated conservative amino acid substitution, such as replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine, will not have a major effect on the biological activity of the resulting molecule. Whether a change in the amino acid sequence of a peptide results in a functional homolog may be readily determined by assessing the ability of the variant peptide to produce a response similar to that of the wild-type peptide (e.g.
ability to bind natural IgM antibodies). Peptides in which more than one replacement has taken place may readily be tested in the same manner.
Mutagenesis of the peptide may give rise to homologs, which have improved in vivo half-lives relative to the corresponding wild-type peptide. For example, the altered peptide may be rendered more stable to proteolytic degradation or other cellular processes which result in destruction or inactivation of the protein.
The amino acid sequences for a population of peptide homologs can be aligned, preferably to promote the highest homology possible. Such a population of variants may include, for example, homologs from one or more species, or homologs from the same species but which differ due to mutation. Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences. In certain embodiments, the combinatorial library is produced by way of a degenerate library of genes encoding a library of polypeptides which each include at least a portion of =
potential peptide sequences. For instance, a mixture of synthetic oligonucleotides may be

- 20 -_ enzymatically ligated into gene sequences such that the degenerate set of potential nucleotide sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display).
There are many ways by which the library of potential homologs may be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence may be carried out in an automatic DNA synthesizer, and the synthetic genes may then be ligated into an appropriate vector for expression. One purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential peptide sequences. The synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al., (1981) Recombinant DNA, Proc. 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp. 273-289; Itakura et al., (1984) Annu. Rev. Biochem.
53:323;
Itakura etal., (1984) Science 198:1056; Ike et al., (1983) Nucleic Acid Res.
11:477). Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al., (1990) Science 249:386-390; Roberts et al., (1992) PNAS
USA
89:2429-2433; Devlin et al., (1990) Science 249: 404-406; Cwirla et al., (1990) PNAS USA
87: 6378-6382; as well as U.S. Patent Nos: 5,223,409, 5,198,346, and 5,096,815).
Alternatively, other forms of mutagenesis may be utilized to generate a combinatorial library. For example, peptide homologs may be generated and isolated from a library by screening using, for example, alanine scanning mutagenesis and the like (Ruf et al., (1994) Biochemistry 33:1565-1572; Wang et al., (1994) J. Biol. Chem.
269:3095-3099;
Balint etal., (1993) Gene 137:109-118; Grodberg et al., (1993) Eur. J.
Biochem. 218:597-601; Nagashima et al., (1993) J. Biol. Chem. 268:2888-2892; Lowman et al., (1991) Biochemistry 30:10832-10838; and Cunningham et al., (1989) Science 244:1081-1085), by linker scanning mutagenesis (Gustin et al., (1993) Virology 193:653-660; Brown et al., (1992) Mol. Cell Biol. 12:2644-2652; McKnight et al., (1982) Science 232:316);
by saturation mutagenesis (Meyers etal., (1986) Science 232:613); by PCR
mutagenesis (Leung et al., (1989) Method Cell Mol. Biol. 1:11-19); or by random mutagenesis (Miller et al., (1992) A Short Course in Bacterial Genetics, CSHL Press, Cold Spring Harbor, NY;
and Greener et al., (1994) Strategies in Mol. Biol. 7:32-34).
A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations and truncations, and for screening cDNA
libraries for gene products having a certain property (e.g., the ability to bind a natural IgM

-21-. WO 2005/085288 PCT/US2005/006276 antibody). Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of peptide homologs. The most widely used techniques for screening large gene libraries typically comprises cloning the =
gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of degenerate sequences created by combinatorial mutagenesis techniques.
In an illustrative embodiment of a screening assay, candidate combinatorial gene products are passed over a column containing beads having attached to it the binding protein, such as an IgM or portion thereof. Those candidate combinatorial gene products that are retained on the column may be further characterized for binding to IgMs in a manner that could be useful in blocking natural IgM antibody binding and treating inflammatory diseases.
In another example, the gene library may be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences may be expressed on the surface of infectious phage, thereby conferring two benefits. First, because these phage may be applied to affinity matrices at very high concentrations, a large number of phage may be screened at one time. Second, because each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage may be amplified by another round of infection. The group of almost identical E. coli filamentous phages M13, fd, and fl are most often used in phage display libraries, as either of the phage gIII or gVIII
coat proteins may be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al., PCT publication WO 90/02909;
Garrard et al., PCT publication WO 92/09690; Marks et al., (1992) J. Biol. Chem. 267:16007-16010;
Griffiths et al., (1993) EMBO J. 12:725-734; Clackson et al., (1991) Nature 352:624-628;
and Barbas et al., (1992) PNAS USA 89:4457-4461). Other phage coat proteins may be used as appropriate.
The invention also provides for mimetics (e.g., non-peptide agents) which are able to mimic binding of the authentic peptide to a natural IgM antibody. For example, the critical residues of a peptide which are involved in molecular recognition of a natural IgM

- 22 -antibody may be determined and used to generate peptidomimetics that bind to a natural IgM antibody.
The peptidomimetic may then be used as an inhibitor of the wild-type protein by binding to the natural IgM antibodies and covering up the critical residues needed for interaction with the wild-type protein, thereby preventing interaction of the protein and the natural IgM antibody.
Peptidomimetic compounds may be generated which mimic those residues in binding to the natural IgM
antibody. For instance, non-hydrolyzable peptide analogs of such residues may be generated using benzodiazepine (e.g., see Freidinger et al., in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al., in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al., in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al., (1986) J. Med. Chem. 29:295;
and Ewenson et al., in Peptides: Structure and Function (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), 13-turn dipeptide cores (Nagai et al., (1985) Tetrahedron Lett 26:647;
and Sato et al., (1986) J Chem Soc Perkin Trans 1:1231), and P-aminoalcohols (Gordon et al., (1985) Biochem Biophys Res Comtnun 126:419; and Dann et al., (1986) Biochem Biophys Res Commun 13471).
6.3.2 Nucleic acids Encoding Peptide Inhibitors The invention also features nucleic acids, which encode the peptides discussed above.
Exemplary nucleic acids are provided in Table 3.
Table 3: Nucleic acids encoding natural IgM antibody-binding peptides SEQ SEQUENCE Name ID
NO:
13 NNN AAY AAY AAY NNN AAY AAY NNN AAY AAY AAY Aparagine-AAY rich Consensus 15 TAY AAY AAY AAY AAY GGN AA.Y TAY ACN TAY MGN P1 AAY

ATG

AAY

- 23 -SEQ SEQUENCE Name ID
NO:
21 TOG AAY AA'S_T AAY GGN MGN AAY GCN TGY AAY GCN P4 AAY

GIN

AAY

AAY

AAY

AAY

AAY
35 YTN ATG AAR AAY ATG GAY CCN YTN AAY GAY AAY Self-1 ATH
37 YTN ATG AAR AAY ATG GAY CCN YTN AAY GAY AAY Self-2 GTN
The isolated nucleic acids in Table 3 reflect degeneracy in the genetic code.
In particular, an "R" corresponds to a base that may be a A or G; a "S"
corresponds to a base that may be a G or C; a "V" corresponds to a base that may be an A, C or G; a corresponds to a base that may be a C or T; a "W" corresponds to a base that may be an A
or T; a "D" corresponds to a base that may be an A, G or T; a "M" corresponds to a base that may be an A or C; a "H" corresponds to a base that may be an A, C or T; a "N"
corresponds to a base that may be an A, C, G or T; a "K" corresponds to a base that may be a G or T and a "B" corresponds to a base that may be a C, G or T.
It is expected that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (from less than 1% up to about 3 or 5% or possibly more of the nucleotides) of the nucleic acids encoding a

-24 -particular peptide of the invention may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymoiphisms are within the scope of this invention. Preferred nucleic acids encode a peptide, which is at least about 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%
homologous or more with an amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or another peptide of the invention. Nucleic acids which encode peptides having an activity of a peptide of the invention and having at least about 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% homology or more with SEQ ID NO: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, or another peptide of the invention are also within the scope of the invention.
Bias in codon choice within genes in a single species appears related to the level of expression of the protein encoded by that gene. Accordingly, the invention encompasses nucleic acid sequences which have been optimized for improved expression in a host cell by altering the frequency of codon usage in the nucleic acid sequence to approach the frequency of preferred codon usage of the host cell. Due to codon degeneracy, it is possible to optimize the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleotide sequence that encodes the peptides set forth in SEQ ID NO: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,38 or other peptides of the invention.
Nucleic acids within the scope of the invention may also contain linker sequences, modified restriction endonuclease sites and other sequences useful for molecular cloning, expression or purification of such recombinant polypeptides.
A nucleic acid encoding a peptide of the invention may be obtained from mRNA
or genomic DNA from any organism in accordance with protocols described herein, as well as those generally known to those skilled in the art. A cDNA encoding a peptide of the invention, for example, may be obtained by isolating total mRNA from an organism, e.g. a bacteria, virus, mammal, etc. Double stranded cDNAs may then be prepared from the total mRNA, and subsequently inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques. A gene encoding a peptide of the invention may also be cloned using established polymerase chain reaction techniques in accordance with the nucleotide sequence information provided by the invention.

-25 -In another aspect of the invention, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a peptide of the invention and operably linked to at least one regulatory sequence. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other protein encoded by the vector, such as antibiotic markers, should also be considered.
As will be apparent, the subject gene constructs may be used to cause expression of a peptide of the invention in cells propagated in culture, e.g., to produce proteins or polypeptides, including fusion proteins or polypeptides, for purification.
This invention also pertains to a host cell transfected with a recombinant gene in order to express a peptide of the invention. The host cell may be any prokaryotic or eukaryotic cell. For example, a polypeptide of the present invention may be expressed in bacterial cells, such as E. coli, insect cells (baculovirus), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art. Additionally, the host cell may be supplemented with tRNA molecules not typically found in the host so as to optimize expression of the peptide. Other methods suitable for maximizing expression of the peptide will be known to those in the art.
6.3.3 Methods of Producing Peptide Inhibitors Peptide inhibitors may be synthesized, for example, chemically, ribosomally in a cell free system, or ribosomally within a cell. Chemical synthesis of peptides of the invention may be carried out using a variety of art recognized methods, including stepwise solid phase synthesis, semi-synthesis through the confomiationally-assisted re-ligation of peptide fragments, enzymatic ligation of cloned or synthetic peptide segments, and chemical ligation. Merrifield et al. in J. Am. Chem. Soc., Volume 85, page 2149 (1964), by Houghten et al. in Proc. Natl. Acad. Sci. USA, Volume 82, page 5132 (1985), and by Stewart and Young in Solid Phase Peptide Synthesis, Pierce Chem. Co, Rockford, Ill.
(1984). Native chemical ligation employs a chemoselective reaction of two unprotected peptide segments to produce a transient thioester-linked intennediate. The transient thioester-linked intermediate then spontaneously undergoes a rearrangement to provide the full length ligation product having a native peptide bond at the ligation site. Full length ligation products are chemically identical to proteins produced by cell free synthesis. Full

- 26 -_ length ligation products may be refolded and/or oxidized, as allowed, to form native disulfide-containing protein molecules. (see e.g., U.S. Patent Nos. 6,184,344 and 6,174,530;
and T. W. Muir et al., Curr. Opin. Biotech. (1993): vol. 4, p 420; M. Miller, et al., Science (1989): vol. 246, p 1149; A. Wlodawer, et al., Science (1989): vol. 245, p 616; L. H.
Huang, etal., Biochemistry (1991): vol. 30, p 7402; M. Schnolzer, et al., Int.
J. Pept. Prot.
Res. (1992): vol. 40, p 180-193; K. Rajarathnam, et al., Science (1994): vol.
264, p 90; R.
E. Offord, "Chemical Approaches to Protein Engineering", in Protein Design and the Development of New therapeutics and Vaccines, J. B. Hook, G. Poste, Eds., (Plenum Press, New York, 1990) pp. 253-282; C. J. A. Wallace, et al., J. Biol. Chem. (1992):
vol. 267, p 3852; L. Abrahmsen, et al., Biochemistry (1991): vol. 30, p 4151; T. K. Chang, et al., Proc.
Natl. Acad. Sci. USA (1994) 91:12544-12548; M. Schnlzer, etal., Science (1992): vol., 3256, p 221; and K. Akaji, etal., Chem. Pharm. Bull. (Tokyo) (1985) 33: 184).
In another variation, peptide production may be achieved using in vitro translation systems. An in vitro translation systems is, generally, a translation system which is a cell-free extract containing at least the minimum elements necessary for translation of an RNA
molecule into a protein. An in vitro translation system typically comprises at least ribosomes, tRNAs, initiator methionyl-tRNAMet, proteins or complexes involved in translation, e.g., elF2, eIF3, the cap-binding (CB) complex, comprising the cap-binding protein (CBP) and eukaryotic initiation factor 4F (eIF4F). A variety of in vitro translation systems are well known in the art and include commercially available kits.
Examples of in vitro translation systems include eukaryotic lysates, such as rabbit reticulocyte lysates, rabbit oocyte lysates, human cell lysates, insect cell lysates and wheat germ extracts.
Lysates are commercially available from manufacturers such as Promega Corp., Madison, Wis.; Stratagene, La Jolla, Calif.; Amerslaarn, Arlington Heights, Ill.; and G113CO/BRL, Grand Island, N.Y. In vitro translation systems typically comprise macromolecules, such as enzymes, translation, initiation and elongation factors, chemical reagents, and ribosomes.
In addition, an in vitro transcription system may be used. Such systems typically comprise at least an RNA polymerase holoenzyme, ribonucleotides and any necessary transcription initiation, elongation and termination factors. In vitro transcription and translation may be carried out within in the same reaction to produce peptides from one or more isolated DNAs.
Nucleic acids encoding peptide inhibitors may be expressed in vitro by DNA
transfer into a suitable host cell. Expression of peptides may be facilitated by inserting the

-27-= 60412-4434D1 nucleic acids encoding the peptides into a vector, such as a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the natural antibody-binding peptide genetic sequences. Such vectors contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, et al., Gene, 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem., 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells.
The DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (e.g., T7, metallothionein I, or polyhedrin promoters).
Nucleic acids encoding peptide inhibitors may be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect, and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors can incorporate DNA
sequences of the invention. Methods which are well known to those skilled in the art can be used to construct vectors containing the natural antibody-binding peptide coding sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA
techniques, synthetic techniques, and in vivo recombination/genetic techniques. (See, for example, the techniques described in Maniatis et al., 1989 Molecular Cloning A
Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.) A variety of host-expression vector systems may be utilized. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors; yeast transformed with recombinant yeast expression vectors; plant cell systems infected with recombinant virus expression vectors (e.g, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid); insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus); or animal cell systems infected with recombinant virus expression vectors (e.g., retroviruses,

- 28 -=

adenovirus, vaccinia virus), or transformed animal cell systems engineered for stable expression.
Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see e.g., Bitter et al., 1987, Methods in Enzymology 153:516-544). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage 7, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K
promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used.
In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et al., 1987, Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds. Wu & Grossman, 319 87, Acad. Press, N.Y., Vol. 153, pp.516-544; Glover, 1986, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684;
and The Molecular Biology of the Yeast Saccharomyces, 1982, Eds. Strathem et al., Cold Spring Harbor Press, Vols. I and H. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used (Cloning in Yeast, Ch. 3, R.
Rothstein In:
DNA Cloning Vol, 11, A Practical Approach, Ed. D M Glover, 1986, IRL Press, Wash., D.C.). Alternatively, vectors may be used which promote integration of foreign DNA
sequences into the yeast chromosome.
Eukaryotic systems, and preferably mammalian expression systems, allow for proper post-translational modifications of expressed mammalian proteins to occur.
Eukaryotic cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, phosphorylation, and advantageously, plasma membrane insertion of the gene product may be used as host cells.
Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression

-29-vectors, a natural antibody-binding peptide coding sequence may be ligated to an adenovirus transcription/-translation control complex, e.g., the late promoter and tripartite leader sequence. Alternatively, the vaccinia virus 7.5K promoter may be used.
(e.g., see, Mackett et al., 1982, Proc. Natl. Acad. Sci. USA 79: 7415-7419; Mackett et al., 1984, J.
\Tirol. 49: 857-864; Panicali et al., 1982, Proc. Natl. Acad. Sci. USA 79:
4927-4931). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver, et al., 1981, Mol. Cell. Biol.
1: 486).
Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as, for example, the neo gene. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of a natural antibody-binding peptide gene in host cells (Cone & Mulligan, 1984, Proc.
Natl. Acad. Sci.
USA 81:6349-6353). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine HA promoter and heat shock promoters.
For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with a cDNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.) and a selectable marker. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11: 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci.
USA 48:
2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:
817) genes can be employed in tk-, hgprt- or aprf cells respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77: 3567; O'Hare, et al., 1981, Proc. Natl.
Acad. Sci. USA

- 30 -78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan &
Berg, 1981, Proc. Natl. Acad Sci. USA 78: 2072; neo, which confers resistance to the aminoglycoside G-418 (Colben-e-Garapin, et al., 1981, J. Mol. Biol. 150: 1); and hygro, which confers resistance to hygrornycin (Santerre, et al., 1984, Gene 30: 147) genes.
Additional selectable genes include trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hattinan & Mulligan, 1988, Proc. Natl.
Acad. Sci. USA 85: 8047); and ODC (omithine decarboxylase) which confers resistance to the omithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-omithine, DFMO
(McConlogue L., 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.).
For stable recombinant cell lines, suitable cell types include but are not limited to cells of the following types: NIH 3T3 (Murine), C2C12, L6, and P19. C2C12 and myoblasts will differentiate spontaneously in culture and form myotubes depending on the particular growth conditions (Yaffe and Saxel, 1977; Yaffe, 1968) P19 is an embryonic carcinoma cell line. Such cells are described, for example, in the Cell Line Catalog of the American Type Culture Collection (ATCC). These cells can be stably transformed by a method known to the skilled artisan. See, for example, Ausubel et al., Introduction of DNA
Into Mammalian Cells, in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, sections 9.5.1-9.5.6 (John Wiley & Sons, Inc. 1995). "Stable" transformation in the context of the invention means that the cells are immortal to the extent of having gone through at least 50 divisions.
When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, elech-oporation, insertion of a plasmid encased in liposomes, or virus vectors may be used.
Eukaryotic cells can also be cotransformed with DNA sequences encoding natural antibody-binding peptides, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (see for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).
To interact with natural antibodies or for isolation and purification, natural antibody-binding proteins may need to be secreted from the host cell.
Accordingly a signal sequence may be used to direct the peptide out of the host cell where it is synthesized.

-31 -Typically, the signal sequence is positioned in the coding region of nucleic acid sequence, or directly at the 5 end of the coding region. Many signal sequences have been identified, and any that are functional in the selected host cell may be used.
Accordingly, the signal sequence may be homologous or heterologous to the polypeptide. Additionally, the signal sequence may be chemically synthesized using recombinant DNA techniques well known in the art.
The amount of peptide produced in the host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, HPLC
separation, immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.
When natural antibody-binding peptides are secreted from the host cells, the majority of the peptide will likely be found in the cell culture medium. If, however, the peptide is not secreted, it will be present in the cytoplasm (for eukaryotic, Gram-positive bacteria, and insect host cells) or in the periplasm (for Gram-negative bacteria host cells).
If the natural antibody-binding peptide remains in the intracellular space, the host cells are typically first disrupted mechanically or osmotically to release the cytoplasmic contents into a buffered solution. The peptide is then isolated from this solution.
Purification of the peptide from solution can thereafter be accomplished using a variety of techniques. If the peptide has been synthesized such that it contains a tag such as hexahistidine or other small peptides at either its carboxyl or amino terminus, it may be purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag or for the peptide directly (i.e., a monoclonal antibody). For example, polyhistidine binds with great affinity and specificity to nickel, thus an affinity column of nickel (such as the Qiagen nickel columns) can be used for purification. (See, for example, Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1994).
Where, on the other hand, the peptide has no tag and it is not practical to use an antibody to purify the peptide, other well known procedures for purification can be used.
Such procedures include, without limitation, ion exchange chromatography, molecular sieve chromatography, HPLC, native gel electrophoresis in combination with gel elution,

- 32 -_ and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific). In some cases, two or more of these techniques may be combined to achieve increased purity.
If it is anticipated that the peptide will be found primarily in the periplasmic space of the bacteria or the cytoplasm of eukaryotic cells, the contents of the periplasm or cytoplasm, including inclusion bodies (e.g., Gram-negative bacteria) if the processed peptide has formed such complexes, can be extracted from the host cell using any standard technique known to the skilled artisan. For example, the host cells can be lysed to release the contents of the periplasm by the use of a French press, homogenization, and/or sonication. The homogenate can then be centrifuged.
6.3.4 Antibody Inhibitors of Natural IgM Antibodies IgM inhibitors may also be antibodies that compete with natural IgMs in binding to antigen. Methods of producing antibodies are well known in the art. For example, a monoclonal antibody against a target (e.g., a pathogenic immunoglobulin or an ischemia specific antigen on a cell) can be produced by a variety of techniques, including conventional monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256:495 (1975).
Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibody can be employed e.g., viral or oncogenic transformation of B
lymphocytes. The preferred animal system for preparing hybridomas is the murine system. Hybridoma production in the mouse is a very well-established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.
Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than mouse immunoglobulin genes. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741;
Lonberg et al. International Application WO 92/03918; Kay et al. International Application 92/03917;
Lonberg, N. et al. 1994 Nature 3 68:856-859; Green, L.L. et al. 1994 Nature Genet. 7:13-21; Morrison, S.L. et al. 1994 Proc. Natl. Acad.
Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immuno. 17:33-40; Tuaillon etal. 1993 PNAS
90:3720-3724; Bruggeman et al. 1991 Eur. J. Immunol 21:1323-1326). In one

- 33 -embodiment, hybridomas can be generated from human CD5+, B-1 cells.
Alternatively, "humanized" murine hybridomas can be used that recognize cross-reactive "ischernic antigen".
Monoclonal antibodies can also be generated by other methods known to those skilled in the art of recombinant DNA technology. An alternative method, referred to as the "combinatorial antibody display" method, has been developed to identify and isolate antibody fragments having a particular antigen specificity, and can be utilized to produce monoclonal antibodies (for descriptions of combinatorial antibody display see e.g., Sastry et al. 1989 PNAS 86:5,728; Huse et al. 1989 Science 246:1275; and Orlandi et al.

86:3833). After immunizing an animal with an immunogen as described above, the antibody repertoire of the resulting B-cell pool is cloned. Methods are generally known for obtaining the DNA sequence of the variable regions of a diverse population of immuno globulin molecules by using a mixture of oligomer primers and PCR. For instance, mixed oligonucleotide primers corresponding to the 5' leader (signal peptide) sequences and/or framework 1 (FR1) sequences, as well as primer to a conserved 3' constant region primer can be used for PCR amplification of the heavy and light chain variable regions from a number of murine antibodies (Larrick et al., 1991, Biotechniques 11:152-156). A
similar strategy can also been used to amplify human heavy and light chain variable regions from human antibodies (Larrick et al., 1991, Methods: Conzpanion to Methods in Enzymology 2:106-110).
In an illustrative embodiment, RNA is isolated from B lymphocytes, for example, peripheral blood cells, bone marrow, or spleen preparations, using standard protocols (e.g., U.S. Patent No. 4,683,202; Orlandi, et al. PNAS (1989) 86:3833-3837; Sastry et al., PNAS
(1989) 86:5728-5732; and Huse et al. (1989) Science 246:1275-1281.) First-strand cDNA is synthesized using primers specific for the constant region of the heavy chain(s) and each of the K. and 2. light chains, as well as primers for the signal sequence. Using variable region PCR primers, the variable regions of both heavy and light chains are amplified, each alone or in combination, and ligated into appropriate vectors for further manipulation in generating the display packages. Oligonucleotide primers useful in amplification protocols may be unique or degenerate or incorporate inosine at degenerate positions.
Restriction endonuclease recognition sequences may also be incorporated into the primers to allow for the cloning of the amplified fragment into a vector in a predetermined reading frame for expression.

- 34 -The V-gene library cloned from the immunization-derived antibody repertoire can be expressed by a population of display packages, preferably derived from filamentous phage; to folio an antibody display library. Ideally, the display package comprises a system that allows the sampling of very large variegated antibody display libraries, rapid sorting after each affinity separation round, and easy isolation of the antibody gene from purified display packages. In addition to commercially available kits for generating phage display libraries (e.g., the Pharmacia Recombinant Phage Antibody System, catalog no.
27-9400-01;
and the Stratagene SurfZAPTM phage display kit, catalog no. 240612), examples of methods and reagents particularly amenable for use in generating a variegated antibody display library can be found in, for example, Ladner et al. U.S. Patent No.
5,223,409; Kang et al. International Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Marldand et al.
International Publication No. WO 92/15679; Breitling et al. International Publication WO
93/01288; McCafferty et al. International Publication No. WO 92/01047; Garrard et al.
International Publication No. WO 92/09690; Ladner et al. International Publication No.
WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) HUMa71 Antibody Hybridornas 3:81-85; Huse etal. (1989) Science 246:1275-1281;
Griffths et al.
(1993) Ell4B0 J12:725-734; Hawkins et al. (1992) J. Mol. Biol. 226:889-896;
Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad etal.
(1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nue. Acid Res.
19:4133-4137; and Barbas et all. (1991) PNAS 88:7978-7982.
In certain embodiments, the V region domains of heavy and light chains can be expressed on the same polypeptide, joined by a flexible linker to form a single-chain Fv fragment, and the scFV gene subsequently cloned into the desired expression vector or phage genome. As generally described in McCafferty et all., Nature (1990) 348:552-554, complete VH and VL domains of an antibody, joined by a flexible (G1y4-Ser)3 linker can be used to produce a single chain antibody which can render the display package separable based on antigen affinity. Isolated scFV antibodies immunoreactive with the antigen can subsequently be formulated into a pharmaceutical preparation for use in the subject method.
Once displayed on the surface of a display package (e.g., filamentous phage), the antibody library is screened with the target antigen, or peptide fragment thereof, to identify and isolate packages that express an antibody having specificity for the target antigen.
Nucleic acid encoding the selected antibody can be recovered from the display package

- 35 -(e.g., from the phage genome) and subcloned into other expression vectors by standard recombinant DNA techniques.
Specific antibody molecules with high affinities for a surface protein can be made according to methods known to those in the art, e.g., methods involving screening of libraries (Ladner, R.C., et al., US. Patent 5,233,409; Ladner, R.C., et al., US. Patent 5,403,484). Further, these libraries can be used in screens to obtain binding determinants that are mimeties of the structural determinants of antibodies.
In particular, the Fv binding surface of a particular antibody molecule interacts with its target ligand according to principles of protein-protein interactions, hence sequence data for VII and VL (the latter of which may be of the lc or X chain type) can be used in protein engineering techniques known to those with skill in the art. Details of the protein surface that comprises the binding determinants can be obtained from antibody sequence information, by a modeling procedure using previously determined three-dimensional structures from other antibodies obtained from NMR studies or crystallographic data. See for example Bajorath, J. and S. Sheriff, 1996, Proteins: Struct., Funct., and Genet. 24 (2), 152-157; Webster, D.M. and A. R. Rees, 1995, "Molecular modeling of antibody-combining sites," in S. Paul, Ed., Methods in Molecular Biol. 51, Antibody Engineering Protocols, Humana Press, Totowa, NJ, pp 17-49; and Johnson, G., Wu, T.T. and E.A.
Kabat, 1995, "Seqhunt: A program to screen aligned nucleotide and amino acid sequences,"
in Methods in Molecular Biol. 51, op. cit., pp 1-15.
In one embodiment, a variegated peptide library is expressed by a population of display packages to form a peptide display library. Ideally, the display package comprises a system that allows the sampling of very large variegated peptide display libraries, rapid sorting after each affinity separation round, and easy isolation of the peptide-encoding gene from purified display packages. Peptide display libraries can be in, e.g., prokaryotic organisms and viruses, which can be amplified quickly, are relatively easy to manipulate, and which allow the creation of large number of clones. Preferred display packages include, for example, vegetative bacterial cells, bacterial spores, and most preferably, bacterial viruses (especially DNA viruses). However, the present invention also contemplates the use of eukaryotic cells, including yeast and their spores, as potential display packages. Phage display libraries are described above.

-36-=
Other techniques include affinity chromatography with an appropriate 'receptor, e.g., a target antigen, followed by identification of the isolated binding agents or ligands by conventional techniques (e.g., mass spectrometry and NMR). Preferably, the soluble receptor is conjugated to a label (e.g., fluorophores, colorirnetric enzymes, radioisotopes, or luminescent compounds) that can be detected to indicate ligand binding.
Alternatively, immobilized compounds can be selectively released and allowed to diffuse through a membrane to interact with a receptor.
Combinatorial libraries of compounds can also be synthesized with "tags" to encode the identity of each member of the library (see, e.g., W.C. Still et al., International Application WO 94/08051). In general, this method features the use of inert but readily detectable tags that are attached to the solid support or to the compounds.
When an active compound is detected, the identity of the compound is determined by identification of the unique accompanying tag. This tagging method permits the synthesis of large libraries of compounds which can be identified at very low levels among the total set of all compounds in the library.
An antibody of the present invention can be one in which the variable region, or a portion thereof, e.g., the complementarity determining regions (CDR or CDRs), are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibodies generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.
Any modification is within the scope of the invention so long as the antibody has at least one antigen binding portion.
Chimeric antibodies (e.g. mouse-human monoclonal antibodies) can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted. (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496;
Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO
86/01533; Cabilly etal. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 Science 240:1041-1043); Liu et al.
(1987) PNAS

-37-84:3439-3443; Liu at al., 1987, J. Inununol. 139:3521-3526; Sun et al. (1987) PNAS
84:214-218; Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al., 1988, J. Natl. Cancer Inst. 80:1553-1559).
A chimeric antibody can be further humanized by replacing sequences of the Fv variable region which are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. L., 1985, Science 229:1202-1207 by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US
5,693,762, the contents of all of which are hereby incorporated by reference. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a'heavy or light chain: Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from 7E3, An anti-GPIVLI, antibody producing hybridoma. The recombinant DNA encoding the chimeric antibody, or fragment thereof, can then be cloned into an appropriate expression vector. Suitable humanized antibodies can alternatively be produced by CDR substitution. U.S. Patent 5,225,539; Jones et al. 1986 Nature 321:552-525;
Verhoeyan at al. 1988 Science 239:1534; and Beidler at al. 1988 J Immunol.
141:4053-4060.
Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR
substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced.
See e.g., U.S. Patent 5,225,539; Jones etal. 1986 Nature 321:552-525;
Verhoeyan et al.
1988 Science 239:1534; Beidler etal. 1988 J. Immunol. 141:4053-4060; Winter US
5,225,539.
Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539).
A humanized or CDR-grafted antibody will have at least one or two but generally all recipient CDRs (Of heavy and/or light immunoglobulin chains) replaced with a donor CDR. Preferably, the donor will be a rodent antibody, e.g., A rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the . immunoglobulin providing the CDRs is called the "donor" and the immunoglobulin providing the framework is called the "acceptor." In one embodiment, the donor

- 38 -immunoglobulin is a non-human (e.g., rodent). The acceptor framework can be a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence about 85%
or higher, preferably 90%, 95%, 99% or higher identical thereto.
All of the CDRs of a particular antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to the Fe receptor.
Also within the scope of the invention are chimeric and humanized antibodies in which specific amino acids have been substituted, deleted or added. In particular, preferred humanized antibodies have amino acid substitutions in the framework region, such as to improve binding to the antigen. For example, a humanized antibody will have framework residues identical to the donor framework residue or to another amino acid other than the recipient framework residue. As another example, in a humanized antibody having mouse CDRs, amino acids located in the human framework region can be replaced with the amino acids located at the corresponding positions in the mouse antibody. Such substitutions are known to improve binding of humanized antibodies to the antigen in some instances.
Antibody fragments of the invention are obtained using conventional procedures known to those with skill in the art. For example, digestion of an antibody with pepsin yields F(ab1)2 fragments and multiple small fragments. Mercaptoethanol reduction of an antibody yields individual heavy and light chains. Digestion of an antibody with papain yields individual Fab fragments and the Fe fragment.
In another aspect, the invention also features a modified natural immunoglobulin, e.g., which functions as an agonist (mimetic) or as an antagonist. Preferably the modified natural immunoglobulin, e.g., modified pathogenic immunoglobulin, functions as an antagonist of complement activation. Variants of the pathogenic immunoglobulin can be generated by mutagenesis, e.g., discrete point mutation, the insertion or deletion of sequences or the truncation of a pathogenic immunoglobulin. An agonist of the natural immunoglobulin can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a natural immunoglobulin can inhibit one or more of the activities of the naturally occurring form of the pathogenic immunoglobulin by, for example, being capable of binding to an ischemic specific antigen,

-39 -but incapable of activating a complement pathway. Thus, specific biological effects can be elicited by treatment with a variant of limited function.
In one embodiment, the site within the natural immunoglobulin (e.g., a pathogenic IgM) that binds Clq can be mutated such that it is no longer capable of binding Clq. For example, the CH2 domain of an IgG and the CH4 domain of an IgM, which are known to contain binding sites for Clq, can be mutated (see WO 94/29351). For example, the carboxyl terminal half of the CH2 domain of an IgG (residues 231 to 239, preferably.
within 234 to 239), which appear to mediate Clq binding and subsequent complement activation, can be mutated. As another example, Wright et al. have demonstrated that a single nucleotide change in the IgM constant region domain renders the antibody defective in initiating complement-dependent cytolysis. The single nucleotide change results in the encoding of a serine residue, rather than the normal proline residue, at amino acid position 436 in the third constant domain (Wright etal. 1988, J. BioL Chem. 263:
11221). The amino acid substitutions that can be made to antibodies in order to alter complement .
binding or activity are well known in the art (see for example, Wright et al.
1988, J. Bid.
Chetn. 263: 11221; Shulman et al. (1986), Proc. Natl. Acad. Sci. USA 83: 7678-7682; Arya et al., (1994) J. ImmunoL 253: 1206-1212; Poon et al., (1995) J. Biol. Chem.
270: 8571-8577. Accordingly, in one embodiment, the antibodies of the present invention have a mutation that alters complement binding or activity. Antibodies in which amino acids have been added, deleted, or substituted are referred to herein as modified antibodies or altered antibodies.
As will be appreciated by the skilled artisan, the methods used for causing such changes in nucleotide or amino acid sequence will vary depending upon the desired results.
Variants of a natural immunoglobulin can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a natural immunoglobulin for agonist or antagonist activity.
Libraries of fragments e.g., N terminal, C terminal, or internal fragments, of a natural immunoglobulin coding sequence can be used to generate a variegated population of fragments for screening and subsequent selection of variants of this protein.
Variants in which a cysteine residue is added or deleted or in which a residue that is glycosylated is added or deleted are particularly preferred.

-40 -Methods for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants (Arkin and Yourvan (1992) Proc. Natl.
Acad. Sci. USA
89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
Cell based assays can be exploited to analyze a variegated library. For example, a library of expression vectors can be transfected into a cell line, e.g., a cell line, which ordinarily responds to the protein in a substrate-dependent manner. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the pathogenic immunoglobulin-substrate, and the individual clones further characterized.
The invention also features a method of making a natural immunoglobulin, e.g., a pathogenic immunoglobulin having a non-wild type activity, e.g., an antagonist, agonist, or super agonist of a naturally occurring pathogenic immunoglobulin. The method includes:
altering the sequence of a natural immunoglobulin, e.g., by substitution or deletion of one or more residues of a non-conserved region, a domain or residue disclosed herein, and testing the altered polypeptide for the desired activity.
Further, the invention features a method of making a fragment or analog of a natural immunoglobulin, e.g., a pathogenic immunoglobulin having an altered biological activity of a naturally occurring pathogenic immunoglobulin. The method includes: altering the sequence, e.g., by substitution or deletion of one or more residues, of a pathogenic immunoglobulin, e.g., altering the sequence of a non-conserved region, or a domain or residue described herein, and testing the altered pol3peptide for the desired activity. In an exemplary embodiment, the modified natural immunoglobulin may have a reduced ability to activate complement. For example, one or more of the amino acid residues involved in complement binding and/or activation are mutated.
In certain embodiment, the modified natural antibody may comprise at least the CDR1 region of SEQ ID NO: 8 (SEQ ID NO: 10), or antigen binding portions thereof, and/or at least the CDR2 region of SEQ ID NO: 8 (SEQ ID NO: 12), or antigen binding portions thereof. In another embodiment, the modified antibody may comprise at least the CDR1 region of SEQ ID NO: 2 (SEQ ID NO: 4), or antigen binding portions thereof,

- 41 -._ and/or at least the CDR2 region of SEQ ID NO: 2 (SEQ ID NO: 6), or antigen binding portions thereof In an exemplary embodiment, the modified antibody comprises the CDR1 region of SEQ ID NO: 8 (SEQ ID NO: 10) and the CDR2 region of SEQ ID NO: 8 (SEQ
ID NO: 12) or antigen binding portions thereof. In another exemplary embodiment, the modified antibody comprises the CDR1 region of SEQ ID NO: 2 (SEQ ID NO: 4) and the CDR2 region of SEQ ID NO: 2 (SEQ ID NO: 6) or antigen binding portions thereof. The modified antibody may also comprise the CDR1 region of SEQ ID NO: 8 (SEQ ID
NO: 10) and the CDR2 region of SEQ ID NO: 8 (SEQ ID NO: 12) and the modified antibody comprises the CDR1 region of SEQ ID NO: 2 (SEQ ID NO: 4) and the CDR2 region of SEQ ID NO: 2 (SEQ ID NO: 6) or antigen binding portions thereof The modified natural antibody can be a human antibody having a binding affinity to the ischemic-specific antigen, similar, e.g., greater than, less than, or equal to, the binding affinity of the antibody produced by the hybridoma deposited with the ATCC, having the accession number PTA-3507. In another embodiment, the natural antibody can be a non-human antibody, e.g., a cow, goat, mouse, rat, sheep, pig, or rabbit. In an exemplary embodiment, the non-human antibody is a murine antibody. The natural antibody may also be a recombinant antibody. In an exemplary embodiment, the natural antibody is a humanized antibody. The modified natural antibody may be an IgG or IgM
antibody. In another embodiment, the isolated natural immunoglobulin possess the same antigenic specificity as the immunoglobulin produced by the hybridoma deposited with the ATCC, having accession number PTA-3507.
6.4 Screening Assay to Identib, Additional Inhibitors Other inhibitors of an interaction between a natural IgM antibody and an antigen or a component of the complement pathway may beidentified from one or more (e.g., a plurality of) test compounds, comprising (i) providing a reaction mixture which includes the natural IgIVI antibody and the antigen or the component of the complement pathway under conditions that allow binding of the natural IgM antibody and the antigen or the component of the complement pathway to occur; (ii) contacting the natural IgM
antibody and the antigen or the component of the complement pathway with one or more test compounds (e.g., members of a combinatorial library); and (iii) detecting any changes in binding of the natural IgM antibody and the antigen or the component of the complement in

- 42 -=
the presence of a given test compound relative to that detected in the absence of the test compound. A change (e.g., decrease) in the level of binding between the natural IgM
antibody and the antigen or the component of the complement pathway in the presence of the test compound relative to that detected in the absence of the test compound indicates that the test compound is an inhibitor of the interaction between the natural IgM antibody and the antigen or the component of the complement pathway.
The method can further include pre-treating the natural IgM antibodies with one or more test compounds. The pre-treated natural IgM antibodies can then be injected into mice deficient in natural immunoglobulins.
In certain embodiments, the methods is performed in vitro. In an exemplary embodiment, the contacting step is effected in vivo. hi an exemplary embodiment, the antigen is myosin. In other embodiments, the antigen is an endothelial tissue or lysate obtained from a subject e.g., a human patient with reperfitsion or ischemic injury. In another exemplary embodiment, the component of the complement pathway is a component of the classical pathway of complement. In a further exemplary embodiment, the component of the complement pathway is a Cl molecule or a subunit thereof (e.g., Clq).
In exemplary embodiments, either the natural IgM antibody or the antigen (or both) is labeled with a detectable signal, e.g., fluorophores, colorimetric enzymes, radioisotopes, luminescent compounds, and the like. The method can further include repeating at least one step, e.g., the contacting step with a second or subsequent member or members of the library.
In an exemplary embodiment, a plurality of test compounds, e.g., library members, is tested. The plurality of test compounds, e.g., library members, can include at least 10, 102, 103, 104, 105, 106, 107, or 108 compounds. In a preferred embodiment, the plurality of test compounds, e.g., library members, share a structural or functional characteristic. The test compound can be a peptide or a small organic molecule.
In one embodiment, the inhibitor is a small organic molecule that may be identified in a combinatorial library. In one embodiment, the invention provides libraries of inhibitors. The synthesis of combinatorial libraries is well known in the art and has been reviewed (see, e.g., E.M. Gordon et al., J. Med. Chem. (1994) 37:1385-1401 ;
DeWitt, S.
H.; Czarnik, A. W. Ace. Chem. Res. (1996) 29:114; Armstrong, R. W.; Combs, A.
P.;
Tempest, P. A.; Brown, S. D.; Keating, T. A. Acc. Chem. Res. (1996) 29:123;
Ellman, J. A.

-43 -Ace. Chem. Res. (1996) 29:132; Gordon, E. M.; Gallop, M. A.; Patel, D. V. Ace.
Chem.
Res. (1996) 29:144; Lowe, G. Chem. Soc. Rev. (1995) 309, Blondelle et al.
Trends Anal.
Chem. (1995) 14:83; Chen et al. J.. Am. Chem. Soc. (1994) 116:2661; U.S.
Patents 5,359,115, 5,362,899, and 5,288,514; PCT Publication Nos. W092/10092, W093/09668, W091/07087, W093/20242, W094/08051).
Libraries of compounds of the invention can be prepared according to a variety of methods, some of which are known in the art. For example, a "split-pool"
strategy can be implemented in the following way: beads of a functionalized polymeric support are placed in a plurality of reaction vessels; a variety of polymeric supports suitable for solid-phase peptide synthesis are known, and some are commercially available (for examples, see, e.g., M. Bodansky "Principles of Peptide Synthesis", 2nd edition, Springer-Verlag, Berlin (1993)). To each aliquot of beads is added a solution of a different activated amino acid, and the reactions are allowed to proceed to yield a plurality of immobilized amino acids, one in each reaction vessel. The aliquots of derivatized beads are then washed, "pooled" (i.e., recombined), and the pool of beads is again divided, with each aliquot being placed in a separate reaction vessel. Another activated amino acid is then added to each aliquot of beads. The cycle of synthesis is repeated until a desired peptide length is obtained. The amino acid residues added at each synthesis cycle can be randomly selected; alternatively, amino acids can be selected to provide a "biased"
library, e.g., a library in which certain portions of the inhibitor are selected non-randomly, e.g., to provide an inhibitor having known structural similarity or homology to a known peptide capable of interacting with an antibody, e.g., the an anti-idiotypic antibody antigen binding site. It will be appreciated that a wide variety of peptidic, peptidomimetic, or non-peptidic compounds can be readily generated in this way.
The "split-pool" strategy results in a library of peptides, e.g., inhibitors, which can be used to prepare a library of test compounds of the invention. In another illustrative synthesis, a "diversomer library" is created by the method of Hobbs DeWitt et al. (Proc.
Natl. Acad. Sci. USA 90:6909 (1993)). Other synthesis methods, including the "tea-bag"
technique of Houghten (see, e.g., Houghten et al., Nature 354:84-86 (1991)) can also be used to synthesize libraries of compounds according to the subject invention.
Libraries of compounds can be screened to determine whether any members of the library have a desired activity, and, if so, to identify the active species. Methods of screening combinatorial libraries have been described (see, e.g., Gordon et al., J Med.
Chem.,

- 44 -=
supra). Soluble compound libraries can be screened by affinity chromatography with an appropriate receptor to isolate ligands for the receptor, followed by identification of the isolated ligands by conventional techniques (e.g., mass spectrometry, NMR, and the.
like). Immobilized compounds can be screened by contacting the compounds with a soluble receptor; preferably, the soluble receptor is conjugated to a label (e.g., fluorophores, colorimetric enzymes, radioisotopes, luminescent compounds, and the like) that can be detected to indicate ligand binding. Alternatively, immobilized compounds can be selectively released and allowed to diffuse through a membrane to interact with a receptor. Exemplary assays useful for screening the libraries of the invention are described below.
In one embodiment, compounds of the invention can be screened for the ability to interact with a natural immunoglobulin by assaying the activity of each compound to bind directly to the immunoglobulin or to inhibit an interaction between the immunoglobulin and an ischemic antigen, e.g., by incubating the test compound with an immunoglobulin and a lysate, e.g., an endothelial cell lysate, e.g., in one well of a multiwell plate, such as a standard 96-well microtiter plate. In this embodiment, the activity of each individual compound can be determined. A well or wells having no test compound can be used as a control. After incubation, the activity of each test compound can be determined by assaying each well. Thus, the activities of a plurality of test compounds can be determined in parallel.
6.5 Modified Inhibitors and Pharmaceutical and Diagnostic Preparations IgM inhibitors may be modified, for example to increase solubility and/or facilitate purification, identification, detection, and/or structural characterization.
Exemplary modifications, include, for example, addition of: glutathione S-transferase (GST), protein A, protein G, calmodulin-binding peptide, thioredoxin, maltose binding protein, HA, myc, poly-arginine, poly-His, poly-His-Asp or FLAG fusion proteins and tags. In various embodiments, an IgM inhibitors may comprise one or more heterologous fusions.
For example, peptides may contain multiple copies of the same fusion domain or may contain fusions to two or more different domains. The fusions may occur at the N-terminus of the peptide, at the C-terminus of the peptide, or at both the N- and C-terminus of the peptide. It is also within the scope of the invention to include linker sequences between a peptide of

- 45 -the invention and the fusion domain in order to facilitate construction of the fusion protein or to optimize protein expression or structural constraints of the fusion protein. In another embodiment, the peptide may be constructed so as to contain protease cleavage sites between the fusion peptide and peptide of the invention in order to remove the tag after protein expression or thereafter. Examples of suitable endoproteases, include, for example, Factor Xa and TEV proteases.
Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene may be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR
amplification of gene fragments may be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments, which may subsequently be annealed to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons: 1992).
IgM inhibitors may be chemically modified based on linkage to a polymer. The polymer is typically water soluble so that the inhibitor to which it is attached does not precipitate in an aqueous environment, such as a physiological environment.
The polymer may have a single reactive group, such as an active ester for acylation or an aldehyde for alk-ylation, so that the degree of polymerization may be controlled. A
preferred reactive aldehyde is polyethylene glycol propionaldehyde, which is water stable, or mono Cl -C10 alkoxy or aryloxy derivatives thereof (see U.S. Pat. No. 5,252,714). The polymer may be branched or unbranched. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable. The water soluble polymer, or mixture thereof if desired, may be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol.
IgM inhibitors may be labeled, for example with an isotopic label to facilitate its detection using nuclear magnetic resonance or another applicable technique.
Exemplary

-46-_ isotopic labels include radioisotopic labels such as, for example, potassium-40 (40K), carbon-14 (14C), tritium (3H), sulphur-35 (35S), phosphorus-32 (32P), technetium-99m (99mTc), thallium-201 (201T1), gallium-67 (67Ga), indium-111 (1111n), iodine-123 (1231), iodine-131 (131I), yttrium-90 (90Y), samarium-153 (153Sm), rhenium-186 ('86R
e), rhenium-188 (188Re), dysprosium-165 (165Dy) and holmium-166 (166H0) .
The isotopic label may also be an atom with non zero nuclear spin, including, for example, hydrogen-1 (1H), hydrogen-2 (2H), hydrogen-3 (3H), phosphorous-31 (31P), sodium-23 (23Na), nitrogen-14 (14N), nitrogen-15 (15N), carbon-13 (13C) and fluorine-19 (19F). In certain embodiments, the inhibitor is uniformly labeled with an isotopic label, for example, wherein at least 50%, 70%, 80%, 90%, 95%, or 98% of the inhibitor is labeled. In other embodiments, the isotopic label is located in one or more specific locations within the inhibitor, for example, the label may be specifically incorporated into one or more of the leucine residues of a peptide. A single inhibitor may comprise two or more different isotopic labels, for example, a peptide may comprise both 15N and 13C labeling.
Inhibitors may be labeled with a fluorescent label. In an exemplary embodiment, an inhibitor is fused to a heterologous polypeptide sequence which produces a detectable fluorescent signal, including, for example, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), Renilla renifornzis green fluorescent protein, GFPmut2, GFPuv4, enhanced yellow fluorescent protein (EYFP), enhanced cyan fluorescent protein (ECFP), enhanced blue fluorescent protein (EBFP), citrine and red fluorescent protein from discosoma (dsRED).
Toxicity and therapeutic efficacy of natural antibody inhibitors including natural IgM antibody-binding peptides or modified natural IgM antibodies can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
Natural antibody inhibitors which exhibit large therapeutic effects are preferred. While natural antibody inhibitors or natural antibody-binding peptides that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such peptides or modified antibodies to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

- 47 -_ The data obtained from the cell culture assays and animal studies can be used in foimulating a range of dosage for use in humans. The dosage of a natural antibody inhibitor or a natural antibody-binding peptides lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration =
utilized. For any inhibitor or peptide used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
In another embodiment, a single bolus of a natural antibody inhibitor including a natural IgM antibody-binding peptide and modified natural IgM antibodies is administered prior to, contemporaneously with, or subsequent to a tissue injury. Typically a single dose injection will be a few hours, a few days or a few weeks after tissue injury.
The present invention is based in part upon the discovery that a natural IgM antibody inhibitor preventsreperfusion injury. A single unit dosage delivery can be immediately adjacent to the site of injury or can be, for example, to a vessel that drains or flows to the site of injury.
90 A natural IgM antibody inhibitor such as natural IgM antibody-binding peptide Or modified natural IgM antibody is administered initially at a point in time prior to the time of damage of the target organ or tissue. This may be a useful approach in subjects who are determined to be at risk for reperfusion injury, such as those with a history of reperfusion injury or those about to undergo surgery.
In yet another embodiment, a single bolus of a natural IgM antibody inhibitor can be followed by subsequence administrations of a natural IgM antibody inhibitor as continuous infusions or additional single bolus deliveries. The inhibitor may be administer in sequential exposures over a period of hours, days, weeks, months or years. In addition, it is contemplated that additional therapeutic agents can be combined with, administered prior to or subsequent to administration of a natural antibody-binding peptide or another natural antibody inhibitor. Other therapeutic agents that may be administered with an natural IgM
antibody inhibitor include, but are not limited to, anti-coagulation agents and complement inhibitors.

-48-=
=

The subject inhibitors may be provided in pharmaceutically acceptable carriers or formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Rernmington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. In certain embodiments, the inhibitor is provided for transmucosal or transdermal delivery. For such administration, penetrants appropriate to the bather to be permeated are used in the formulation with the polypeptide. Such penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives.
In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays or using suppositories. For topical administration, the inhibitors of the invention are formulated into ointments, salves, gels, or creams as generally known in the art.
The pharmaceutical compositions according to the invention are prepared by bringing a natural IgM antibody inhibitors into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers.
Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptablecarriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed. Washington:
American Pharmaceutical Association (1975). The pH and exact concentration of the various =
components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed.).
The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories and including, for example, alginate based pH dependent release gel caps. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses are necessary. Under certain

-49 -=
circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or by several smaller dose units and also by multiple administration of subdivided doses at specific intervals.
The pharmaceutical compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject. As discussed above, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders.
Various considerations are described, e.g., in Langer, Science, 249: 1527, (1990); Gilman et al. (eds.) (1990) .
In one embodiment, the invention provides a pharmaceutical composition useful for administering a natural antibody-binding peptide to a subject in need of such treatment.
"Administering" the pharmaceutical composition of the invention may be accomplished by any means known to the skilled artisan. Preferably a "subject" refers to a Mammal, most preferably a human.
The natural IgM antibody inhibitor can be administered parenterally, enterically, by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, rectally and orally.
Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions.
Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation = 30 excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners and elixirs containing inert diluents commonly used in the art, such as purified water. Where the disease or disorder is a = gastrointestinal disorder oral formulations or suppository formulations are preferred.

-50-60412-4434D1 =
Sterile injectable solutions can be prepared by incorporating a natural antibody-binding peptide in the required amount (e.g., about 10 Lig to about 10 mg/kg) in an appropriate solvent and then sterilizing, such as by sterile filtration.
Further, powders can be prepared by standard techniques such as freeze drying or vacuum drying.
In another embodiment, a natural IgM antibody inhibitor is prepared with a , biodegradable carrier for sustained release characteristics for either sustained release in the GI tract or for target organ implantation with long term active agent release characteristics to the intended site of activity. Biodegradable polymers include, for example, ethylene vinyl acetate, polyanhydrides, polyglycolic acids, polylactic acids, collagen, polyorthoesters, and poly acetic acid. Liposomal formulation can also be used.
Another means of delivering natural IgM antibody inhibitor (e.g., a natural IgM
antibody-binding peptide) is by delivering host cells that express natural antibody-binding peptides to a site or tissue in need of repair. Alternatively, the cells may be delivered in conjunction with various delivery vehicles, including biocompatible biodegradable or non-biodegradable sponges (e.g., collagen, or other extracellular matrix materials), cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran, polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound formed into a three-dimensional structure (see, for example, 'U.S. Pat. No. 5,858,721 to Naughton et al.
Any route of administration compatible with the active principle can be used.
The preferred is parenteral administration, such as subcutaneous, intramuscular or intravenous injection. The dose of the active ingredient to be administered depends on the basis of the medical prescriptions according to age, weight and the individual response of the patient.
The daily non-weighted dosage for the patient can be between about 2.5-5.0 mg/Kg, e.g., about 2.5-3.0 mg/Kg, about 3.0-3.5 mg/Kg, about 3.5-4.0 mg/Kg, about 4.0-4.5 mg/Kg, and about 4.5-5.0 mg/Kg. =
The pharmaceutical composition for parenteral administration can be prepared in an injectable form comprising the active principle and a suitable vehicle.
Vehicles for the parenteral administration are well known in the art and comprise, for example, water, saline solution, Ringer solution and/or dextrose.

- 51 -=
The vehicle can contain small amounts of excipients in order to maintain the stability and isotonicity of the pharmaceutical preparation.
The preparation of the cited solutions can be carried out according to the ordinary modalities.
The present invention has been described with reference to the specific embodiments, but the content of the description comprises all modifications and substitutions which can be brought by a person skilled in the art without extending beyond the meaning and purpose of the claims. The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.
6.6 Diseases and conditions that can be treated with natural Igllf antibody inhibitors IgM inhibitors, such as natural IgM antibody-binding peptides or modified natural IgM antibodies, may be used for treating a number of inflammatory diseases and conditions that are triggered by binding of natural IgM antibodies. For instance, the inhibitors may be used to treat inflammatory diseases or cOnditions such as reperfusion injury, ischemia injury, stroke, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, rheumatoid arthritis, celiac disease, hyper-IgM immunodeficiency, arteriosclerosis, coronary artery disease, sepsis, myocarditis, encephalitis, transplant rejection, hepatitis, thyroiditis (e.g., Hashimoto's thyroiditis, Graves disease), osteoporosis, polymyositis, dermatomyositis, Type I diabetes, gout, dermatitis, alopecia areata, systemic lupus erythematosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, pelvic inflammatory disease, periodontal disease, arthritis, juvenile chronic arthritis (e.g., chronic iridocyclitis), psoriasis, osteoporosis, nephropathy in diabetes mellitus, asthma, pelvic inflammatory disease, chronic inflammatory liver disease, chronic inflammatory lung disease, lung fibrosis, liver fibrosis, rheumatoid arthritis, chronic inflammatory liver disease, chronic inflammatory lung disease, lung fibrosis, liver fibrosis, Crohn's disease, ulcerative colitis, bum injury (or thermal injury), and other acute and chronic inflammatory diseases of the Central Nervous System (CNS; e.g., multiple sclerosis), gastrointestinal system, the skin

- 52 -and associated structures, the immune system, the hepato-biliary system, or any site in the body where pathology can occur with an inflammatory component.
An inflammatory condition such as reperfusion or ischemic injury may result following a naturally occurring episode, e.g., as a stroke or myocardial infarction.
Reperfusion or ischemic injury may also occur during and/or following a surgical procedure. Exemplary surgical procedures that cause can cause injury include a vessel-corrective technique selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery. In an exemplary embodiment, reperfusion or ischemic injury occurs in a cardiovascular tissue, such as the heart.
In addition, diseases or conditions that are triggered by binding of natural IgM
antibodies may be treated or prevented in a subject by removing from the subject or inactivating a natural or pathogenic IgM and/or B cells producing the pathogenic immunoglobulin (e.g., B-I cells as described herein), thereby reducing the amount of the pathogenic immunoglobulin and/or B cells present in the subject.
The methods described herein may comprise removing from the subject or inactivating a pathogenic immunoglobulin, e.g., a pathogenic IgM as described herein, and/or B-cells producing the pathogenic IgM (e.g., B-1 cells as described herein), thereby reducing the amount of the pathogenic immunoglobulin and/or B cells present in the subject.
In one embodiment, the removing or inactivating step is performed ex vivo. The pathogenic immunoglobulins or B cells can be removed by hemoperfusion.
Alternatively, the B cells can be removed using a B cell-specific antibody (e.g., an anti-B-1 antibody or an anti-CD5 antibody or anti-CD 11 G/CD 18). The pathogenic immunoglobulin, e.g., an IgM, can be removed by contacting blood from a subject with an immobilized antigen (e.g., an ischemia-specific antigen) or an immobilized anti-idiotypic antibody. The removing or inactivating step of the pathogenic immunoglobulin may be performed by administering an anti-idiotypic antibody to the subject. In another embodiment, the removing or inactivating step of the B cell is performed by administering to the subject a B cell targeting moiety (e.g., an antibody or an antigen binding fragment thereof, or an antigen) coupled to a toxin, e.g., ricin or diphteria toxin. The subject is a mammal, e.g., a rodent (e.g., a mouse) or a primate (e.g., a human). In a exemplary embodiment, the subject has sustained a reperfusion or ischemic injury following a naturally occurring episode, e.g., as a stroke, and

- 53 -the removing step is carried out within minutes, one to five hours, five to ten hours, ten to twenty hours, one to five days, following the naturally occurring episode. In another exemplary embodiment, the reperfusion or ischemie injury occurs in a cardiovascular tissue, e.g., the heart, and the reperfusion or ischemic injury is prevented and/or decreased by, removing from the subject, the pathogenic immunoglobulin, and/or the B
cells, prior to, during, and/or following the surgical procedure. For example, the removing step can be carried out at least one to five hours, five to ten hours, ten to twenty hours, or one, two or three days prior to the surgical procedure. The removing step can also be continued for appropriate time intervals during and after the surgical procedure.
6.7 Diagnostic Assays The invention further provides a method for detecting the presence of a natural IgM
antibody in a biological sample. Detection of a natural IgM antibody in a subject, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of an inflammatory disease or condition in the subject. In general, the method involves contacting the biological sample with a compound or an agent capable of detecting natural IgM antibody of the invention or a nucleic acid of the invention in the sample. The term "biological sample" when used in reference to a diagnostic assay is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.
The detection method of the invention may be used to detect the presence of a natural IgIVI antibody or a nucleic acid of the invention in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of a nucleic acid of the invention include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of polypeptides of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, inununofluoreseenee, radioimmunoassays and competitive binding assays.
Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Nucleic acids, e.g., DNA and RNA, may be used directly for detection or may be amplified, e.g., enzymatically by using PCR or other amplification technique, prior to analysis. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be

- 54 -_ = WO

made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing a nucleic acid, e.g., amplified DNA, to a nucleic acid of the invention, which nucleic acid may be labeled.
Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA
fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g.
Myers et al., Science, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., Proc. Natl. Acad. Sci., USA, 85: 4397-4401 (1985).
Agents for detecting a nucleic acid of the invention, e.g., comprising the sequence set forth in a subject nucleic acid sequence, include labeled nucleic acid probes capable of hybridizing to a nucleic acid of the invention. The nucleic acid probe can comprise, for example, the full length sequence of a nucleic acid of the invention, or an equivalent thereof, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a subject nucleic acid sequence, or the complement thereof Agents for detecting a polypeptide of the invention, e.g., comprising an amino acid sequence of a subject amino acid sequence, include labeled anti-antibodies capable of binding to a natural IgM antibody of the invention. Anti-idiotypic antibodies may be polyclonal, or alternatively, monoclonal.
An intact anti-idiotypic antibody, or a fragment thereof can be used. Labeling the probe or antibody also encompasses direct labeling of the probe or antibody by coupling (e.g., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
In certain embodiments, detection of a nucleic acid of the invention in a biological sample involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g.
U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al.
(1988) Science 241:1077-1080; and Nakazawa et al. (1994) PNAS 91:360-364), the latter of which can be

- 55 -_ particularly useful for distinguishing between orthologs of polynucleotides of the invention (see Abravaya et al. (1995) Nucleic Acids Res. 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a nucleic acid of the invention under conditions such that hybridization and amplification of the polynucleotide (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.
In one aspect, the present invention contemplates a method for detecting the presence of a natural IgM antibody in a sample, the method comprising: (a) providing a sample to be tested for the presence of a natural IgM antibody; (b) contacting the sample with an anti-idiotypic antibody reactive against about eight consecutive amino acid residues of a subject amino acid sequence from such species under conditions which permit association between the anti-idiotypic antibody and its ligand; and (c) detecting interaction of the anti-idiotypic antibody with its ligand, thereby detecting the presence of a natural IgM antibody in the sample.
In another aspect, the present invention contemplates a method for detecting the presence of a natural IgM antibody in a sample, the method comprising: (a) providing a sample to be tested for the presence of a natural IgM antibody; (b) contacting the sample with an anti-idiotypic antibody that binds specifically to a polypeptide of the invention from such species under conditions which permit association between the anti-idiotypic antibody and its ligand; and (c) detecting interaction of the anti-idiotypic antibody with its ligand, thereby detecting the presence of such species in the sample.
In yet another example, the present invention contemplates a method for diagnosing a patient suffering from an inflammatory disease or condition related to the presence of a natural Ig1\4 antibody, comprising: (a) obtaining a biological sample from a patient; (b) detecting the presence or absence of a polypeptide of the invention, e.g., a natural Ig114 antibody, or a nucleic acid encoding a polypeptide of the invention, in the sample; and (c) diagnosing a patient suffering from such an inflammatory disease or condition based on the presence of a polypeptide of the invention, or a nucleic acid encoding a polypeptide of the invention, in the patient sample.

- 56 -_ The diagnostic assays of the invention may also be used to monitor the effectiveness of a treatment in an individual suffering from an inflammatory disease or condition related to a natural IgM antibody. For example, the presence and/or amount of a nucleic acid of the invention or a polypeptide of the invention can be detected in an individual suffering from an inflammatory disease or condition related to a natural IgM antibody before and after treatment with a natural IgM antibody therapeutic agent. Any change in the level of a polynucleotide or polypeptide of the invention after treatment of the individual with the therapeutic agent can provide information about the effectiveness of the treatment course.
In particular, no change, or a decrease, in the level of a polynucleotide or polypeptide of the invention present in the biological sample will indicate that the therapeutic is successfully combating such disease or disorder.
Alternatively, polypeptides of the invention, e.g., natural IgM antibodies, can be detected in vivo in a subject by introducing into the subject a labeled antibody specific for a polypeptide of the invention, e.g., an anti-idiotypic antibody to detect natural IgM
antibodies. For example, the anti-idiotypic antibody can be labeled with a radionuclide marker whose presence and location in a subject can be detected by standard imaging techniques.
A "radionuclide" refers to molecule that is capable of generating a detectable image that can be detected either by the naked eye or using an appropriate instrument, e.g.
positron emission tomography (PET), and single photon emission tomography (SPECT).
Radionuclides useful within the present disclosure include penetrating photon emitters including gamma emitters and X-ray emitters. These rays accompany nuclear transfoiniation such as electron capture, beta emission and isomeric transition.
Radionuclides useful include those with photons between 80 and 400 keV and positron producers, 511 keV annihilation photons and acceptable radiation doses due to absorbed photons, particles and half life. Radionuclides include radioactive isotopes of an element.
-, Examples of radionuclides include 123I 125 , 1 99mTc, isF, 68Ga, 62cu, Hi/11,131i, 186-e, '"Re, 90y, 212Bi, 211At, 89sr, 166H0, 153sm, 67cu, "Cu, 100F,d, 212pb, 109pd, 67Ga, 94Tc, 105- -1, 95RU, 177Lu, 170L - u "C, and 76Br.
In one embodiment, an anti-idiotypic antibody that recognizes a natural IgM
antibody of the present invention may be labeled with 99mTc. 99'Tc, a commonly used radionuclide in Nuclear Medicine, combines desirable physical properties with a 6 hr half-

- 57 -_ life and a 140-KeV gamma energy (85% as gamma photons) and widespread availability, since it can readily be eluted from molybdenum generators.
The imaging agents of the disclosure may be used in the following manner. An effective amount of the imaging agent (from 1 to 50 mCi) may be combined with a pharmaceutically acceptable carrier for use in imaging studies. In accordance with the disclosure, "an effective amount" of the imaging agent of the disclosure is defined as an amount sufficient to yield an acceptable image using equipment which is available for clinical use. An effective amount of the imaging agent of the disclosure may be administered in more than one injection. Effective amounts of the imaging agent of the disclosure will vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual and dosimetry. Effective amounts of the imaging agent of the disclosure will also vary according to instrument and film-related factors. Optimization of such factors is well within the level of skill of a person skilled in the art.
The amount of imaging agent used for diagnostic purposes and the duration of the imaging study will depend upon the nature and severity of the condition being treated, on the nature of therapeutic treatments which the patient has undergone, and on the idiosyncratic responses of the patient. Ultimately, the attending physician will decide the amount of imaging agent to administer to each individual patient and the duration of the imaging study.
The pharmaceutically acceptable cattier for an imaging agent of the disclosure may include any and all solvents, dispersion media, coatings, antibacterial and antifimgal agents, isotonic agents, absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. The imaging agent of the disclosure may further be administered to an individual in an appropriate diluent or adjuvant, co-administered with enzyme inhibitors or in an appropriate carrier such as human serum albumin or liposomes. Supplementary active compounds can also be incorporated into the imaging agent of the disclosure. Pharmaceutically acceptable diluents; include saline and aqueous buffer solutions. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and nhexadecyl polyethylene ether. Enzyme inhibitors include pancreatic trypsin inhibitor, diethylpyrocarbonate, and trasylol. Liposomes include water-in-oil-in-water CGF
emulsions as well as conventional liposomes (Strejan et al. (1984)J.
Neuroimmunol. 7, 27).

- 58 -In one embodiment, the imaging agent of the disclosure is administered parenterally as injections (intravenous, intramuscular or subcutaneous). The imaging agent may be formulated as a sterile, pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to p1-I, isotonicity, stability, and the like, is within the skill in the art. Certain pharmaceutical compositions of this disclosure suitable for parenteral administration comprise one or more imaging agents in combination with one or more pharmaceutically acceptable sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. A
formulation for injection should contain, in addition to the cardiovascular imaging agent, an isotonic vehicle such as sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, lactated Ringer's solution, dextran solution, sorbitol solution, a solution containing polyvinyl alcohol, or an osmotically balanced solution comprising a surfactant and a viscosity-enhancing agent, or other vehicle as known in the art. The formulation used in the present disclosure may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
The invention also encompasses kits for detecting the presence of a natural IgM
antibody in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting a polynucleotide or polyp eptide of the invention in a biological sample; means for determining the amount of a natural IgM antibody in the sample; and means for comparing the amount of a natural IgM antibody in the sample with a standard.
An unlabeled compound may also be provided with instructions for labeling the compound.
The compound or agent can be packaged in a suitable container_ The kit can further comprise instructions for using the kit to detect a pc:lb/nucleotide or polypeptide of the invention.
Exemplification The invention, having been generally described, may be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way.

-59-Example 1: Mechanism of Ischemia-Reperfusion Injury This Example shows that mice deficient in the complement system were resistant to ischemia-reperfusion injury.
To examine the mechanism of ischemia-reperfusion injury, mice deficient in complement C3 were treated in the hindlimb model. The C3-/- mice were partially =
protected from injury based on an approximate 50% reduction in permeability index (see Weiser et al. (1996) J. Exp. Med. 1857-1864). Thus, complement C3 is essential for induction of full injury in this murine model.
The experiments in Weiser et al. did not identify how complement was activated.
The serum complement system can be activated by at least three distinct pathways, classical, lectin or alternative. Knowing which pathway is involved, is important as it suggests a mechanism for injury. For example, the classical pathways is activated very efficiently by IgM and IgG isotypes of immunoglobulin or by the serum recognition protein C-reactive protein. Whereas, the lectin pathway is activated following recognition of specific carbohydrates such as mannan by mannan binding lectin (MBL) (Epstein et al., (1996) Inununo18, 29-35). In both pathways, complement C4 is required in forming an enzyme complex with C2 that catalyzes cleavage of the central component C3. By contrast, the alternative pathway activates spontaneously leading to conversion of C3 to its active form (C3b) and attachment to foreign-or self-tissues. The pathway is tightly regulated as all host cells express inhibitors of amplification of the complement pathway by inactivating, or displacing the C3 convertase (Muller-Eberhard, H.J., (1988) Ann. Rev.
Bioehein. 57, 321-347). One approach for determining the pathway involved is use of mice deficient in C4, i.e., cannot form C3 convertase via classical or lectin pathways. Comparison of mice deficient in either C3 or C4 with wild type (WT) controls in the hindlimb model, revealed that C4 was also required for induction of full injury (Weiser et al.
supra). This finding was important as it suggested that antibody or MBL might be involved.
Example 2: Natural IgM Mediates Ischemia Reperfusion (I/R) Injury This Example shows that mice deficient in immunoglobulin were resistant to ischemia-reperfusion injury.
To determine if antibody was involved in mediating I/R injury, mice totally deficient in immunoglobulin, RAG2-/- (recombinase activating gene-2 deficient) were characterized along with the complement deficient animals in the intestinal model.
Significantly, the RAG-2-/- mice were protected to a similar level as observed in the

- 60 -=

=
complement deficient animals (Weiser et al. supra). Since the RAG2-/- animals are also missing mature lymphocytes, it was important to determine that the pathogenic effect was antibody dependent (Shinkai et al. (1992) Cell 68, 855-867). To confirm that injury was mediated by serum antibody, the deficient animals were reconstituted with either normal mouse sera (Weiser et al. supra) or purified IgM (William_s et al.
(1999) J. Appl. Physiol 86; 938-42). In both cases, the reconstituted RAG-2-1-mice were no longer protected and injury was restored. In the latter experiments, a model of intestinal injury was used as in this model, injury is thought to be mediated primarily by complement.
The interpretation of these results is that during the period of ischemia, neoantigens are either expressed or exposed on the endothelial cell surface.
Circulating IgMs appear to recognize the new determinant, bind and activate classical pathway of complement. While the nature of the antigen is not known, IgM rather than IgG
seems to be primarily responsible for activation of complement as reconstitution of deficient mice with pooled IgG did not significantly restore injury in the mice. An alternative hypothesis is that there is another initial event such as the MBL pathway that recognizes the altered endothelial surface, induces low level complement activation which in turn exposes new antigenic sites and the pathway is amplified by binding of IgM.
Example 3: Pathogenic IgM is a Product of B-1 cells Since a major fraction of circulating IgM is thought to represent natural antibody, i.e. product of rearranged germline genes, it is possible that mice bearing deficiencies in the B-1 fraction of lymphocytes might also be protected. B-1 cells have a distinct phenotype from more conventional B-2 cells in that they express low levels of Ig19 and CD23 and a major fraction express the cell surface protein CD5 (Hardy et al., (19 94) Immunol. Rev.: 137, 91; Kantor etal. (1993) Annu. Rev. Inununol. 11, 501-538, 1993. B-1 cells are also distinguished by reduced circulation in mice, limited frequency in the peripheral lymph nodes and spleen and are primarily localized within the peritoneal cavity.
To examine a role for B-1 cells as a source of pathogenic IgM, antibody-deficient mice (RAG-2-/-) were reconstituted with 5 X 105 peritoneal B-1 cells and rested approximately 30 days before treatment. Circulating IgM levels reach a near normal range within a month following adoptive transfer. Characterization of the B-1 cell reconstituted mice in the intestinal ischemia model confirmed that B-1 cells were a major source of pathogenic IgM

- 61 -(see Williams et al. (1999) supra). This was an important observation because the repertoire of B-1 cell natural antibody is considerably more limited than would be expected for conventional B-2 cells. Therefore, it is possible that the pathogenic antibody represents a product of the germline.
Example 4: Cr2-/- Mice are protected from Ischemia Reperfusion Injury The initial characterization of Cr2-/- knockout mice revealed an approximate 50%
reduction in the frequency of B-la or CD5 + B-1 cells (Abeam et al. (1996) Immunity 4:
251-262). Although characterization of another strain of Cr2-deficient mice did not identify a similar reduction (Molina et al. (1996)Proc. Natl. Acad. Sci. USA 93, 3357-3361).
Whether the difference in frequency of CD5 + cells was due to variation in strain background or environmental differences is not known. Despite the reduced frequency of B-1 a cells in the Cr2-/- mice, circulating levels of IgM were within the normal range. These findings suggested that the repertoire of IgM might be different in the Cr2-deficient animals. To test this hypothesis, mice in the intestinal PR model were characterized.
Surprisingly, the Cr2-/- mice were equally protected as the complete-antibody deficient mice (Figure 3). Comparison of survival over a five-day period following treatment in the intestinal model demonstrated a significant increase in mortality of the WT
compared to Cr2-deficient animals. Consistent with an increased mortality, a dramatic reduction in injury was observed in tissue sections harvested from treated WT or Cr2-/- deficient mice.
Extensive injury to the mucosal layer of the intestine was observed in WT mice or Cr2-/- mice reconstituted with pooled IgM or B-1 cells. By contrast, tissue sections isolated from treated Cr2-/- mice were similar to that of sham controls. Thus, despite normal circulating levels of IgM, the Cr2-deficient mice were protected from injury. These results not only confirm the importance of 13-1 cells as a source of pathogenic antibody but suggest that the complement system is somehow involved in formation or maintenance of the repertoire of natural antibody. For example, complement may be involved in positive selection of B-1 cells.
Example 5: Identification of Pathogenic IgMs This Example describes the generation of a specific hybridoma clone from normal B-1 cells and the identification of one clone that produces a pathogenic IgM. The pathogenic IgM was shown to restore injury in vivo to antibody deficient mice.

- 62 --= CA 02812132 2013-04-04 =
Studies in mice bearing a deficiency in complement receptors CD21/CD35, revealed that the mice were missing the pathogenic antibody. This finding was unexpected because they have a normal level of IgM in their blood. These findings led to the hypothesis that a special population of B cells termed B-1 cells are responsible for secreting the pathogenic IgM. For example, engraftment of the receptor deficient mice (Cr2-/-) with B-1 cells from normal mice restored injury, confirming the importance of B-I cells. To identify the specific antibody or antibodies responsible for injury, a panel of hybridoma clones were constructed from an enriched pool of peritoneal B-1 cells harvested from normal mice. The general approach for preparing hybridomas from enriched fraction of peritoneal cells includes harvesting peritoneal cells from mice treated 7 days earlier with IL-10 and subsequently enriched for CD23 negative B cells by negative selection with magnetic beads.
Enriched B
cells are analyzed by FACS following staining with IgM, Mac-1 and CD23 specific Mab.
The enriched population is further activated by culturing with LPS for 24 hours. Activated cells are hybridized with fusion partner myeloma cells in the presence of PEG
and grown in HAT-selective medium. Hybridomas are screened for IgM secreting clones by ELISA , and positive wells are expanded for purification of IgM.
Twenty-two IgM-secreting hybridoma clones were analyzed by pooling an equal amount of IgM product from each of the clones. Treatment of antibody-deficient mice with the pooled IgM restored injury similar to that seen with pooled IgM from serum. This finding confirmed that the pathogenic IgM was among the twenty-two hybridomas produced. By dividing the pools into two fractions, i.e., 1-11 and 12-22, and treatment mice with the two fractions, the pathogenic antibody was found to fractionate with the pool that included clone # 22. Finally, mice were reconstituted with either clone 17 or 22.
Clone 22 restored injury whereas the other clones did not (see Figure 4).
Example 6: Complement involvement in B-1 cell selection Two different models have been proposed to explain the development of B-1 cells.
The lineage hypothesis proposes that B-1 cells develop in early fetal life as a distinct population (Kantor et al. (1993) supra). Alternatively, B-1 cells develop from the same progenitors as conventional B cells but depending on their environment, i.e., encounter with antigen, they develop into B-1 or retain the B-2 cell phenotype (Wortis, H.H.
(1992) Int.
Rev. Immunol. 8, 235; Clarke, J. (1998) Exp. Med. 187, 1325-1334).
Irrespective of their origin, it is known that B-1 cells are not replenished from adult bone marrow at the same

- 63 --frequency as B-2 cells and that their phenotype is more similar to that of early fetal liver B cells or neonatal bone marrow (BM) cells. Consistent with an early origin, their repertoire tends to be biased towards expression of more proximal VH genes and N-nucleotide addition is limited (Gu et al. (1990) EMBO J 9, 2133; Feeney, J. (1990) Exp. Med 172, 1377). It seems reasonable that given the reduced replenishment by adult BM stem cells, B-1 cells are self-renewed and that antigen stimulation might be important in their renewal, expansion or even initial selection (Hayakawa et al., (1986)Eur. J
Immunol. 16, 1313). Indeed inherent to the conventional model, B-1 cells must be antigen selected.
Evidence in support of a B-cell receptor (BCR) signaling requirement for positive selection of B-1 cells comes from mice bearing mutations that alter BCR
signaling. For example, impairment of BCR signaling through CD 19, vav, or Btk dramatically affects development of B-1 cells.
By contrast, loss of negative selection such as in CD22- or SHIP-1 deficient mice can lead to an increase in B-1 cell frequency (O'Keefe etal. (1996) Science 274, 798-801; Shultz et al.
(1993) Cell 73, 1445). Recent, elegant studies with mice bearing two distinct Ig transgenes, VIII 2 (B-1 cell phenotype) or VHB1-8 (B-2 cell phenotype) support the view that B-1 cells are positively selected by self-antigens. For example, B cells expressing VH12 either alone or together with B1-8 developed a B-1 cell phenotype. Whereas, few if any B cells were identified that expressed the B1-8 transgene only. Thus, these results suggested that encounter of transgenic B cells with self-PtC resulted in expansion of those expressing VH12. Selection of B-1 cells was recently reported by Hardy et al. (1994) Immunol. Rev. 137, 91).
In their model, B cells expressing an immunoglobulin transgene specific for Thy 1.1 were selected and expanded in mice expressing the cognate antigen. By contrast, transgene +B-1 cells were not found in mice that expressed the alternative allotype Thy 1.2.
Where does complement fit into B-1 cell development? The overall reduction in B-1 a cell frequency and the more specific loss of B-1 cells expressing IgM involved in I/R injury suggests a role for CD21/CD35 in either positive selection or maintenance of B-1 a cells. One possible role for complement is that it enhances BCR signaling on encounter with cognate antigen. Biochemical studies and analysis of CD21/CD35 deficient mice demonstrate the importance of co-receptor signaling in activation and survival of conventional B cells (Carroll, M.C., (1998)Ann. Rev. Immunol. 16, 545-568;
Fearon et al. (1995)Annu.
Rev. Immunol. 13, 127-149). It is very likely that B-1 cells likewise utilize co-receptor signaling to enhance the BCR signal. For example, bacteria express typical B-1

- 64 -cell antigens such as phosphoryl choline and it is not unreasonable that coating of bacteria with complement ligand C3d would enhance crosslinking of the co-receptor with the BCR
and enhance overall signaling. Thus, antigens expressed at lower concentrations might require complement enhancement in order for the cognate B-cell to recognize it and expand or be positively selected. Another role for complement receptors is in localizing antigen on follicular dendritic cells (FDC) within the lymphoid compartment. However, since the major population of B-1 cells occupy the peritoneal tissues it is not clear if they would encounter FDC within lymphoid structures. The actual site or sites in which B-I cells undergo positive selection are not known. It is possible that they must encounter cognate antigen in early fetal development or in neonatal BM. If this is the case, it might be expected that complement receptors on stromal cells within these compartments bind antigen for presentation to B cells. It is possible that complement receptors could participate in both stages of development. First, they might enhance antigens signaling in initial positive selection. Secondly, as selected B-1 cells are replenished at peripheral sites, complement receptors might again be involved in enhancement of BCR signaling.
Figure 5 is a schematic diagram of the proposed role for complement and complement receptors in positive selection of peritoneal B-1 lymphocytes. The interaction of complement-ligand coated antigens (self- and non-self) results in co-ligation of the CD21/CD19 co-receptor and BCR on the cell surface leading to enhanced signaling and positive selection.
Example 7: Materials and Methods for Examples 8-11 Phage display peptide library and peptide synthesis A 12-mer M-13 phage display library (New England Biolab, MA) was screened by 4 rounds with MBL-beads coated with Igmcm-22 and 2 rounds with IgMcm-75 according to the manufacturer's recommendation. Phage clones were selected from the enriched pool and the nucleotide sequence of the relevant phage gene determined for at least ten clones.
Selected peptides were synthesized with purity>95% in Harvard Proteomic Core or New England Peptide, Inc. (Gardner, MA).
Binding assays ELISA was performed as described earlier (Zhang et al. (2004) PNAS USA
101:3886-91). Briefly, IgM binding to phage or phage-specific peptides was determined by

- 65 -coating a 96-well plate with saturating amounts of antigen. Subsequent to blocking, IgM was added (1 or 10 ig/ml) for 2 hr at 37 C. Plates were washed and then developed with alkaline phosphatase-labeled goat anti-mouse IgM (Sigma, MO). Binding of IgM to NMFIC-II was determined by culturing 96-well plates previously coated with specific rabbit antibody (NMI-IC-HA & B; Covance Research Products;
NMHC-II C a gift from Dr. Adelstein, NHLBI, NTH, Bethesda, MD) or pan-myosin Hc (Sigma, MO) with intestinal lysates prepared from IgMcm-22 reconstituted RAG-14- mice either sham treated or treated for ischemia as described (Zhang et al. (2004) PNAS USA 101:3886-91). Lysates were prepared as described for immune precipitation (see below). Alkaline-phosphatase labeled goat anti-mouse IgM (Sigma, MO) was then used to detect bound IgM.
Intestinal RI model Surgical protocol for RI was performed as previously described (Zhang et at.
(2004) PNAS USA 101:3886-91). Briefly, a laparotomy is performed, and a microclip (125g pressure, Roboz, MD) was applied to the superior mesenteric artery and bilateral circulation limited with silk sutures flanking a 20 cm segment of the jejunum. After 40 minutes of ischemia, the microclip was removed, and reperfusion of the mesenteric vasculature was confirmed by the return of pulsation to the vascular arcade and a change to pink color. The incision was closed, and all animals kept warm for 3 hours. Reconstituted RAG-14' animals received either IgM mixed with peptide or saline in 0.2 ml volume intravenously 30 min before the initial laparotomy. WT animals were treated with saline or peptide i.v. 5 minutes prior to reperfusion. At the end of reperfusion, the ischemic segment of the jejunum was harvested and the central 4 cm was cut for pathological analysis.
Histopathology and immuno-histochemistry analysis Cryostat sections of intestinal tissues were stained by hematoxylin and eosin (H&E) and examined by light microscopy for mucosa! damage. Pathology score was assessed based on procedure by Chiu (Chiu et al, Arch Surg 101:484-488, 1970; Chiu, et at, Arch Surg 101:478-483, 1970) that included direct inspection of all microvilli over a 4 cm stretch ofjejuneum as described. Zhang etal. (2004) PNAS
USA 101:3886-91. For immuno-fluorescence, cryosections fixed with 4% (w/v) paraformaldehyde were incubated for varying periods with either biotin-labeled anti-mouse IgM
(Becton Dickinson, CA) followed by 1 hour with streptavidin-Alexa-568 (1: 500 dilution, Molecular Probes, OR).
C4 deposition was detected by staining with FITC-labeled rabbit anti-huC4c (DAKO, CO),

- 66 -= WO 2005/085288 followed by anti-rabbit-Alexa 488 (Molecular Probes, OR). The specificity of anti-C4c staining was confirmed by staining serial sections with biotin-labeled anti-mouse C4 for 1 hour followed by streptavidin-FITC (Becton Dickinson, CA). C3 deposition was detected =
by treating with FITC-labeled anti-C3 (DAKO, CO). Sections were mounted in Anti-fade Mounting Medium with DAPI (Molecular Probes, OR).
SPR analysis of peptide binding to antibody An IgM (IgMCM-22 or IgMcm-31' ) antibody was immobilized by amine coupling in a BiaCore SPR CM5Tm chip flowcell at a density of 33,400 response units (RU) ¨33 ng/mm2 as described. Vorup-Jensen et al, PNAS USA 100: 1873-1878, 2003. Briefly, a reference flow cell was prepared by coupling of ethanolamine-HC1. Peptides, diluted in PBS running buffer, were flowed separately over the IgM-coupled surface and the reference at a rate of 10 I/min at 25 C and with the data collection rate at 10 Hz. The injection phase had a duration of 240 s (end of injection phases are marked by arrow heads in Figures 9A, B and D). Binding isotherms were derived by subtracting the response in the reference cell from the response of the IgM-coupled surface. Following each run, the surface was regenerated by injecting 40 gl 0.05% (v/v) polyoxyethylenesorbitan monolaureate/PBS.
Immune precipitation Frozen tissues were homogenized in a lysis buffer containing detergent and a cocktail of enzyme inhibitors. A sample of lysate is analyzed for total protein content (Bio-Rad kit) to insure similar levels of protein for analysis. Lysates are mixed with sepharose beads coated with rat anti-mouse IgM for 1 hr at 4 C. Subsequently, beads were pelleted gently, washed in lysis buffer and then boiled in SDS-sample buffer under reducing conditions to elute bound complexes. Samples were fractionated on 6% (w/v) polyacrylamide SDS gels and subsequently fixed and then stained with either coomassie blue or silver stain to identify protein bands.
Protein identification by tandem mass spectrometry Individual Coomassie Blue-stained bands were excised from SDS-gels, destained, and subjected to enzyme digestion as described previously. Borodovsky et al, Chem Biol 9:
1149-1159, 2002. The peptides were separated using a nanoflow liquid coupled chromatography system (Waters Cap LC) and amino acid sequences determined by tandem mass spectrometer (Q-TOF micro, Waters, MA). MS/MS data were processed and

- 67 -=

subjected to database searches using Mascot (Matrixscience) against Swissprot, TREMBL/New or the NCBY non-redundant database.
Example 8: Identification of asparagine-rich peptides that bind natural IgM
antibody We previously identified a hybridoma clone of a natural IgM antibody (IgMc 2) that binds ischemic tissue in the intestinal RI model, which support our hypothesis that ischemic tissue was altered relative to normal tissue and that neo-epitopes expressed during ischemia were targets for an innate response to self. To characterize the ligand bound by pathogenic IgMC4-22, a M-I 3 phage-display library of random 12-mer amino acid sequences was screened using beads coated with the specific IgM.
After four rounds of specific screening and two rounds with a control IgM
(clone IgMcm:15), ten phage clones were isolated and the nucleotide sequence of the relevant M-13 gene sequenced. Notably, all ten clones contain sequences rich in asparagine.
Five of the clones were selected for a relative binding assay with IgM2m-22 and one of these clones, P8, which bound with the highest efficiency was selected for further study (Table 4 and Figure 6A).
Table 4: Phage displayed peptides bind to IgmCM-22 Phage Clone Sequence SEQ ID NO:

Asparagine-rich Consensus xNNNxNNxNNNN 14

- 68 -_ A 12- amino acid peptide (P8) was synthesized based on the phage sequence and assayed for inhibition of phage P8 binding to IgMcm"22 (Figure 6B). Titration of increasing amounts of P8 peptide yielded 50% inhibition at an estimated concentration of 10 umol.
This assay indicates a reasonable overall avidity of binding based on multiple binding sites expressed on the phage surface. This result suggested that IgmCM-22 binding to phage PS
was specific for the peptide region and that the synthetic peptide could be used as a mimotope for the actual antigen. To further characterize binding of P8 peptide to IgMcNA-22 ELISA plates were coated with the peptide and tested with IgMcm"22 or control IgMcm"75 for binding (Figure 6C). At the lower concentration of 1 jig/ml, neither IgM bound above background. However, at 10 jig/ml, significantly more IgMcm-22 bound than IgMcm:75.
Together, the three results suggest that peptide P8 binds specifically to IgMavl"22 and can be used for identification of the actual antigen.
Example 9: Asparagine-rich peptide P8 blocks intestinal RI
Previous studies had demonstrated that intestinal RI in RAG-14" mice was IgM-dependent and that IgMcm"22 alone was sufficient to restore injury. As expected, reconstitution of RAG-14- mice with IgMem-22 but not saline prior to reperfusion resulted in RI (Figure 7A(i) and Figure 7B). By contrast, mixing of igmcm-22 with P8 prior to injec-tion in ischemic mice significantly blocked apparent injury (mean pathology score 6 3 versa s 31 13; p<0.001) (Figure 7Aii and Figure 7B). Previous titration of peptide with Ig4CM-22 suggested an optimal concentration of 10 IIM of P8 was sufficient to block 50-100 lag of IgMem"22 (0.1-0.2 jtM).
Immunohistological analyses of serial sections of reperfiised intestinal tissue (jejuneum) following RI identified co-localization of IgM and complement C4 and C3 within the microvilli in RAG-14" mice reconstituted with Igmcm-22 (Figure 7Ci-iv). By contrast, sections prepared from mice receiving P8 showed no evidence of IgM
or complement binding (Figure 7Cv-viii). No binding of IgM or complement was observed in Ig4cm-22 reconstituted sham controls, nor RAG-I1 mice reconstituted with control IgMc.m-31 or RAG- 14" mice reconstituted with saline only (Zhang et al. (2004) PNAS
USA
101:3886-91). Thus, P8 blocks the binding of IgMcm"22 and the induction of injury in vi-vo.
The identification of a single natural IgM antibody that could initiate RI in mice led to the general question of the number of possible neo-epitopes expressed on

- 69 -= CA 02812132 2013-04-04 ischemic tissues and the corresponding number of pathogenic clones of IgM in the repertoire of wild type (WT) mice. It might be predicted that the number of antibodies is limited based on the current understanding that the repertoire of natural IgMs is relatively small. Herzenberg et al, Inzmwzol Today 14: 79-83, discussion 88-90, 1993;
Arnold et al, J
Exp Med 179: 1585-1595, 1994.. Moreover, ligands of natural IgM antibodies are considered highly conserved structures and also are probably limited in number. To test if P8 represented a mimotope for a major self-antigen, WT mice were pretreated with P8 (approximately 10 piM) five minutes prior to reperfusion in the intestinal model. Analysis of jejuneum tissues of mice treated with saline or a control peptide prior to reperfusion identified significant injury to the microvilli as expected (Figure 7Aiii). By contrast, pretreatment of WT mice with P8 five minutes prior to reperfusion blocked apparent injury (mean pathology score 5+3 versus 24+16 and 23+19; p<0.005 and 0.027, respectively) (Figure 7A(iv) and Figure 7B). As expected, IgM, C4 and C3 co-localized within microvilli of RI treated WT mice (Figure 7Cix-xii). By contrast, no apparent deposits of IgM or complement were observed in reperfused tissues of mice administered P8 (Figure 7Cxiii-xvi). These results suggest that the number of key epitopes required to initiate RI is limited as a single peptide blocks injury and deposition of IgM and complement.
Example 10: Immunoprecipitation of self-peptides with IgMcm-22 Using the amino acid sequence of PS, a homology search of the genomic database revealed no exact matches. Therefore, an immune-precipitation approach was used to identify the ischemia antigen/antigens in RAG-1I- mice reconstituted with IgMcm-22.
RAG-11- mice were reconstituted with an optimal amount of IgMCM-22, treated for intestinal ischemia and reperfused for varying lengths of time, i.e., 0 minutes or 15 minutes before harvesting of tissues. Immune complexes of IgM-antigen were isolated from lysates of jejuneum at the varying time points and fractionated by SDS-PAGE under reducing conditions. Analysis of the stained gels indicated common bands at lower molecular weight for all time points (Figure SA). However, at 15 minutes, a band at high molecular weight (>200 kD) was identified (Figure 8A).
Protein bands were excised from stained gels, enzymatically digested and peptides =
analyzed by Tandem Mass Spec as described. Kocks et al, Mol Cell Proteonzics 2: 1188-1197, 2003. Analysis of eluted peptides indicated that the common bands at approximately

- 70 -25, 50 and 75 kDa represented immunoglohnlin light chain (Lc), and IgG heavy chain (Hc) and IgM Re, respectively. Analysis of the high molecular weight band yielded peptide sequences homologous to non-muscle myosin heavy chain (NMHC) type II isoforms A and C (Table 5).

Table 5: Mass Spectrometry Results Matched proteins Mass Spectroscopy sequenced peptides Mouse non muscle myosin heavy chain LI-A VVFQEFR (MS-1; SEQ ID NO: 39) (gi/20137006; GenBankTM Accession NO: CNGVLEGIR (MS-2; SEQ ID NO: 40) NP 071855) KFDQLLAEEK (MS-3; SEQ ID NO: 41) total score=130; peptides matched=6 KFDQLLAEEK
EQADFAIEALAK (MS-4; SEQ ID NO: 42) QLLQANPILEAFGNAK (MS-5; SEQ ID
NO: 43) Mouse non muscle myosin heavy chain CNGVLEGLR.
TI-C (g1,733638127; GenBankTM Accession VKPLLQVTR (MS-6; SEQ ID NO: 44) NO: AAQ24173) KFDQLLAEEK
total score 133; peptides matched=7 KFDQLLAEEK
EQADFALEALAK
LAQAEEQLEQESR (MS-7; SEQ ID NO:
45) QLLQANPILEAFGNAK (MS-8; SEQ ID
NO: 46) *Score is -10XLog (P), where P is the probability that the observed match is a random event. Individual ion scores >53 indicate identity or extensive homology (p<0.05).
In similar experiments using lysates prepared fiom WT mice treated for 3 hours in intestinal RI, a similar size band at 200 kD was also observed and sequence analysis identified NMHC-A and C peptides.

- 71 -Three forms of type II NMHC have been identified (A, B and C) in the mouse and human genome. Golomb et al, J Biol Chem 279: 2800-2808, 2004; Kelley et al, J
Cell Biol 134: 675-687, 1996. All eukaryotic cells express type II NMHC but the distribution of the three isoforms varies. NMHC-II A and B are approximately 85% homologous;
wherea.s NMHC-II C is approximately 65% similar. Golomb et al, J Biol Chem 279: 2800-280S, 2004. The three isotypes are highly conserved among mice and humans.
To confirm the binding of IgmCM-22 to type II NMHC, an ELISA approach was used. Plates were coated with antibody specific for each of the three forms of NMHC cif with a pan-myosin antibody to capture the relevant antigen from lysates prepared from jejuneum of RAG-14" mice. Subsequently, I
gMcm-22 or IgMcm-31 were added and then developed with a labeled anti-mouse IgM antibody. Above background binding of IgIVICM-22 but not IgMcm-3I to all three of the isoforms of NMHC-II was observed (Figure 8B). The combined sequence analysis and ELISA results show that IgMcm-22 recognizes a conserved region of the type II NMHC.
To determine whether myosin is exposed to circulating antibody following ischemia, RAG-14- mice were reconstitute with a purified IgG fraction of rabbit anti-pan myosin heavy chain. Analysis of tissues of sham treated RAG-14- following reconstitution with the rabbit IgG mice showed no evidence of injury or deposition of IgG. By contrast, ischemic RAG-14" mice reconstituted with the pan-myosin IgG prior to reperfiision developed significant RI compared to saline controls (33 11 versus 11 8, p<0.028) (Figure 8C). Accordingly, myosin is exposed to antibody in circulation following ischemia.
Comparison of the sequences of the three NMHC-II isoforms with the P8 peptide sequence identified one region of apparent homology (Table 6). All three isoforms include a motif of NxxxxNxNx that has similarity with the P8 sequence. A 12- amino acid ser-peptide (N2) sequence (NMHC-II C isoform) was prepared for further study.
Table 6: Conserved homologous sequence in NMHC-II A-C
Phage Clone Sequence P8 NGNNVNGNRNNN (SEQ ID NO:30) Consensus xNNNx(N/D)NxN(N/D)N(N/V) (SEQ ID NO:14) NMHC-II Sequence Mouse-11A (542-556) LMKNMDPLNDI (SEQ ID NO:36) Human-IA (585-596) LMKNMDPLNDI
Mouse-JIB (592-603) LMKNMDPLNDNV (N2; SEQ ID NO:38) Human-BB (592-603) LMKNMDPLNDNV

- 72 -Mouse-IIC (607-619) LMKNMDPLNDNV (N2; SEQ ID NO:38) Human-TIC (611-622) LMKNMDPLNDNV
To test that this region bound IgMcm-22 surface, plasmon resonance analysis was used (Figure 9). N2 peptide was injected over a surface coupled with IgmCM-22 (Figure 9A) and generated a robust response, which corresponded to a KID of 123+61 1.LM
(mean+SD, n=2) as calculated from the steady-state response levels (Figure 9C). In contrast, no binding was observed when a control peptide was injected over the specific IgM-coupled surface (Figure 9B) or when the N2 peptide was injected over a surface coupled with the IgMcm-3I control (Figure 9D).
Example 11: Self-peptide N2 blocks intestinal RI
To test the functional binding of N2 with pathogenic IgM, approximately 100 nmoles of the peptide (or saline control) was mixed with IgmCM-22 prior to reconstitution of RAG-14- mice and treatment in the RI model. Analysis of histology of tissue sections prepared from the reperfused jejuneum of IgMCM-22_ and saline-treated mice identified injury and deposition of IgM and complement as expected (Figure 5Ai and 5B).
By contrast, mixing the N2 peptide with IgMCM-22 prior to reperfusion was protective from injury (mean pathology score 13+8 versus 31+10; p<0.049) (Figure 10Aii and 10B). In addition, no deposition of IgM and complement was observed in reperfused jejuneum when IgMCM-22 was mixed with the N2 peptide prior to injection in RAG-14_ mice (Figure 10Ci-viii). Thus, as observed with the synthetic peptide P8, the self-peptide N2 blocked functional binding of IgMcm-22 in vivo.
To test if self-peptide N2 represents the major self-epitope in intestinal RI, WT mice were treated with approximately 40 p,M of the synthetic peptide P8 prior to reperfusion in the intestinal model. Histological analysis of tissue sections of saline treated WT mice identified injury and deposition of IgM and complement as expected (Figure 10Aiii and 10Cix-xii). By contrast, treatment of WT mice with self-peptide N2 blocked both injury (mean pathology score 8+5 versus 22+17) and deposition of IgM and complement (Figure 10Aiv; Figure 10B; Figure 10Cxiii-xvi). These results suggest that a conserved region within type II NMEIC proteins represents the major epitope for binding of natural IgM
following ischemia in the intestinal model.

-73 -Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

- 74 -SEQUENCE LISTING
<110> Immune Disease Institute, Inc, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc. .
<120> NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF
<130> 60412-4434D1 <140> CA 2,560,066 <141> 2005-03-01 <150> 60/588,648 <151> 2004-07-16 <150> 60/549,123 <151> 2004-03-01 <160> 65 <170> PatentIn Ver. 3.3 <210> 1 <211> 402 <212> DNA
.<213> Mus musculus <400> 1 caggttcagc tgcagcagtc tggggctgag ctggtgaagc ctggggcctc agtgaagatt 60 tcctgcaaag cttctggcta cgcattcagt agctactgga tgaactgggt gaagcagagg 120 cctggaaagg gtcttgagtg gattggacag atttatcctg gagatggtga tactaactac 180 aacggaaagt tcaagggcaa ggccacactg actgcagaca aatcctccag cacagcctac 240 atgcagctca gcagcctgac ctctgaggac tctgcggtct atttctgtgc aagagaagat 300 tactacggta gtgactggta cttcgatgtc tggggcacag ggaccacggt caccgtctcc 360 tcaggtaagc tggctttttt ctttctgcac attccattct ga 402 <210> 2 <211> 133 <212> PRT
<213> Mus musculus <400> 2 Gin Val Gin Leu Gin Gin Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15' Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr Trp Met Asn Trp Val Lys Gin Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Gin Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gin Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Glu Asp Tyr Tyr Gly Ser Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser Gly Lys Leu Ala Phe Phe Phe Leu His Ile Pro Phe <210> 3 <211> 15 <212> DNA
<213> Mus musculus <400> 3 agctactgga tgaac 15 <210> 4 <211> 5 <212> PRT
<213> Mus musculus <400> 4 Ser Tyr Trp Met Asn <210> 5 <211> 57 <212> DNA
<213> Mus musculus ,<400> 5 cagatttatc ctggagatgg tgatactaac tacaacggaa agttcaaggg caaggcc 57 <210> 6 <211> 17 <212> PRT
<213> Mus musculus <400> 6 Gin Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly <210> 7 <211> 324 <212> DNA
<213> Mus musculus <400> 7 attgtgatga cccagtctgc tgcttcctta gctgtatctc tggggcagag ggccaccatc 60 tcatacaggg ccagcaaaag tgtcagtaca tctggctata gttatatgca ctggaaccaa 120 cagaaaccag gacagccacc cagactcctc atctatcttg tatccaacct agaatctggg 180 gtccctgcca ggttcagtgg cagtgggtct gggacagact tcaccctcaa catccatcct 240 gtggaggagg aggatgctgc aacctattac tgtcagcaca ttagggagct tacacgttcg 300 gaggggggac caagctggaa ataa 324 <210> 8 <211> 107 <212> PRT
<213> Mus musculus <400> 8 Ile Val Met Thr Gin Ser Ala Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gin Gin Lys Pro Gly Gin Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro 65 70= 75 80 Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gin His Ile Arg Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys <210>9 <211> 45 <212> DNA
<213> Mus musculus <400> 9 agggccagca aaagtgtcag tacatctggc tatagttata tgcac 45 <210> 10 <211> 15 <212> PRT
<213> Mus musculus <400> 10 Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His <210> 11 <211> 21 <212> DNA
<213> Mus musculus <400> 11 cttgtatcca acctagaatc t 21 <210> 12 <211> 7 <212> PRT
<213> Mus musculus <400> 12 Leu Val Ser Asn Leu Glu Ser <210> 13 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified base <222> (1)..(3) <223> a, c, g or t <220>
<221> modified base <222> (13)..(15) <223> a, c, g or t <220>
<221> modified base <222> (22)..(24) <223> a, c, g or t <400> 13 nnnaayaaya aynnnaayaa ynnnaayaay aayaay 36 <210> 14 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <220>
<221> MOD RES
<222> (1) <223> Variable amino acid <220>
<221> MOD RES
<222> (5)¨

<223> Variable amino acid <220>
<221> MOD RES
<222> (8)¨

<223> Variable amino acid <400> 14 Xaa Asn Asn Asn Xaa Asn Asn Xaa Asn Asn Asn Asn <210> 15 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (18) <223>a, c, g or t <220>
<221> modified_base <222> (27) <223> a, c, g or t <220>
<221> modified_base <222> (33) <223> a, c, g or t <400> 15 tayaayaaya ayaayggnaa ytayacntay mgnaay 36 <210> 16 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 16 Tyr Asn Asn Asn Asn Gly Asn Tyr Thr Tyr Arg Asn <210> 17 <211> 36 <212> DNA
<213> Artificial Sequence =
<220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified base <222> (3) <223> a, c, g or t <220>
<221> modified_base <222> (9) <223> a, c, g or t <220>
<221> modified base <222> (12) <223> a, c, g or t <220>
<221> modified base <222> (18) <223> a, c, g or t <220>
<221> modified_base <222> (21) <223> a, c, g or t <220>
<221> modified_base <222> (24) <223> a, c, g or t <400> 17 gcnaayacnm gnaayggngc nacnaayaay aayatg 36 <210> 18 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 18 Ala Asn Thr Arg Asn Gly Ala Thr Asn Asn Asn Net <210> 19 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (9) <223> a, c, g or t <220>
<221> modified_base <222> (12) <223> a, c, g or t <220>
<221> modified_base <222> (21) <223> a, c, g or t <220>
<221> modified_base <222> (24) <223> a, c, g or t <220>
<221> modified_base <222> (27) <223> a, c, g or t <400> 19 tgygaywsnw sntgygayws ngtnggnaay tgyaay 36 <210> 20 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 20 Cys Asp Ser Ser Cys Asp Ser Val Gly Asn Cys Asn <210> 21 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (15) <223> a, c, g or t <220>
<221> modified_base <222> (18) <223> a, c, g or t <220>
<221> modified_base <222> (24) <223> a, c, g or t <220>
<221> modified_base <222> (33) <223> a, c, g or t <400> 21 tggaayaaya ayggnmgnaa ygcntgyaay gcnaay 36 <210> 22 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 22 Trp Asn Asn Asn Gly Arg Asn Ala Cys Asn Ala Asn <210> 23 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (9) <223> a, c, g or t <220>
<221> modified_base <222> (12) <223> a, c, g or t <220>
<221> modified base <222> (15) <223> a, c, g or t <220>
<221> modified base <222> (21) <223> a, c, g or t <220>
<221> modified base <222> (36) <223> a, c, g or t <400> 23 cayaaywsna cnwsnaaygg ntgyaaygay aaygtn 36 <210> 24 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 24 His Asn Ser Thr Ser Asn Gly Cys Asn Asp Asn Val <210> 25 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified base <222> (6) <223> a, c, g or t <220>
<221> modified base <222> (12) <223> a, c, g or t <220>
<221> modified base <222> (15) <223> a, c, g or t <220>
<221> modified base <222> (18) <223> a, c, g or t <220>
<221> modified base <222> (21) <223> a, c, g or t <220>
<221> modified base <222> (24) <223> a; c, g or t <220>
<221> modified _base <222> (30) <223> a, c, g or t <400> 25 aaywsnaayw snmgntanaa nwsnaaywsn aayaay 36 <210> 26 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 26 Asn Ser Asn Ser Arg Tyr Asn Ser Asn Ser Asn Asn <210> 27 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified base <222> (6) <223> a, c, g or t <220>
<221> modified_base <222> (30) <223> a, c, g or t <220>
<221> modified_base <222> (33) <223> a, c, g or t <400> 27 aarmgnaaya aycayaayaa ycayaaymgn wsnaay 36 <210> 28 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 28 Lys Arg Asn Asn His Asn Asn His Asn Arg Ser Asn <210> 29 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (6) <223> a, c, g or t <220>
<221> modified_base <222> (15) <223> a, c, g or t <220>
<221> modified_base <222> (21) <223> a, c, g or t <220>
<221> modified_base <222> (27) <223> a, c, g or t <400> 29 aayggnaaya aygtnaaygg naaymgnaay aayaay 36 <210> 30 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 30 Asn Gly Asn Asn Val Asn Gly Asn Arg Asn Asn Asn <210> 31 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (6) <223> a, c, g or t <220>
<221> modified_base <222> (9) <223> a, c, g or t <220>
<221> modified_base <222> (24) <223> a, c, g or t <220>
<221> modified_base <222> (33) <223> a, c, g or t <400> 31 aaygtngcna aycayaayaa ywsnaaycay ggnaay 36 <210> 32 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 32 Asn Val Ala Asn His Asn Asn Ser Asn His Gly Asn <210> 33 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified base <222> (3) <223> a, c, g or t <220>
<221> modified base <222> (24) <223> a, c, g or t <220>
<221> modified base <222> (27) <223> a, c, g or t <220>
<221> modified base <222> (33) <223> a, c, g or t <400> 33 wsntayaaya ayaayaayca ygtnwsnaay mgnaay 36 <210> 34 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 34 Ser Tyr Asn Asn Asn Asn His Val Ser Asn Arg Asn <210> 35 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (3) <223> a, c, g or t <220>
<221> modified_base <222> (21) <223> a, c, q or t <220>
<221> modified_base <222> (24) <223>a, c, g or t <400> 35 ytnatgaara ayatggaycc nytnaaygay aayath 36 <210> 36 <211> 12 <212> PRT
<213> Artificial Sequence <220>
, <223> Description of Artificial Sequence: Synthetic peptide <400> 36 Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Ile <210> 37 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic DNA
sequence <220>
<221> modified_base <222> (3) <223> a, c, q or t <220>
<221> modified_base <222> (21) <223> a, c, g or t op <220>
<221> modified base <222> (24) <223> a, c, g or t <220>
<221> modified base <222> (36) <223> a, c, g or t <400> 37 ytnatgaara ayatggaycc nytnaaygay aaygtn 36 =
<210> 38 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 38 Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val <210> 39 <211> 7 <212> PRT
<213> Mus musculus <400> 39 Val Val Phe Gin Glu Phe Arg <210> 40 <211> 9 <212> PRT
<213> Mus musculus <400> 40 Cys Asn Gly Val Leu Glu Gly Ile Arg <210> 41 <211> 10 <212> PRT
<213> Mus musculus <400> 41 Lys Phe Asp Gin Leu Leu Ala Glu Glu Lys <210> 42 <211> 12 <212> PRT
<213> Mus musculus <400> 42 Glu Gin Ala Asp Phe Ala Ile Glu Ala Leu Ala Lys <210> 43 <211> 16 <212> PRT
<213> Mus musculus <400> 43 Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys <210> 44 <211> 9 <212> PRT
<213> Mus musculus <400> 44 Val Lys Pro Leu Leu Gin Val Thr Arg <210> 45 <211> 13 <212> PRT
<213> Mus musculus <400> 45 Leu Ala Gin Ala Glu Glu Gin Leu Glu Gin Glu Ser Arg <210> 46 <211> 16 <212> PRT
<213> Mus musculus <400> 46 Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys <210> 47 <211> 7355 <212> DNA
<213> Mus musculus <400> 47 tgggcagggc acggaaggct caagaacctg acctgctgca gcttccagtc tcgcgttcgc 60 o8f7E oqpbuebppb qopobbqp42 ebpubpoqob 4o5eebppbe ebbqbebpoo b5qqopb4o5 ozD,E bpDbqq6p6b e5bebbee6P eoo6bqobec 5Tebepo4o5 e6po6e4pbe obo6bpoo4D
09Ec be5qp644eb pooPbqbeo4 oppbe3P334 ou6P6bbeb6 qobpe36oqb opopbeubpb 00EE b44bebbpob bebeDbeebe 5bebbbe4bo D4006pbebe ebbqoaeboo ep4eb4euo5 CiZE bpbopobppo epbepogobP Poo6b400bP beeooqbPeb ebb-ebb-26pp bb4eo400pe ogTE ooP4opoq.qp pb4obeqbeb eoPbePbb4o bqoe2Pbppb ebbpeoobbq oPpeobqopp ozTE 6poppb6p6b qeo4p34pbp ope6bebbe6 b4Dpepbpp6 qobeepabbe bpoppopb4.6 090E bppopb4436 eob4obeebe obboopfio6e be6bebbebb e6b44beobe bbe6443ee6 .
000E beopgeoe2b eob2ob4ebe Pb2PbuPbeb oobbpobqoo pq.bpoobqob obpbbpbbeb 0176z bebbeb54bb bpoobbe654 oopb4poob4 oqebp5b2bb qobebbeobe ebeebobpop oggz bqogb000bb booqobebbe bl.obbeboob qb4b4obebp ppbp66obbe 36qDbpobeb 038 bp31436pob 4pEreebpbeo ar4P3436e3 q3qbeob4e0 opbpbb4ebp bepe5-4366e.

Pbebeobq obb434eppe ebebEboqqb bpepopb4o2 ebbobbpbbe poo5P44b4o ooLz beb4pb5ebq poebeegepo qoePbqqbqo 000bppoqbb pPoopo44o4 obbeb64b.54 of79z bpobbqopeo 8ob4ob5eoq ooeqbobqob qbqopebbeb porqooqbbe eblepobooe oggz b4obeopeob pobbebepoo b4440065pe bbeoobbi.00 24obbbbpob 4obqo3bbeo OZSZ 344pbb44P0 4poq.b4pboo poqpbepb4o oebbbobebe ebbebb400e opobpi.obqb 0917z ebbeo.5.650o qq.o.44b4bee pDbebeopbb o4po5oopq5 qopepobeop bqqobebblq o0D,z oobepeo4pb quo4obgbqb 4bo5epobee obbqebbqeo ggobbbeebo oporpooqose of7Ez op000po400 4p6ebqeq5b ebuobboo4q 0P66epoqqo .4601.660p3p p33344-4o6b 08ZZ beooboob40 4ebboo4eob bbeb4googb obb4epob4o bob4o6eooe bb4ob4bb44 ozzz opob000ebb 4oeppobboo bbeebeetPb Tpoopeoopq qpoi.Pobqob o54boq.qo2p ogTz DOD3PP3DU4 pPb6a6446D Poo5b4eoqo bpeoobbqob epbe5bevop q5qobeoebb OOTZ 04640e4b0D 4464p3bb5y p66o3oP6ep oq40354664 poeqpeobeo e6pbo3464P
OVOZ ebb43bb4be eo3ebb443b 6q4uo4ebb3 4ebbqb4ebb ebbqb4obe b4o4346444 0861 bpeopbeoqo o4be33Poq4 0.6-436oupob.oqpopeoebo eebqqoopop 6.64.2o2t6pe 0z6T b4pbgobbqb eboebqobap eq.e4oebbgb beeobboobq eqopooTeqq. pabqp444p5 0981 1.366Peop5t. eeb4ouP36p Poop62ebuo 344beepopo poo3eo6.6.6e o5pbbeD6qb 008T b4.66pp6ebb 46344obe5e eppb4pe3ob bue4004446 64ob4befibe b4a6p43b4o ObLT pobb4o042o bbeoopoogb bbobboobpe bebg4pogoo Ebb o5 3bpob400eb oggT b400bbo44o eboquoqi.op eb5qbPbo4e obbbebebob pooporbpbbe b5eobebb4o 0z91 oq.poqqbqeo OPDPOOPPOq 4b4obeobP3 bqobppbpbo PEDOPOP4OP poTeob464o 09ST beDbeboqqo p4aee6404p 6q4434Pbe6 444 66436o qe3e6b4304 ebbbo4e444 00ST eo4Dobobbb eobbpbe2oD ebeeD26.643 4obuePpeeo quobo44obq 6.64005;36D
oppi og4b4e6bo6 ebTeqope4o 5bpPoob64q op5bebT4po p644.4opb4o 66eobe5eep 08E1 40u6o5o55 ee6pD64bge qopbebeobb bq6bpuoqeo boeopooeoq ooqeobbebe ozET ope34qopb3 oeb464pPoq P6Mb4opqo 3pp33qb466 epppoqobqo bppeoePoeb 09Z1 bo3bqe334b obbeopebqo epeebbobeb beebeeog43 3b44e3eep6 .644obeo44o 0OZT oqbbbbqoqo 4po4bbbo64 ob4qp6b6qe buobeb4266 ebeoppguq6 b54p44epbP
of/TT b4po3bbebb gpPop5p55p oog4b4pop6 bePoPbbeob pobbb4opoq. p3o2o45oPo 0801 6bbopepoqb 4Do4-40.63oP 4uevoeeoPq epobPb6446 looqoqpbqo pfieptqopeo OZOT epbebbo3b6 6.6q3464364 33 3E3; 34p3poo443 opb6obebbp beeepobeep 096 Dboo424obq boqoqeeube bb.404404e4 43ebeb4gpo pepa64.6044 bqqpop4obb 006 qepoq.bgpbq 4qoPeoqp4b 044eDqq-ePP 455044'2504 ogooqoppoe b4ep6ep5qb OD'8 bopbeepobo peebbqqqoo bbebeq.00qe g000ppoobb eopqobqobe o5b3bebb4g 08L 0ebb666voo pbbpp6pp3b pbepoPopoq 33433bb4b4 ppeobbqope 4bp334p346 on eeebeeoDeo eebebeoe62 Pbbbeobebb 4o4bebbbb6 oeDbqbqopq epo4b2ogeb 099 epbbbooebb Pobqeb4p3b Pb6o3P433b qoP4ebe3po gpooboeqoq. PDPODOOPOD
oog b4p5pb3e3b bPbPpbepob 5bPeoe4b4p bp.b.b4.504eb ebbebpoqoe qoqpo33b4o urG 3pe6eeqe44 3o3ee34P3q. bb4bqbqoqq. bqoobbeoq4 e43oP3pl3q P4.40655234 = 08f7 3p43pleb35 pbbPeoqoop P3e3b4ob4b bo44obeebo Pe343pb4b3 po4obebeob ozt7 bqeoebbebb 4bbeepoq.oq qbP2303P33 32Pbqebee6 pool.eopboe 6bepopebqb ogE beebqbbeeb epbbbqeebp beqbbgobeb elbqq.poobb ebeebebbbq bbebbpbbee ooc oqoobeq.obe ooPebqqqab bqeebPeobe ooTloob4bb 54eq.bb4qbp ebepo3b4ob ot,z bb4opb4obp p333bb4ob3 33pe4Pe342 3443pepeeq. ebb4b4eq34 opegbppopb 081 eob43bbe3b eo43554Poo pogbeeoboa bb4004bbe3 4q515po3oe5 eobbbo3oo4 ozT 4bq33b3beo opebeebboq opooqbeePb etoqobobeb opoboo5obo ob0000p000 0069 e5bee3eopq qopfyi.oq5P.E, 34qabeTeqo qoepoopoo6 4.6qobv5D45 Bqbb6eeDo6 0D,e9 55b4De5bpq poqoqoo646 bqoqobabqb qpPopofiebb 4abbbeeop4 EleutPoobp 09/.9 obbqoobbbe Dbqqa2b6be Pqq5b4Ppq4 4P4P4PePOO pabbbpqpqa p3bpo3p434 0n9 qobb4E633.4 qopbeopupo b6eppb-eqp4 peo3e6beD4 pobbbeopbp opeppobbal 0999 o3e3bb43pq booPbeopbb ep3ofq4333 433304333p bleupbqbET. 343463oeee 0099 4e0q0P63343 0436qoq3pb 4E643235e 6bb;044poo 43e33o3334 eebbb4o4oe Of7S9 3bbeib4p3ee be3b466643 46404oDbet, beebeo34bb q424o335b6 403344330D , 08179 obb4e4o3ob qopei.eqop eeqbboepeo epqepobbqq 5q36gooppo ogbooppoqb 0z179 3p334bga5b oqopeboopo 4pooeqqb45 24be4oqop5 buoqabe4e6 4444ebupeq 09E9 utpoqq04b4 444P434ePb 4e4pq4qqbe b2popo5b24 bebb4qppob bobbbeebep 00E9 365645Elq5.6 boeobpppbq pobqqopqop q_bg4oq55bp oepoo2b4e5 boobbuoqob 09 bqobbepo45 ebeeepoe4P 5404pebpbq qqopouqpoo qop45uopq4 oDobeob4o6 0819 q043DT4o55 qqeobbbubo 3pq4pobbeu oDo4o34poo poqbgpoob 43.435qopece 019 Eqqop6qopo 3POP001030 PP00000430 0'400640435 53PPPOPM4 pabobbpoop 0909 Beo5qp040.4 qobebbegee 5.436poMpe opEgeboobb ElbqebpobPP Pqbboeboqb 0009 bpbbebDebe oqabqopbo6 b4Dpo5beee bboqqbqqep booboqDpb4 bpqbqqqeop 0P68 b4oppElbaq bobbebloee popefieeb4o 334obpo4b6 eb3b33ep64 p4ob4pb4ob 0888 Daefiebppeo 084pbpu664 obeb4bobeo Bqobeebboo boe3-400bqu poobBbobeo U8S 3obbebbeb2 eb43bbebbe be4obeabbo eee44obe3b eeb4035300 e3o4bpbbee 09L8 oeb4o5beo3 ebbeeo4qbe oeebboboee bbubbobubo ebbebbqbbe obqDbqobgb ping oebb2e6405 ee5e2bebbo ebb3DB3b4b be3b2eop4o obpo5b2o3b obpbbueope 0f79s bsbo22Debb 43bPoeebbe aq.obPoPob 44eee23obb ebbqqoobbo boTepoqopb 088 beeou4epeo 34b2up46qo Eqbpbebb4p p-e5thob4ob ppoo5bpeog obpbbeeoPu 0zgs beoobouebb 4obea5eaeb obo542e5e5 gesbubeop ofopoofmob oppb54o3Pp 09fi8 bqopeboopo -2.2-egeeeooe boTebeobqo opPoobbueb ?e6qab5oqu 5opeoqe54o 00; babbopoupo bbbpopubbP 56E16438Pb 5p6be55435 goopbqqeob DooE162654o 0pEg p6o5bobppb e5bebeqqe3 5eqopobb6b speobbqbpo bpoeeooboq efipbTetqob 08Z8 b4obpboebb boeebbeoPe opobbeoqbp bpsqobqbob Etqabqobeo bbqopPbbpb OZZg beo54obepq Tebqubpboo E6P6E.Te3bp bepbqobpeb ee5e6qeebe EbeppobbPo 0918 bobbqop4pb ebbebbb000 goobabobae pubopbbwb PbbbobTeo6 qopMePbge 00Tg beopobbepq qobppbbob4 obeopeeoqe pobbpbepE6 booppEtueqP PoobpoPoeb ()PDS 44-eopoupa, Pbbgoopbbe eb4a4e5bqe be.664pee2b eeoboeoboo bbgeoobbqe 08617 ooqobobeob eebbebefqe bbebb4obeb bobbebb4eb ebbbobqbEle oebeD45bqo 0Z617 beDbeebeeb eebebbebob ebepeebgeb bboobbbeob goqebbbobe b4qqbeopob 098P beeb4v035b vobqopeebq 6bp6bwobo o43.6Poob4 eBbubbopDp Bbeo54obpb 00817 4eb5ebbqo6 0bbe5b43be opoebpp54? b5 b56 Pobuobebb4 qpobboobpe 017Lp opT5pbe5b qobbopoo4 5.45pbeeobb 5-4bopb4pbb Peooqobpbq eoqpoebbub 089D, bqebebbopo booqqbpobe PoPuo4obbo bee&go6pbe 0b6ue6ceo6P bbgepabbET) 09t7 5Pbqqobobb bpopb5.4peo qp4o6p6beP poe6Pbbep5 Pb4boopb5e Eq.o6626qa6 098f, ebou5q6o.6 ebbe6?obq2 462Poo55pq oqepoPE)put, ebbuboobeq op4o6pooP5 oogD, 3446eubpub eobee8epue bbqooPepoq ombobebeob boo P bbqopebqql, 0D,7 bqobqoopbo e6bqa5e5bP obpobqoffo eppbsepoef, eubpbbqobe eqeboewob 08E17 qobbqbbepb ebbet4q3b6 obppobebqo obbPpbbqqo ebbppbpoqq obbebbobeP
up7 bobbebbebe 3bqoubet64 pob4bbbel5 4bEopb5ef6 Tebpebepbe pb4popboop 09Z17 b4b6e330bq popqoboeDo 5o4pbPo5ep 5p6b44opuo bobppoobbe bfipbbpbbeb 00n, bebbqobea6 efibbeaqq.Do 4peepPebeb 4ebbab6qeb pobeeogo6P eopeolyebqo 0PT17 o5eb4obppb eobbooeebe bbebElepoqo 6446ebbeop peoe6beoq4 obeapogbeb 080f7 b405381.040 443ebbeebo e44Dbeepbe opqbeeobeo eb4o4bepob e4qopqp4bb uo ope.64546po e5b4Dee544 15b2o5435ee opeogbbpeo eboobb4De2 bopepbobqb 096E obp52beb55 eb3beo4gbe Poqbbeob4o eube2ob4ob Po6obbpbb4 bbppbePpbo 006E beuEobpbe 34Dpbobbbe Ppbb2e3b43 bqopobelePb qUeb4eeop bb4obbpbb osc bbobe642e5 ebbqDoppbP obeebbbe 5,254qoppeg obPeeeqbbb obeeboebeD
08LE bebb4qbeo4 ebeof&gobe 6bebb45q36 Ecepeoqpeob ePbeobbebq PEIPHeooge uti be3o35bebq =oebpeoo 5.bbov.b5e6 5qoTo2Eyee5 eebqoo4uob ebqb5ebb2o 099E 625qbobepb o4b5-86.4obe 662Dbuopo6 ;of:60'8034o u661.3.bouoe bbubbqobeb 009 ep2beeb4D6 3bbeb.64o6e bbebebbbqo qebbboepeb upbeebeboo beeeqeebbe 0178 304006e605 ebboqbebbq poebbebbeo oqobebqoqo qebpoqopee Ã643pebe5o tgcttttgaa agaaaaaaaa aggttttatt tttcccttct tgtagtaagt gctctagttc 6960 tgggtgtctt cactgccttg ccctggaact gtgtttagaa gagagtagct tgccctacaa 7020 tgtctacact ggtcgctgag ttccctgcgc actgcacctc actgtttgta aatgctgtga 7080 ttaggttccc ttatggcagg aaggcttttt ttttcttttt ttttttcttt tctttttttt 7140 ttttttaaag gaaaaccagt caaatcatga agccacatac gctagagaag ctgaatccag 7200 gtcccaaagg cgctgtcata aaggagcaag tgggacccgc accccttttt ttatataata 7260 caagtgcctt agcatgtgtc gcagctgtca ccactacagt aagctggttt acagatgttt 7320 ccactgagcg tcacaataaa gagtaccatg tccta 7355 <210> 48 <211> 1960 -<212> PRT
<213> Mus musculus <400> 48 Met Ala Gin Gin Ala Ala Asp Lys Tyr Leu Tyr Val Asp Lys Asn Phe Ile Asn Asn Pro Leu Ala Gin Ala Asp Trp Ala Ala Lys Lys Leu Val Trp Val Pro Ser Ser Lys Asn Gly Phe Glu Pro Ala Ser Leu Lys Glu Glu Val Gly Glu Glu Ala Ile Val Glu Leu Val Glu Asn Gly Lys Lys Val Lys Val Asn Lys Asp Asp Ile Gin Lys Met Asn Pro Pro Lys Phe Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Lys Glu Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Asn Leu Pro Ile Tyr Ser Glu Glu Ile Val Glu Met Tyr Lys Gly Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Thr Asp Thr Ala Tyr Arg Ser -Met Met Gin Asp Arg Glu Asp Gin Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gin Tyr Leu Ala His Val Ala Ser Ser His Lys Ser Lys Lys Asp Gin Gly Glu Leu Glu Arg Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Asn Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Her Arg Ala Ile Arg Gln Ala, Lys Glu Glu Arg Thr Phe His Ile Phe Tyr Tyr Leu Leu Ser Gly Ala Gly Glu His Leu Lys Thr Asp Leu Leu Leu Glu Pro Tyr Asn Lys Tyr Arg Phe Leu Ser Asn Gly His Val Thr Ile Pro Gly Gin Gin Asp Lys Asp Met Phe Gin Glu Thr Met Glu Ala Met Arg Ile Met Gly Ile Pro Glu Asp Glu Gin Met Gly Leu Leu Arg Val Ile Ser Gly Val Leu Gin Leu Gly Asn Ile Ala Phe Lys Lys Glu Arg Asn Thr Asp Gin Ala Ser Met Pro Asp Asn Thr Ala Ala Gin Lys Val Ser His Leu Leu Gly Ile Asn Val Thr Asp Phe Thr Arg Gly Ile Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Glu Gin Ala Asp Phe Ala Ile Glu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Met Phe Arg Trp Leu Val Leu Arg Ile Asn Lys Ala Leu Asp Lys Thr Lys Arg Gin Gly Ala Ser Phe Ile Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Asp Leu Asn Ser Phe Glu Gin Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gin Gin Leu Phe Asn His Thr Met Phe Ile Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Glu Trp Asn Phe Ile Asp Phe Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Lys Pro Ala Gly Pro Pro Gly Ile Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys Val Val Gin Glu Gin Gly Thr His Pro Lys Phe Gin Lys Pro Lys Gin Leu Lys Asp Lys Ala Asp .Phe Cys Ile Ile His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Asp Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Ile Ala Thr Leu Leu His Gin Ser Ser Asp Lys Phe Val Ser Glu Leu Trp Lys Asp Val Asp Arg Ile Ile Gly Leu Asp Gin Val Ala Gly Met Ser Glu Thr Ala Leu Pro Gly Ala Phe Lys Thr Arg Lys Gly Met She Arg Thr Val Gly Gin Leu Tyr Lys Glu Gin Leu Ala Lys Leu Met Ala Thr Leu Arg Asn Thr Asn Pro Asn Phe Val Arg Cys Ile Ile Pro Asn His Glu Lys Lys Ala Gly Lys Leu Asp Pro His Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Val Val She Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ser Ile Pro Lys Gly She Met Asp Gly Lys Gin Ala Cys Val Leu Met Ile Lys Ala Leu Glu Leu Asp Ser Asn Leu Tyr Arg Ile Gly Gin Ser Lys Val She She Arg Ala Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp Leu Lys Ile Thr Asp Val Ile Ile Gly Phe Gin Ala Cys Cys Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala Lys Arg Gin Gin Gin Leu Thr Ala Met Lys Val Leu Gin Arg Asn Cys Ala Ala Tyr Leu Arg Leu Arg Asn Trp Gin Trp Trp Arg Leu Phe Thr Lys Val Lys Pro Leu Leu Asn Ser Ile Arg His Glu Asp Glu Leu Leu Ala Lys Glu Ala Glu Leu Thr Lys Val Arg Glu Lys His Leu Ala Ala Glu Asn Arg Leu Thr Glu Met Glu Thr Met Gin Ser Gin Leu Met Ala Glu Lys Leu Gin Leu Gin Glu Gin Leu Gin Ala Glu Thr Glu Leu Cys Ala Glu Ala Glu Glu Leu Arg Ala Arg Leu Thr Ala Lys Lys Gin Glu Leu Glu Glu Ile Cys His Asp Leu Glu Ala Arg Val Glu Glu Glu Glu Glu Arg Cys Gin Tyr Leu Gin Ala Glu Lys Lys Lys Met Gin Gin Asn Ile Gin Glu Leu Glu Glu Gin Leu Glu Glu Glu Glu Ser Ala Arg Gin Lys Leu Gin Leu Glu Lys Val Thr Thr Glu Ala Lys Leu Lys Lys Leu Glu Glu Asp Gin Ile Ile Met Glu Asp Gin Asn Cys Lys Leu Ala Lys Glu Lys Lys Leu Leu Glu Asp Arg Val Ala Glu Phe Thr Thr Asn Leu Met Glu Glu Glu Glu Lys Ser Lys Ser Leu Ala Lys Leu Lys Asn Lys His Glu Ala Met Ile Thr Asp Leu Glu Glu Arg Leu Arg Arg Glu Glu Lys Gin Arg Gin Glu Leu Glu Lys Thr Arg Arg Lys Leu Glu Gly Asp Ser Thr Asp Leu Ser Asp Gin Ile Ala Glu Leu Gin Ala Gin Ile Ala Glu Leu Lys Met Gin Leu Ala Lys Lys Glu Glu Glu Leu Gin Ala Ala Leu Ala Arg Val Glu Glu Glu Ala Ala Gin Lys Asn Met Ala Leu Lys Lys Ile Arg Glu Leu Glu Thr Gin Ile Ser Glu Leu Gin Glu Asp Leu Glu Ser Glu Arg Ala Ser Arg Asn Lys Ala Glu Lys Gin Lys Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu Lys Thr Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Ala Gin Gin Glu Leu Arg Ser Lys Arg Glu Gin Glu Val Ser Ile Leu Lys Lys Thr Leu Glu Asp Glu Ala Lys Thr His Glu Ala Gin Ile Gin Glu Met Arg Gin Lys His Ser Gin Ala Val Glu Glu Leu Ala Asp Gin Leu Glu Gin Thr Lys Axg Val Lys Ala Thr Leu Glu 1205 , 1210 1215 Lys Ala Lys Gin Thr Leu Glu Asn Glu Arg Gly Glu Leu Ala Asn Glu Val Lys Ala Leu Leu Gin Gly Lys Gly Asp Ser Glu His Lys Arg Lys Lys Val Glu Ala Gin Leu Gin Glu Leu Gin Val Lys Phe Ser Glu Gly Glu Arg Val Arg Thr Glu Leu Ala Asp Lys Val Thr Lys Leu Gin Val Glu Leu Asp Ser Val Thr Gly Leu Leu Ser Gin Ser Asp Ser Lys Ser Ser Lys Leu Thr Lys Asp Phe Ser Ala Leu Glu Ser Gin Leu Gin Asp Thr Gin Glu Leu Leu Gin Glu Glu Asn Arg Gin Lys Leu Ser Leu Ser Thr Lys Leu Lys Gin Met Glu Asp Glu Lys Asn Ser Phe Arg Glu Gin Leu Glu Glu Glu Glu Glu Ala Lys Arg Asn Leu Glu Lys Gin Ile Ala Thr Leu His Ala Gin Val Thr Asp Met Lys Lys Lys Met Glu Asp Gly Val Gly Cys Leu Glu Thr Ala Glu Glu Ala Lys Arg Arg Leu Gin Lys Asp Leu Glu Gly Leu Ser Gin Arg Leu Glu Glu Lys Val Ala Ala Tyr Asp Lys Leu Glu Lys Thr Lys Thr Arg Leu Gin Gin Glu Leu Asp Asp Leu Leu Val Asp Leu Asp His Gin Arg Gin Ser Val Ser Asn Leu Glu Lys Lys Gin Lys Lys Phe Asp Gin Leu Leu Ala Glu Glu Lys Thr Ile Ser Ala Lys Tyr Ala Glu Glu Arg Asp Arg Ala Glu Ala Glu Ala Arg Glu Lys Glu Thr Lys Ala Leu Ser Leu Ala Arg Ala Leu Glu Glu Ala Met Glu Gin Lys Ala Glu Leu Glu Arg Leu Asn Lys Gin Phe Arg Thr Glu Met Glu Asp Leu Met Ser Ser Lys Asp Asp Val Gly Lys Ser Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Gin Gin Val Glu Glu Met Lys Thr Gin Leu Glu Glu Leu Glu Asp Glu Leu Gin Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu Val Asn Leu Gin Ala Met Lys Ala Gin Phe Glu Arg Asp Leu Gin Gly Arg Asp Glu Gin Ser Glu Glu Lys Lys Lys Gin Leu Val Arg Gin Val Arg Glu Met Glu Ala Glu Leu Glu Asp Glu Arg Lys Gin Arg Ser Met Ala Met Ala Ala Arg Lys Lys Leu Glu Met Asp Leu Lys Asp Leu Glu Ala His Ile Asp Thr Ala Asn Lys Asn Arg Glu Glu Ala Ile Lys Gin Leu Arg Lys Leu Gin Ala Gin Met Lys Asp Cys Met Arg Glu Leu Asp Asp Thr Arg Ala Ser Arg Glu Glu Ile Leu Ala Gin Ala Lys Glu Asn Glu Lys Lys Leu Lys Ser Met Glu Ala Glu Met Ile Gin Leu Gin Glu Glu Leu Ala Ala Ala Glu Arg Ala Lys Arg Gin Ala Gin Gin Glu Arg Asp Glu Leu Ala Asp Glu Ile Ala Asn Ser Ser Gly Lys Gly Ala Leu Ala Leu Glu Glu Lys Arg Arg Leu Glu Ala Arg Ile Ala Leu Leu Glu Glu Glu Leu Glu Glu Glu Gin Gly Asn Thr Glu Leu Ile Asn Asp Arg Leu Lys Lys Ala Asn Leu Gin Ile Asp Gin Ile Asn Thr Asp Leu Asn Leu Glu Arg Ser His Ala Gin Lys Asn Glu Asn Ala Arg Gin Gin Leu Glu Arg Gin Asn Lys Glu Leu Lys Ala Lys Leu Gin Glu Met Glu Ser Ala Val Lys Ser Lys Tyr Lys Ala Ser Ile Ala Ala Leu Glu Ala Lys Ile Ala Gin Leu Glu Glu Gin Leu Asp Asn Glu Thr Lys Glu Arg Gin Ala Ala Ser Lys Gin Val Arg Arg Thr Glu Lys Lys Leu Lys Asp Val Leu Leu Gin Val Glu Asp Glu Arg Arg 1845 1850 1855 =
Asn Ala Glu Gin Phe Lys Asp Gin Ala Asp Lys Ala Ser Thr Arg Leu Lys Gin Leu Lys Arg Gin Leu Glu Glu Ala Glu Glu Glu Ala Gin Arg 1875. =1880 1885 Ala Asn Ala Ser Arg Arg Lys Leu Gin Arg Glu Leu Glu Asp Ala Thr Glu Thr Ala Asp Ala Met Asn Arg Glu Val Ser Ser Leu Lys Asn Lys Leu Arg Arg Gly Asp Leu Pro Phe Val Val Thr Arg Arg Ile Val Arg Lys Gly Thr Gly Asp Cys Ser Asp Glu Glu Val Asp Gly Lys Ala Asp Gly Ala Asp Ala Lys Ala Ala Glu <210> 49 <211> 7474 <212> DNA
<213> Homo sapiens <400> 49 atacgactca ctatagggcg atcaggtgct ggaaagaagg ctaagcaagg ctgacctgct 60 gcagctcccg cctcgtgcgc tcgccccacc cggccgccgc ccgagcgctc gagaaagtcc 120 tctcgggaga agcagcgcct gttcccgggg cagatccagg ttcaggtcct ggctataagt 180 caccatggca cagcaagctg ccgataagta tctotatgtg gataaaaact tcatcaacaa 240 tccgctggcc caggccgact gggctgccaa gaagctggta tgggtgcctt ccgacaagag 300 tggctttgag ccagccagcc tcaaggagga ggtgggcgaa gaggccatcg tggagctggt 360 ggagaatggg aagaaggtga aggtgaacaa ggatgacatc cagaagatga acccgcccaa 420 gttctccaag gtggaggaca tggcagagct cacgtgcctc aacgaagcct cggtgctgca 480 caacctcaag gagcgttact actcagggct catctacacc tattcaggcc tgttctgtgt 540 ggtcatcaat ccttacaaga acctgcccat ctactctgaa gagattgtgg aaatgtacaa 600 gggcaagaag aggcacgaga tgccccctca catctatgcc atcacagaca ccgcctacag.660 080P 4DbeeDbeoo 4beeobeoeb Da4beppbeD 404qobbbpo eb4boeepeb b43bebbqbb ont7 pobqobeeop 23466ppop6 op66.4obP6v puo6364.5ob obpbE,6bbeb pueoqq6ueo 096E qbbpobqobp bbeobqpbeo bobbPbbqbe ePbePobobe Poeobebboq opbbb6epPo 006E bbbtob4ob4 obqbbeeb4b bebo22oobb 4oba6bb6bb DbPbopubeb bqD4oPbeDb om3E pe2obbeebp bogopeepo6 PePb4665o6 epboubpo6e b6-436eo6p5 536.6436e66 08L p6b4boobbe peoqpeobpP bPobbPb4pb ebbpooqpbp poobbpEopo 3pe6pp33bb onc ebbebbebb4 popubeebee b4op4eoPPb 4.6beE6Pobp bqbopeepoq bbpoqo6ebb 099 po5po3obqo 5eoepoq4p6 64o602p265 e66446p5po ePPe54o6o6 6ebpqobebe 009E ebb.66q4pop bbboeeebPo BuTbebqobv ePqePbbepo 44obqbo6eb qpqbebbqoo ot,sE ebpebbeop4 ospb4oqoqe beoqpqppbb 4obubbbooq efreebppo4o po55qepee6 086E eebpoop6qo 6Pe5be6pe6 646p6poo66 4opo50066p pogo62b6P6 6e6eaebuPo OE obbgobeobq ebupp436E6 bo6aTebeop obbepoqobp bpobogutcep opbobeoqop 09EE pbecuopqop bpbbbebbqo bepbbooboo opbspbpbbq DbebBeobo beobeubpb.6 00u e5,55poboo4 3obo6u,beub 64qoe5qopo qebqpeobbe bqpobpeope bueoqp6peo ovz obpqaobpbe eqoqppe5e6 bebbebeebe oep4opeepo eoopoqqbeb qobe4pebea 08ft fyeebbgobq peeebeeeeb bepoobb4ob peob4oeubp oppb&ebbqo oqeogebeob 0TE p6bebbebbq obeppee6qo buTtobbEto opopubqbbv ebebbqpbpo bqobpe6u3.6 09H boopbDbebe bbubbebbeb bqabeobubb pb44obe5be oo;bz 54ebee6 ocw eebee62bbo bbeobqopeo 6eop.6qpb3b eb52bbebbe aye56q5b6e 3p5.6e6eq.3p Of76Z Pbqppob1.34 p6e6ep6pqg Pebbeobps6 pepoboou64 pob000bb6o oqp6eb6e64 088Z obbpb3ob4b 4b4obaboae ePbuobbeop 43buobebbp D64peyeabg4 ee2.52623b5 OZ8Z gPogob?p4o q5eo.64o5ou .6256qpbe66 peo4D66epe e6P66ob4D5 54o5e3.6ePE, 09L fy4b6q3but 6Pbbe6b2po obb4pbqpbe bbpb6ebbpo 6b33bu5lbt.
00Lz 2Dbqob4D5o obe2o4b5ee ooep4gal.o.6 bob54b64bp obbq3ppb5D 64pEcepbqop 0v9z p4o36q.D6D5 qoe2Moficeo oqopq6beeb q.Poobopeqq. obea5Po5Po bbobeepo64 08SZ 44Pbbupp66 po0b6400e4 3bbbbp3b43 bq3pbbeop4 qbbbequaqp o4boubooPo ozu qefyeebqoo? bpbobubbeb 6e56qopepo obbqobgb45 boobqboo44 oqqa4bpeep 09T7 bebeop66.44 eoboopqbqo guTo6Poe5o 4o6Pb643oo 6Peeegebqe oqobqbobqb ouz obbsofyeebb boeb64eal4 466fieepooq 4p3o4peeu3 p43ub433qu beb42426eb ovu eo55oq4g5p 5.5e30qq.34.6 b45bbPpeep poo4305.6bp opboob4o4e 4booqeobbb 08ZZ Pb o645 Eoepobgobo 5i.o5repoe66 gob4bogoqp oboopPb643 beeobboDE6 ozu pubeutPfioe poPeo.000qe oqeobqoboo 4bqq.i.oepoo 33ee53eDe2 b6e.b43b3eq.
091Z 066.4e5go62 poo564D6eo 62b5eepPqq. 4ofreob6E64 b4opp6poqq. 53eo.666epb 00-c Baboebepoq 4DoMbEo3o 543eo533P5 P.E6oqbqpob boob54b6p3 oubbqoDbbo 0170Z 420qeobooe .664.64eb5ee bb4b43bebb 3qp4bi.44be eoe5qoqoo4 bepoeop4ob 0861 40"epeop53g epeepe54up bqopoogebb Teop25ee5q e54355.45e5 pebqpbeeeo pqgv.56455p eobboobquq. Depoqeqqeo Egoqqq.p.bqo bppeoebbep bqobeDbeep 0981 Dabeeoepoq. qbeeppopeo ppeobbbeob e5be3b4e54 bbeebubbgb p4gobebueo oogi pbooeoobep poopoqgbbq. ofiqbebbebo pbbqobqopo bbqoqquobb boop000bbp OfiLT obeopbpebe Egqeoqopeb ogPobqpoob eob433eb3g pobbqq4oPb oquoggpepb 0891 biLeboq.eob bbebobobea pe4b25bebb epbebbqooq. up44b4e33p p2o2po4go 0z91 40.6p35p364 obeebubque 0020Pq4PPO Teo54b4a5.2 a5.544-4534 pee6qoqubq 09gT qq34p5e634 qobboobqqe pebbqopqeb 6b3qe34433 qopbobbbpo bbpbueopeb OOST e2opbbqp4o 5be2peepqe obob4ob4bh gob54o5opq qb4ebbo5ab 4e4poeEob5 ovvi puopbfq.qop b5E,60-4Poob 444pubi.obb Pobebeupgo .2.6.2o6066pe &Boo-450244 08ET P565oe555q. 6.6Peo4pobo boopoPoqop 4pubbpbpoo epq.44Pboop fy4b4peq.e4 OZET 555443qoge 333 5i5 eepD3.6q3.62 opoeeoeboo 354-233q535 be3pebqo23 09-E ee6bobp6be ebeeo.44045 3qeou23563 qoEreoqqoqq. 5555eoqp4e oi.55.6o543.5 00ZI 403E664ePP obpbbpbET.5 eopoqeobbb qPqqubbubq poo55e664u oDp6e66eop oviT 44.54-eop55e .eoebbeobeo bbboopoqeo peo4bos,Dub frTeepoqbqo oqqabooeqp 0801 ueopeoe46D 35ebfq.q.54o p4oTe5oop6 ppbqopeobe bebbqabbbb qpq6qopqoq.
OZOT e44Pq0-440q. p3p334q33p bbope6pe66 epoobppoob pamob-46o 431.Pepbebb 096 41.44oqeqqo ebp.644E,pee Dobebbq4.64 4p3e4o5b4e 204b4pbq44 oe2o4eoboq 006 qpoqq.epeob 53qqabo3oq DoqoeD-26-1. pebeeb4boo e6peoD5oep 565pqqoD55 ovg eb54op4poo 30P2ODUPD b43b4o5pob 636e5b'4Dbe bobbbepoeb beebeepbeb 08L upopo5343o 4b3bbi.5pe3 bo5b4oquq6 eoaqeoqbbe 2622opeoue beb53ebe2o 5bqobe5bqo le7fq..5643-2 obqbqqoqs,D oqeeoqpbep beb3opbeep bqebqpqbeb t7L171. eeee eveeeeeeve 2822884054 54800e2525 0f91,L PPP4PPOPOq PObElq.OPOO 4444642620 244466405e 2462024320 3204640623 08EL 5445464e0-5 eq400b4b2P eP4PP4e4P4 44444D0000 :2400020004 DePP-b45Pb4 ozu 6266222020 4640644620 004E620442 2640406222 0240364242 0540622224 09ZL P425462254 ppqpae0404 02PPOPPe55 2224444T44 4444420652 2622065024 00ZL 4026264420 5436424246 4444b40Pe4 0044P4b440 P444Peb3ob 446540E0-eq.
0D,1L 0365402030 0460405236 2626226244 3644400640 2030344046 2600442222 080L 4P64222422 4644044400 0044444404 4446622422 2206222644 44424E620e 140L 0540020064 03222224;3 624246,2030 2644500205 4002444664 6652600066 0069 2026303522 0004544026 6522446532 233423242u 2002E66644 340POPPODO
(:189 404406646e 0044006206 2005622266 4062204E56 5036406622 0620200.540 0p,s9 2020422064 4464054440 4440040040 0402000005 0520020054 0460854000 08179 3006204504 6e05000005 e66045e455 44440056e5 4086204403 444484042e 0n.9 6424044446 252036E662 6666300306 6235662062 606E264464 262202062e 09E9 2220054403 0400062040 0306620520 026058625u 0552000665 0005662026 00E9 P.E.PPPOOP4P 6434226204 0540000400 0406200440 0004206406 3040044066 0909 0640082800 5b2640ba6 42660E2220 6642624662 6E26026004 0664eb6bb0 0009 06366E2266 3006542260 3603006463 4.644460054 3025656060 5620405220 OP6S 8262284000 4062046286 0503225420 06426036bo 2.52.640203.6 0266266406 088s 260E068364 3282563060 0040050820 0E6E052300 6526626226 3355266266 0Z8S 405206506e 20405E062e 6400600024 3420662232 600E620025 6220245206 09Ls 8606632266 25E0626386 4266465235 4064064.642 .662254062e 6226260026 OOLS 6046064568 3822064006 2366233636 2562230262 5p-22026643 6236266266 08ss 6662664262 6620643622 3456224406 2562202262 006022E640 6205205603 oess 06422.62632 2628620006 0200620635 2664008254 0026002022 042E1200260 09; 4252064008 2006622622 6405600260 2203264058 6502022055 6206256266 0017S 2564368552 6626640620 3063420600 3652664046 0660622686 626244505b OPES 4000626522 206506206e 0820050325 26026405.63 0626426650 525E805200 08ZS 366200506e 2005463626 6063062065 4382662652 0544523042 6426260366 ozs 2E54205262 86405225221260225252 2200652000 5640042626 5254604040 09Is 0606030202 6485643626 0635420640 2E6226426e 0006583640 6226605406 001s 202234233 6225025550 022E820220 0650302604 2080606625 5400255286 Of7OS 4008664262 6640522622 6600060065 4620664260 406062062e 6526260266 098P 256435605.4 0522006425 2260020066 2053062602 6526640626 2256306206 008' 0252263252 5526646620 6206252400 0655052800 4522626630 6250200464 , 0f7L' 6268806663 6326426522 0040625384 1002668664 2626502050 0436206220 089, 22040E6052 5640586606 6226205265 3800622552 5640006650 0055305046 09; 2200640403 2002522626 5266055300 4058008644 3582522520 5226226266 012,t,f7 2053066060 2682008522 5266405820 8502300500 6646528685 6260805606 0n, 5455664E35 2386586638 6226222885 3232630bb4 5683336123 0133323063 09ZP 4862052262 5640022020 6820355266 86.52.6.62662 6640520626 6600440044 00n, 8262262602 6585545583 6223435883 3835863306 2643628523 6630226256 0vu, 2662064064 0686580402 0266205406 8000452564 0506004044 0266220020 <210> 50 <211> 1960 <212> PRT
<213> Homo sapiens <400> 50 Met Ala Gin Gin Ala Ala Asp Lys Tyr Leu Tyr Val Asp Lys Asn Phe Ile Asn Asn Pro Leu Ala Gin Ala Asp Trp Ala Ala Lys Lys Leu Val Trp Val Pro Ser Asp Lys Ser Gly Phe Glu Pro Ala Ser Leu Lys Glu Glu Val Gly Glu Glu Ala Ile Val Glu Leu Val Glu Asn Gly Lys Lys Val Lys Val Asn Lys Asp Asp Ile Gin Lys Met Asn Pro Pro Lys Phe Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Lys Glu Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Asn Leu Pro Ile Tyr Ser Glu Glu Ile Val Glu Met Tyr Lys Gly Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Thr Asp Thr Ala Tyr Arg Ser Met Met Gin Asp Arg Glu Asp Gin Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gin Tyr Leu Ala Tyr Val Ala Ser Ser His Lys Ser Lys Lys Asp Gin Gly Glu Leu Glu Arg Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Asn Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Ile Arg Gin Ala Lys Glu Glu Arg Thr Phe His Ile Phe Tyr Tyr Leu Leu Ser Gly Ala Gly Glu His Leu Lys Thr Asp Leu Leu Leu Glu Pro Tyr Asn Lys Tyr Arg Phe Leu Ser Asn Gly His Val Thr Ile Pro Gly Gin Gin Asp Lys Asp Met Phe Gin Glu Thr Met Glu Ala Met Arg Ile Met Gly Ile Pro Glu Glu Glu Gin Met Gly Leu Leu Arg Val Ile Ser Gly Val Leu Gin Leu Gly Asn Ile Val Phe Lys Lys Glu Arg Asn Thr Asp Gin Ala Ser Met Pro Asp Asn Thr Ala Ala Gin Lys Val Ser His Leu Leu Gly Ile Asn Val Thr Asp Phe Thr Arg Gly Ile Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Giu Gin Ala Asp Phe Ala Ile Giu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Met Phe Arg Trp Leu Val Leu Arg Ile Asn Lys Ala Leu Asp Lys Thr Lys Arg Gin Gly Ala Ser Phe Ile Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Asp Leu Asn Ser Phe Glu Gin Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gin Gin Leu Phe Asn His Thr Met Phe Ile Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Glu Trp Asn Phe Ile Asp Phe Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Lys Pro Ala Gly Pro Pro Gly Ile Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys Val Met Gin Glu Gin Gly Thr His Pro Lys Phe Gin Lys Pro Lys Gin Leu Lys Asp Lys Ala Asp Phe Cys Ile Ile His Tyr Ala Gly Lys 565 570 575 .
Val Asp Tyr Lys Ala Asp Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Ile Ala Thr Leu Leu His Gin Ser Ser Asp Lys Phe Val Ser Glu Leu Trp Lys Asp Val Asp Arg Ile Ile Gly Leu Asp Gin Val Ala Gly Met Ser Glu Thr Ala Leu Pro Gly Ala Phe Lys Thr Arg Lys Gly Met Phe Arg Thr Val Gly Gin Leu Tyr Lys Glu Gin Leu Ala Lys Leu Met Ala Thr Leu Arg Asn Thr Asn Pro Asn Phe Val Arg Cys Ile Ile Pro Asn His Glu Lys Lys Ala Gly Lys Leu Asp Pro His Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Val Val Phe Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ser Ile Pro Lys Gly Phe Met Asp Gly Lys Gin Ala Cys Val Leu Met Ile Lys Ala Leu Glu Leu Asp Ser Asn Leu Tyr Arg Ile Gly Gin Ser Lys Val Phe Phe Arg Ala Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp Leu Lys Ile Thr Asp Val Ile Ile Gly Phe Gin Ala Cys Cys Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala Lys Arg Gin Gin Gin Leu Thr Ala Met Lys Val Leu Gln'Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg Asn Trp Gin Trp Trp Arg Leu Phe Thr Lys Val Lys Pro Leu Leu Gin Val Ser Arg Gin Glu Glu Glu Met Met Ala Lys Glu Glu Glu Leu Val Lys Val Arg Glu Lys Gln Leu Ala Ala Glu Asn Arg Leu Thr Glu Met Glu Thr Leu Gin Ser Gin Leu Met Ala Glu Lys Leu Gin Leu Gin Glu Gin Leu Gin Ala Glu Thr Glu Leu Cys Ala Glu Ala Glu Glu Leu Arg Ala Arg Leu Thr Ala Lys Lys Gin Glu Leu Glu Glu Ile Cys His Asp Leu Glu Ala Arg Val Glu Glu Glu Glu Glu Arg Cys Gin His Leu Gin Ala Glu Lys Lys Lys Met Gin Gin Asn Ile Gin Glu Leu Glu Glu Gin Leu Glu Glu Glu Glu Ser Ala Arg Gin 945 950 955 . 960 Lys Leu Gin Leu Glu Lys Val Thr Thr Glu Ala Lys Leu Lys Lys Leu Glu Glu Glu Gin Ile Ile Leu Glu Asp Gin Asn Cys Lys Leu Ala Lys Glu Lys Lys Leu Leu Glu Asp Arg Ile Ala Glu Phe Thr Thr Asn Leu Thr Glu Glu Glu Glu Lys Ser Lys Ser Leu Ala Lys Leu Lys Asn Lys His Glu Ala Met Ile Thr Asp Leu Glu Glu Arg Leu Arg Arg Glu Glu Lys Gin Arg Gin Glu Leu Glu Lys Thr Arg Arg Lys Leu Glu Gly Asp Ser Thr Asp Leu Ser Asp Gin Ile Ala Glu Leu Gin Ala Gin Ile Ala Glu Leu Lys Met Gin Leu Ala Lys Lys Glu Glu Glu Leu Gin Ala Ala Leu Ala Arg Val Glu Glu Glu Ala Ala Gin Lys Asn Met Ala Leu Lys Lys Ile Arg Glu Leu Glu Ser Gin Ile Ser Glu Leu Gin Glu Asp Leu Glu Ser Glu Arg Ala Ser Arg Asn Lys Ala Glu Lys Gin Lys Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu Lys Thr Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Ala Gin Gin Glu Leu Arg Ser Lys Arg Glu Gin Glu Val Asn Ile Leu Lys Lys Thr Leu Glu Glu Glu Ala Lys Thr His Glu Ala Gin Ile Gin Glu Met Arg Gin Lys His Ser Gin Ala Val Glu Glu Leu Ala Glu Gin Leu Glu Gin Thr Lys Arg Val Lys Ala Asn Leu Glu Lys Ala Lys Gin Thr Leu Glu Asn Glu Arg Gly Glu Leu Ala Asn Glu Val Lys Val Leu Leu Gin Gly Lys Gly Asp Ser Glu His Lys Arg Lys 1235 1240 1245 =
Lys Val Glu Ala Gin Leu Gin Glu Leu Gin Val Lys Phe Asn Glu Gly Glu Arg Val Arg Thr Glu Leu Ala Asp Lys Val Thr Lys Leu Gin Val Glu Leu Asp Asn Val Thr Gly Leu Leu Ser Gin Ser Asp Ser Lys Ser Ser Lys Leu Thr Lys Asp Phe Ser Ala Leu Glu Ser Gin Leu Gin Asp Thr Gin Glu Leu Leu Gin Glu Glu Asn Arg Gin Lys Leu Ser Leu Ser Thr Lys Leu Lys Gin Val Glu Asp Glu Lys Asn Ser Phe Arg Glu Gin Leu Glu Glu Glu Glu Glu Ala Lys His Asn Leu Glu Lys Gin Ile Ala Thr Leu His Ala Gin Val Ala Asp Met Lys Lys Lys Met Glu Asp Ser Val Gly Cys Leu Glu Thr Ala Glu Glu Val Lys Arg Lys Leu Gin Lys Asp Leu Glu Gly Leu Ser Gin Arg His Glu Glu Lys Val Ala Ala Tyr Asp Lys Leu Glu Lys Thr Lys Thr Arg Leu Gin Gin-Glu Leu Asp Asp Leu Leu Val Asp Leu Asp His Gin Arg Gin Ser Ala Cys Asn Leu Glu Lys Lys Gin Lys Lys Phe Asp Gin Leu Leu Ala Glu Glu Lys Thr Ile Ser Ala Lys Tyr Ala Glu Glu Arg Asp Arg Ala Glu Ala Glu Ala Arg Glu Lys Glu Thr Lys Ala Leu Ser Leu Ala Arg Ala Leu Glu Glu Ala Met Glu Gin Lys Ala Glu Leu Glu Arg Leu Asn Lys Gin Phe Arg Thr Glu Met Glu Asp Leu Met Ser Ser Lys Asp Asp Val Gly Lys Ser Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Gin Gin Val Glu Glu Met Lys Thr Gin Leu Glu Glu Leu Glu Asp Glu Leu Gin Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu Val Asn Leu Gin Ala Met Lys Ala Gin Phe Glu Arg Asp Leu Gin Gly Arg Asp Glu Gln Ser Glu Glu Lys Lys Lys Gin Leu Val Arg Gin Val Arg Glu Met Glu Ala Glu Leu Glu Asp Glu Arg Lys Gin Arg Ser Met Ala Val Ala Ala Arg Lys Lys Leu Glu Met Asp Leu Lys Asp Leu Glu Ala His Ile Asp Ser Ala Asn Lys Asn Arg Asp Glu Ala Ile Lys Gin Leu Arg Lys Leu Gin Ala Gin Met Lys Asp Cys Met Arg Glu Leu Asp Asp Thr Arg Ala Ser Arg Glu Glu Ile Leu Ala Gin Ala Lys Glu Asn Glu Lys Lys Leu Lys Ser Met Glu Ala Glu Met Ile Gin Leu Gin Glu Glu Leu Ala Ala Ala Glu Arg Ala Lys 1685 1690 1695 =
Arg Gin Ala Gin Gin Glu Arg Asp Glu Leu Ala Asp Glu Ile Ala Asn Ser Ser Gly Lys Gly Ala Leu Ala Leu Glu Glu Lys Arg Arg Leu Glu Ala Arg Ile Ala Gin Leu Glu Glu Glu Leu Glu Glu Glu Gin Gly Asn Thr Glu Leu Ile Asn Asp Arg Leu Lys Lys Ala Asn Leu Gin Ile Asp Gin Ile Asn Thr Asp Leu Asn Leu Glu Arg Ser His Ala Gin Lys Asn Glu Asn Ala Arg Gin Gin Leu Glu Arg Gin Asn Lys Glu Leu Lys Val Lys Leu Gin Glu Met Glu Gly Thr Val Lys Ser Lys Tyr Lys Ala Ser Ile Thr Ala Leu Glu Ala Lys Ile Ala Gin Leu Glu Glu Gin Leu Asp Asn Glu Thr Lys Glu Arg Gin Ala Ala Cys Lys Gin Val Arg Arg Thr Glu Lys Lys Leu Lys Asp Val Leu Leu Gin Val Asp Asp Glu Arg Atg Asn Ala Glu Gin Tyr Lys Asp Gin Ala Asp Lys Ala Ser Thr Arg Leu Lys Gin Leu Lys Arg Gin Leu Glu Glu Ala Glu Glu Glu Ala Gin Arg Ala Asn Ala Ser Arg Arg Lys Leu Gin Arg Glu Leu Glu Asp Ala Thr Glu Thr Ala Asp Ala Met Asn Arg Glu Val Ser Ser Leu Lys Asn Lys Leu Arg Arg Gly Asp Leu Pro Phe Val Val Pro Arg Arg Met Ala Arg 1925 1930 1935 ' Lys Gly Ala Gly Asp Gly Ser Asp Glu Glu Val Asp Gly Lys Ala Asp Gly Ala Glu Ala Lys Pro Ala Glu <210> 51 <211> 7666 <212> DNA
<213> Mus musculus <400> 51 gtctttcctg ggagatgggc gcgcaaaccg accagtgggt ctgggggcgg cagtgatggg 60 cgtggagatg gcccaatgag ggtgggagtg ggtggggcag gcgcgagcag cagtgctaaa 120 ggagcccggc ggaggcagcg gtgggtttgg aattgagacg ctggatctgt ggtcgctgct 180 ggggacgtgt gccggcgcca ccatcttcgg ctgaagaggc aattactttt gggtccttct 240 gtttacaatg gcccagagaa ctggactgga ggatcccgag aggtatctct ttgtggacag 300 ggctgtcatc tacaaccctg ccactcaagc tgactggaca gctaaaaagc tggtgtggat 360 tccatcggaa cgccatggtt ttgaggcagc tagtattaaa gaagagcggg gcgatgaggt 420 tatggtggag ctggcagaga atgggaagaa agcaatggtc aacaaagatg acattcagaa 480 gatgaaccca ccaaagttct ccaaggtgga ggatatggca gagctgacat gcttgaacga 540 agcctctgtc ttacataatt tgaaggaccg ctactattca ggacttatct atacttactc 600 tggactcttc tgtgtggtga taaatcctta caagaacctt ccaatttact ctgagaatat 660 tattgaaatg tatagaggga agaaacgcca tgagatgcca ccacacatct acgccatatc 720 agagtctgct tacagatgca tgcttcaaga tcgtgaggac cagtcaattc tatgcacggg 780 tgaatcgggt gccgggaaga cagaaaatac caagaaagtc attcagtacc ttgcccacgt 840 tgcttcttct cacaaaggaa gaaaggacca taatattcct ggggaacttg aacggcagct 900 tttacaagca aatccaattc tggaatcctt tggaaatgcg aagactgtga aaaatgataa 960 ctcatctcgc tttggcaagt ttatccggat caactttgat gtaactggct atattgttgg 1020 ggccaacatt gaaacatacc ttctggaaaa gtctcgtgct gttcgtcaag ctaaagatga 1080 gcgtacattt catatctttt atcagttgct ctctggagca ggggaacacc tgaaatccga 1140 cttactcctg gaaggtttca acaactacag attcctctcc aatggctata ttcctattcc 1200 tggacagcaa gacaaggata acttccagga gaccatggaa gccatgcaca tcatgggctt 1260 gOT
oggp obbub4obee b4DbbboDub bbobebeebu 3b4p4o5D4o b43404e066 beeeebeebe ozgp obb4qbqo6e opeboqqbee beebeoPeeb eububbqqoe epoqoqboqe beopbobeop oggp eopebbqooe bbqbboeb4o oebqebbqoe ebeepeepbq obbopeebee opebeebebb 00c17 40beepubqe 4bo6bqopqb beebebbubb qobbobepob eb4obobbub bqb4ebbeep oppp q3b4Deeebe epePoobeeb bebbmbeb ebaq.PPoebb 6bqopeb4eb oebbqbeeeb 08EP eebeeppeou bgobbgobeo opq.beobqoq. o554.4b4bbe obeebebbqo oeebeebbeo ozEp obbebbebbe bbubbebbeo beobebbeoq. qopbepeebe ebebbebbeb bqobeobboo 09ZP 4ebboq.beob ebqopeubqo eeebeobboe oebebeebbe oqqopqabub beoppeoebb 00ZP upeqopeo4o qbeboqoqbb gobuobTebb uebobqqqbe eqqeqbbeee 5eebeb4obe 017TP ebeebb4ob4 poopeo4b4b qeeq.ebbqob ebquebeoug obeepeueob eeebeboobb 080t7 qobebpqbbb epqobbeoeb qbbbebeoqb bb cob poi.obebbeo oqbbeopobi.
OZOD' ebb4obee6e ebbebeeoep bebeo4beb5 obbeebqbbe obeobqob4b beebqbbe64 096E b4bobbqobe bbeeoeepeb eoebebbqop bbbe3peepe ebeebebbqo peepobeeeo 066 4.465eeee6p beeDbebbqo be3bebooqq qDbpbbebbq Db3bPD2006 4eobbebe3e opgE bebqeoebbe 33-4pbeoqob eeboob eeqoppebqe bbebqqp4ob bepbeeb4ob 08L 6p36bqbue bbe3beb4bo eepeopoboD qoepbbeobe o4obeobeoe oop3ebeq3D
0LE opoebbpbbq Dbebeoebee bqoq.obeebb 4obebbebqb ebqqoebbbo pepeeoeeeb oggE efq_obbee3e ebEyeeoqqob beepebqp-46 pfy4qqop6ee 66 c66 poboqeeepo 009E obbeD5gobe bbboeobg4b pee-440E064 eegeebeepe obqoeoebeb 4ebTebe6be opgE beoobbqobc bbbbbeoggo bebbebbebb Pebeepoubq qbeopqbeue ogobubqebo ogpE qbbe3e3bbe o6qobeb4ob oqebeooebb eobqoqeboo eepeeebbbb qe664o6eeb opE bDeeepobbe eeebb4oueb beoeboqope eubebbebbe ebee644obo eebeebeqqo ogEE e6bo4o4ebq ebqbeebeeo beeqeebbuo qeeee3obbq 4peeeepeob beeeebeebb 00EE ebeeb4obb4 obep4ogoog 4b4bebgobq quebopebee bbgeogoepe beeppbeeeo opE ge4ggepepo 4geebeopeb pebob 4344bbebbe beebbgebee beeogeppeg 08TE obbebeobeo pbqbbeebeb b4obeob4ob Peepobboop bbbbbebbeb bebqebb4De OZTE poeebeebeg opebbeogge peobobbeob qebeebeebe ebebgeebeo egoogebepo ogoc eebbobebee bbebbebbeb bqbbbeopqb ebo4poubqe opqoqi.ebpb bebb4Deebb 000E pobeeepeoo b4ob43obbe pobebeb4e6 ebeebeobee bqoboqqoqo bebooebebo Of76Z obeeobqoeu oePbeobbqo oqeqeebeeb ebeebbgobq obeobeopeo beebbobebb 088Z 4ebub6ebgq. obubbbbeeb bqbeeeepub uobeebebee ubqbbeebqo b4o6ebbebq 0Z8Z Ebeepeobbe 334peebeeb bubbepoboo oeb4beeoog poqoqoobee b456eebouo 09/2 qqoqbqbobb qbbqbeDbb.q. peoebobqob Peb400eq5p bbobqb4oPp bbDbe36qqo OOLZ qbbeeeqqop bqbee4peep eepbeoeueb eeoobqqqop bbeeeb000b oqopeqobbe opgz beob4e4b4o beeooqqqq.4.34eoquo4e4 eb4peoqeee eernebebe eebeebeebe 080Z 440e0505b4 44q.bebbi.ob p.5=444442 qebeepbebe oebbqqeebe qe4bqopeee ozg poDebb4oee be44gobebo oqebqeebob eb4bqbo6be peeeobb4e5 5qeD44pbbe ogp eeqoolqeqo bqeeDooqoe eqopqebebq eqebebeoeb eoqqeebbeo oqqqqbeqeb oop booeuppopq qbbbbeoobo qbqoqebboo qebbbeebbq paq.bobboee 4b4oboqq.ob opE epq.eboqobq boqopeoboo aebb4pueub bb4obbbobe ebeboeo4ue eopqq.eo4Po 083 64060o-450-4 4opeooppeu oppoeupboo qoqoeeobbq e64obeepoe oqoqoqbebb ozz eeDe4p4obe o6b6o4600p eb3oqq.bqeo bbbeebeeoo eeeepegeob go4o6644gb ogTz obDoebebqo ebTebbbwe oqbppoTebb qoqbbuqbqq Pebooebb4b oeb6eebb44 OOTZ 4Dbeb4obb4 b444ebeoub bp400gbeop pobgoog000 upobbgboue oebqeebqDb Of7OZ 000ebbquDe e6ee64ebqo bbqbeb4e6e o66ee4e4oe bbqbbeebbb boboe4opoo 0861 4e0qeo6qpq qoebDobeue oebeee643P upoboboobp Ebeoqqqbee op4Deopoq4 OZ61 bbeeobubbe oqqbbqobee ePbqq.b4.44e opuee4ebeo eqobeeepoo oqqbbqobqe 0981 ebeebgebbq o3400066qo bqbobbqopo oo4eeDobq3 Debubebege bqopeboquo 0081 bqoopbeabi. 33e5.Eq.Dobb oqqopboqpi. qqopebbqbe bogeobbbeb ebobepougb opLT ebbebbeabe bbqop4Poqq bT230E3PDD ueoqqbqobe DbeDbi.obee bebopeooeo 0891 eqopeoqeob 1.bgobuobeb 3q4poqope6 qobebqq444 eeebq.44-45b qab4bb Toomeb5.54i, poqqooqqob ebbbeoo6oP eeopebbeqe bbqobobeee Teepqeoboo ogsT ep4T6DqDbb goboqq4b44 abobefqeqo peqobeeeep bb44eobeeb bmbeobmq.
0001 ebgabbpobe beuppoubeo pobee2buop qbopq4ebb5 oDbbqqbbee o4eb6eDo3b OPP' progoogeqo bbboqoeoql 525b4Pbqbq Pebqebbb34 Dbqaoe3ob4 34obeebPDP
08E1 05045P0202 2b26boo5qp poqopbepoo ebqDeoPeeb ebeffeeeee oqqqololeo ozET epe.56-4qqbe o6lofq.62o; goTe4boqfre, epT4o5qpeo qoqooqebeb eeboeol.pqo sninosnm snyq <EI>
Did <ZIZ>
9L6I <IIZ>
Zg <OTZ>
999L PUPPET' PPEEPPPePP ePbPqreqqP0 qqeq4qeueg eepebeeqbq 0Z9L 44q4eb4eup Ebeqoqq4e4 uppoqquqbq 40444.4o4e4 eeeobqoubq OOPOPEIPOOP
09sL opubqqbqob bqouqbqque 54e4bqopoo qqqeb-4-44o4 eebbqq4bbb qeoupqbbqo 00gL eebeebbebq bqp4ppee44 4o6eeee44b E644q4DDeb boubeeeebb qob4bqebob 0f7f,/, b4booeb000 obeeoebqbe qqbqbeoqee ebbeoebqbe oqqeoeeebb obqebeqbee 08L b4beqoqoqo pe4b4eo4u4 ebqqabqbqo eb4oqqbeeq qeqb4uu4qo eupeequqpq 03EL obbqqqeqqe qeqeeeqqbq PPOP5PPq3P qbeoeqbeou beq4Dobqbe eebeoeqqeo 09z7_, ebqoeeebbe bqqbeqeb4q bbqqqq46qo lmeobe44ou beebqeeopq qbqbebebb4 00L 44opq4poo4 qqopoqq4qe 3q4obbe6q6 4bobbbobeo obqeoebqqb 4eub400b43 0pTL Tepobqebee beepqopbeq eqabbebTee bqbqq4beeD oqqbqbqbbe bbbqbqeqq4 080L 4beq4eqpeb bbopupeopo bpbqqqobqo pobbeoqqee pobT4o4pob beebqbobe 00L eb3434pobb eebeoboqob 4bbb544poo ubqbqoqopb eb4bebbeaq. 4eeb4boobq 0969 ee4eb44obb q3q,bqbebqo o4oqbbq6be poqqopeqbe peoqepobeo bbqbb5oboo 0069 bqbbeeqebe beebepobbq bebebbebeb ebeDbmbqpq obebeoqoqb eqeeb4bqee 0689 D4oqbooeoo poqbqbb4eo qqeeepqoop obgpopebqb bbbeepooqo leopobqopq 08L9 oqq666b4T4 eboqeobeDb eebbbbqqeb bqqqbbbqbb bbeqqobbob bq443bbbbe 0zL9 bebbbqopee obubqbeoqo qbqpeoqebq beqeebqbqb oqqqebqp4o 4b4bqq.beob 0999 400eP4OOPP bqbqqeoeeb eqqoqp4bbq poepe3DueD qqopT4Dope bqopobbqbq 0099 uo44bqbqp4 qbeqqopeqb beDeb4beqo ombqopobqu ob4b4obqob epqobqbooe 0D,g9 bbboopobqg bbbeeqoobb bqobbqbeop bqqbqqqopo bbeboqopeu peeubqqqq4 08D,9 opeubeuebe ebeeT4epeo ebqe444420 oebebeeoqu pqmeqbqeop 44gge4oTeo 0D,9 b4q.boqeoqo qbqqebepee eqqeqbobqe Debeeaeopq opepeqeqeq e4.4.444opo3 09E9 b4queoequb eqoebeoqqo bqopqeqeqo ebeobobqoo bbobqqqobb euqqoqbqbq 00E9 opeoqbeeeb beopq4opq4 ebepooqobe eobbquebbb pqabqpeoqb eobqopobeb 0179 44obqoqbeo peobeopp4e p4ouebepob beoebbebqo bqebqbbebe oqbbebbeoe 0819 obbeqeebeo Tepoopoepo beoupeoFbq euoqb4e6qb epoebee4be uebepeoebo 0z19 ebqebeoqbq obebeqpbo4 eobbbbbebq quouobqobe opb3bbDobb qoquboobee 0909 344044qqob eDqueopqbb obbbbobbeo qobbopeebe poqoqbeobe oqbbeboboo 0009 bebqoabbee bqueopbbub 4beboboe5o ebbqobubbb eeeopqopee 4bobboqoqe 0mq oboeeopbqb oupeopbbub eubbebqobb ebeebb4qbe oe6oeeeq4o beobeebqeb 088g be3obqeeqD bbeebebbqe beobubbeel eqbeoqebbo bquobbD46o beboebee64 0z8s q66eD54uoq qoTeeebeee bqoeeebeeb ebupeeboqb po4beqopee ouebobqobe 09Lg obubDbubbe epobeebbeo bebqqobeob ebbebbqobe obbbqqubee pobee6b4op OOLS obeogogepo eqobbeepqq beeopqbeep qbeobbbbbe bbqobebbeo bqpbeepobb 0f79s eebqobubbe epeeeepebo bebbqobepb eobboobbqe eDebqbebee beboobqobb oess bebbobebeo beobbqobeb uoupeebqoe oebebbqbbe obgoboe3De beeobooqq3 cqgg boDubqueoq obqobubbge pueobebeob ebbebbebbq obebbebeeb bqobeoeobo 09t7g 4e65obo6ee bb4pobo6bo beebeb4ebb qqbqobob4o qbeeubbqo4 pobobebeep 00f7s oboqebebqe b4obbqobeb oebebobebb ebbebeobDe DebDoboobb ebobebooqe 0IvEg oqopbbqobe bbubee3bqo beoqqoqqee ebebbeebe4 oqbebeebqo eeebeeeebq 08zg beeebeeeoo qeep4obqqq 44ebebqube be4o4eobeb o4obbebeeb eqpeebgbob 0zzs eoDe4qebbe ubgebupeob beoqqopepo bbq4obeobe eoqebqbeeb gebbboDobe 09-Eq evoeebob4o bbebo4ebeo qobbebbqoo ebbeebqope beqebebb4e beebeebeee 00's oqbDbbqb4b bbqouobbbo beoeeebbob ebqebbebbq obebeobbeb b43bebbb35 060S q56eobee-44 obqbbqobbo beebeeeebe ebqeebebbe b4ebubDope Eppb43Debb 08617 bpbutqqq6-2 opobbeeb4e oDbbebbqeo ee34beubb4 Do5oogo6e2 oobqebbebq 0z617 peopbbuDbq obeboebbeb bqDbeb52bb 436e3oopbb 35-42.6266e5 b4bbeobeo5 098f7 e6b4433bpb obeeboqeee bebq4o62bo epoqbouebe ebbbbqbgeb pebp2eq3qo 008p bpbqebqo32 beebb4eoeb EDE,Pboqqob eobueoepbu o66p5pEoqq 225526beeb cmj, o55e564qop bbebbebqqo pobbbobobb qopoqoqobo bepeopeupb eep6e6p6po <400> 52 Met Ala Gin Arg Thr Gly Leu Glu Asp Pro Glu Arg Tyr Leu Phe Val Asp Arg Ala Val Ile Tyr Asn Pro Ala Thr Gin Ala Asp Trp Thr Ala Lys Lys Leu Val Trp Ile Pro Ser Glu Arg His Gly Phe Glu Ala Ala Ser Ile Lys Glu Glu Arg Gly Asp Glu Val Met Val Glu Leu Ala Glu Asn Gly Lys Lys Ala Met Val Asn Lys Asp Asp Ile Gin Lys Met Asn Pro Pro Lys Phe Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Lys Asp Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Asn Leu Pro Ile Tyr Ser Glu Asn Ile Ile Glu Met Tyr Arg Gly Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Ser Glu Ser Ala Tyr Arg Cys Met Leu Gin Asp Arg Glu Asp Gin Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gin Tyr Leu Ala His Val Ala Ser Ser His Lys Gly Arg Lys Asp His Asn Ile Pro Gly Glu Leu Glu Arg Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ser Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Thr Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Val Arg Gin Ala Lys Asp Glu Arg Thr Phe His Ile Phe Tyr Gin Leu Leu Ser Gly Ala Gly Glu His Leu Lys Ser Asp Leu Leu Leu Glu Gly Phe Asn Asn Tyr Arg Phe Leu Ser Asn Gly Tyr Ile Pro Ile Pro Gly Gin Gin Asp Lys Asp Asn Phe Gin Glu Thr Met Glu Ala Met His Ile Met Gly Phe Ser His Glu Glu Ile Leu Ser Met Leu Lys Val Val Ser Ser Val Leu Gin Phe Gly Asn Ile Ser Phe Lys Lys Glu Arg Asn Thr Asp Gin Ala Ser Met Pro Glu Asn Thr Val Ala Gin Lys Leu Cys His Leu Leu Gly Met Asn Val Met Glu Phe Thr Arg Ala Ile Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Glu Gin Ala Asp Phe Ala Val Glu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Leu Phe Arg Trp Leu Val His Arg Ile Asn Lys Ala Leu Asp Arg Thr Lys Arg Gin Gly Ala Ser Phe Ile Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Glu Leu Asn Ser Phe Glu Gin Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gin Gin Leu Phe Asn His Thr Met Phe Ile Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Glu Trp Asn Phe Ile Asp Phe Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro Pro Gly Val Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Thr Phe Val Glu Lys Leu Val Gin Glu Gin Gly Ser His Ser Lys Phe Gin Lys Pro Arg Gin Leu Lys Asp Lys Ala Asp Phe Cys Ile Ile His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Asp Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val Ala Thr Leu Leu His Gin Ser Ser Asp Arg Phe Val Ala Glu Leu Trp Lys Asp Val Asp Arg Ile Val Gly Leu Asp Gin Val Thr Gly Met Thr Glu Thr Ala Phe Gly Ser Ala Tyr Lys Thr Lys Lys Gly Met Phe Arg Thr Val Gly Gin Leu 645 ' 650 655 Tyr Lys Glu Ser Leu Thr Lys Leu Met Ala Thr Leu Arg Asn Thr Asn Pro Asn Phe Val Arg Cys Ile Ile Pro Asn His Glu Lys Arg Ala Gly Lys Leu Asp Pro His Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Ile Val Phe Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile Pro Lys Gly Phe Met Asp Gly Lys Gin Ala Cys Glu Arg Met Ile Arg Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Ile Gly Gin Ser Lys Ile Phe Phe Arg Ala Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp Leu Lys Ile Thr Asp Ile Ile Ile Phe Phe Gin Ala Val Cys Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala Lys Lys Gin Gin Gin Leu Ser Ala Leu Lys Val Leu Gin Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg His Trp Gin Trp Trp Arg Val Phe Thr Lys Val Lys Pro Leu Leu Gin Val Thr Arg Gin Glu Glu Glu Leu Gin Ala Lys Asp Glu Glu Leu Leu Lys Val Lys Glu Lys Gin Thr Lys Val Glu Gly Glu Leu Glu Glu Met Glu Arg Lys His Gin Gin Leu Leu Glu Glu Lys Asn Ile Leu Ala Glu Gin Leu 885 890 895 =

Gin Ala Glu Thr Glu Leu Phe Ala Glu Ala Glu Glu Met Arg Ala Arg Leu Ala Ala Lys Lys Gin Glu Leu Glu Glu Ile Leu His Asp Leu Glu Ser Arg Val Glu Glu Glu Glu Glu Arg Asn Gin Ile Leu Gin Asn Glu Lys Lys Lys Met Gin Ala His Ile Gin Asp Leu Glu Glu Gin Leu Asp Glu Glu Glu Gly Ala Arg Gin Lys Leu Gin Leu Glu Lys Val Thr Ala Glu Ala Lys Ile Lys Lys Met Glu Glu Glu Val Leu Leu Leu Glu Asp Gin Asn Ser Lys Phe Ile Lys Glu Lys Lys Leu Met Glu Asp Arg Ile Ala Glu Cys Ser Ser Gin Leu Ala Glu Glu Glu Glu Lys Ala Lys Asn Leu Ala Lys Ile Arg Asn Lys Gin Glu Val Met Ile Ser Asp Leu Glu Glu Arg Leu Lys Lys Glu Glu Lys Thr Arg Gin Glu Leu Glu Lys Ala Lys Arg Lys Leu Asp Gly Glu Thr Thr Asp Leu Gin Asp Gin lie Ala Glu Leu Gin Ala Gin Val Asp Glu Leu Lys Val Gin Leu Thr Lys Lys 1075 1080 1085 , Glu Glu Glu Leu Gln Gly Ala Leu Ala Arg Gly Asp Asp Glu Thr Leu His Lys Asn Asn Ala Leu Lys Val Ala Arg Glu Leu Gin Ala Gin Ile Ala Glu Leu Gin Glu Asp Phe Glu Ser Glu Lys Ala Ser Arg Asn Lys 1125 1130 1135 .
Ala Glu Lys Gin Lys Arg Asp Leu Ser Glu Glu Leu Glu Ala Leu Lys Thr Glu Leu Glu Asp Thr Leu Asp Thr Thr Ala Ala Gin Gin Glu Leu Arg Thr Lys Arg Glu Gin Glu Val Ala Glu Leu Lys Lys Ala Leu Glu Asp Glu Thr Lys Asn His Glu Ala Gin lie Gin Asp Met Arg Gin Arg 1185 1190 1195 1200 ' His Ala Thr Ala Leu Glu Glu Leu Ser Glu Gin Leu Glu Gin Ala Lys Arg Phe Lys Ala Asn Leu Glu Lys Asn Lys Gin Gly Leu Glu Thr Asp Asn Lys Glu Leu Ala Cys Glu Val Lys Val Leu Gin Gin Val Lys Ala Glu Ser Glu His Lys Arg Lys Lys Leu Asp Ala Gin Val Gin Glu Leu His Ala Lys Val Ser Glu Gly Asp Arg Leu Arg Val Glu Leu Ala Glu . 1265 1270 1275 1280 Lys Ala Asn Lys Leu Gin Asn Glu Leu Asp Asn Val Ser Thr Leu Leu Glu Glu Ala Glu Lys Lys Gly Ile Lys Phe Ala Lys Asp Ala Ala Gly Leu Glu Ser Gin Leu Gin Asp Thr Gin Glu Leu Leu Gin Glu Glu Thr Arg Gin Lys Leu Asn Leu Ser Ser Arg Ile Arg Gin Leu Glu Glu Glu Lys Asn Ser Leu Gln Glu Gln Gln Glu Glu Glu Glu Glu Ala Arg Lys Asn Leu Glu Lys Gln Val Leu Ala Leu Gin Ser Gln Leu Ala Asp Thr Lys Lys Lys Val Asp Asp Asp Leu Gly Thr Ile Glu Ser Leu Glu Glu Ala Lys Lys Lys Leu Leu Lys Asp Val Glu Ala Leu Ser Gln Arg Leu Glu Glu Lys Val Leu Ala Tyr Asp Lys Leu Glu Lys Thr Lys Asn Arg Leu Gln Gln Glu Leu Asp Asp Leu Thr Val Asp Leu Asp His Gln Arg Gln Ile Val Ser Asn Leu Glu Lys Lys Gln Lys Lys Phe Asp Gin Leu Leu Ala Glu Glu Lys Gly Ile Ser Ala Arg Tyr Ala Glu Glu Arg Asp Arg Ala Glu Ala Glu Ala Arg Glu Lys Glu Thr Lys Ala Leu Ser Leu Ala Arg Ala Leu Glu Glu Ala Leu Glu Ala Lys Glu Glu Phe Glu Arg Gln Asn Lys Gln Leu Arg Ala Asp Met Glu Asp Leu Met Ser Ser Lys Asp Asp Val Gly Lys Asn Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Gln Gln Val Glu Glu Met Arg Thr Gln Leu Glu Glu Leu Glu Asp Glu Leu Gln Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu Val Asn Met Gln Ala Met Lys Ala Gln Phe Glu Arg Asp Leu Gln Thr Arg Asp Glu Gln Asn Glu Glu Lys Lys Arg Leu Leu Leu Lys Gln Val Arg Glu Leu Glu Ala Glu Leu Glu Asp Glu Arg Lys Gln Arg Ala Leu Ala Val Ala Ser Lys Lys Lys Met Glu Ile Asp Leu Lys Asp Leu Glu Ala Gln Ile Glu Ala Ala Asn Lys Ala Arg Asp Glu Val Ile Lys Gln Leu Arg Lys Leu Gln Ala Gln Met Lys Asp Tyr Gln Arg Glu Leu Glu Glu Ala Arg Ala Ser Arg Asp Glu Ile Phe Ala Gln Ser Lys Glu Ser Glu Lys Lys Leu Lys Ser Leu Glu Ala Glu Ile Leu Gln Leu Gln Glu Glu Leu Ala Ser Ser Glu Arg Ala Arg Arg His Ala Glu Gln Glu Arg Asp Glu Leu Ala Asp Glu Ile Ala Asn Ser Ala Ser Gly Lys Ser Ala Leu Leu Asp Glu Lys Arg Arg Leu Glu Ala Arg Ile Ala Gln Leu Glu Glu Glu Leu Glu Glu Glu Gln Ser Asn Met Glu Leu Leu Asn Asp Arg Phe Arg Lys Thr Thr Leu Gln Val Asp Thr Leu Asn Thr Glu Leu Ala Ala Glu Arg Ser Ala Ala Gln Lys Ser Asp Asn Ala Arg Gln Gln Leu Glu Arg =
Gin Asn Lys Glu Leu Lys Ala Lys Leu Gin Glu Leu Glu Gly Ala Val Lys Ser Lys Phe Lys Ala Thr Ile Ser Ala Leu Glu Ala Lys Ile Gly Gin Leu Glu Glu Gin Leu Glu Gin Glu Ala Lys Glu Arg Ala Ala Ala Asn Lys Leu Val Arg Arg Thr Glu Lys Lys Leu Lys Glu Ile Phe Met Gin Val Glu Asp Glu Arg Arg His Ala Asp Gin Tyr Lys Glu Gin Met Glu Lys Ala Asn Ala Arg Met Lys Gin Leu Lys Arg Gin Leu Glu Glu Ala Glu Glu Glu Ala Thr Arg Ala Asn Ala Ser Arg Arg Lys Leu Gin Arg Glu Leu Asp Asp Ala Thr Glu Ala Asn Glu Gly Leu Ser Arg Glu Val Ser Thr Leu Lys Asn Arg Leu Arg Arg Gly Gly Pro Ile Ser Phe 1925 1930 , 1935 Ser Ser Ser Arg Ser Gly Arg Arg Gin Leu His Ile Glu Gly Ala Ser Leu Glu Leu Ser Asp Asp Asp Thr Glu Ser Lys Thr Ser Asp Val Asn Asp Thr Gin Pro Pro Gin Ser Glu <210> 53 <211> 7619 <212> DNA
<213> Homo sapiens <400> 53 actgaggcgc tggatctgtg gtcgcggctg gggacgtgcg cccgcgccac catcttcggc 60 tgaagaggca attgcttttg gatcgttcca tttacaatgg cgcagagaac tggactcgag 120 gatccagaga ggtatctctt tgtggacagg gctgtcatct acaaccctgc cactcaagct 180 gattggacag ctaaaaagct agtgtggatt ccatcagaac gccatggttt tgaggcagct 240 agtatcaaag aagaacgggg agatgaagtt atggtggagt tggcagagaa tggaaagaaa 300 gcaatggtca acaaagatga tattcagaag atgaacccac ctaagttttc caaggtggag 360 gatatggcag aattgacatg cttgaatgaa gcttccgttt tacataatct gaaggatcgc 420 tactattcag gactaatcta tacttattct ggactcttct gtgtagttat aaacccttac 480 aagaatcttc caatttactc tgagaatatt attgaaatgt acagagggaa gaagcgtcat 540 gagatgcctc cacacatcta tgctatatct gaatctgctt acagatgcat gcttcaagat 600 cgtgaggacc agtcaattct ttgcacgggt gagtcaggtg ctgggaagac agaaaataca 660 aagaaagtta ttcagtacct tgcccatgtt gcttcttcac ataaaggaag aaaggaccat 720 aatattcctg gggaacttga acggcagctt ttgcaagcaa atccaattct ggaatcattt 780 ggaaatgcga agactgtgaa aaatgataac tcatctcgtt ttggcaaatt tattcggatc 840 aactttgatg taactggcta tatcgttggg gccaacattg aaacatacct tctggaaaag 900 tctcgtgctg ttcgtcaagc aaaagatgaa cgtacttttc atatctttta ccagttgtta 960 tctggagcag gagaacacct aaagtctgat ttgcttcttg aaggatttaa taactacagg 1020 tttctctcca atggctatat tcctattccg ggacagcaag acaaagataa tttccaggag 1080 accatggaag caatgcacat aatgggcttc tcccatgaag agattctgtc aatgcttaaa 1140 gtagtatctt cagtgctaca gtttggaaat atttctttca aaaaggagag aaatactgat 1200 caagcttcca tgccagaaaa tacagttgcg cagaagctct gccatcttct tgggatgaat 1260 gtgatggagt ttactcgggc catcctgact ccccggatca aggtcggccg agactatgtg 1320 caaaaagccc agaccaaaga acaggcagat tttgcagtag aagcattggc aaaagctacc 1380 tatgagcggc tctttcgctg gctcgttcat cgcatcaata aagctctgga taggaccaaa 1440 cgtcagggag catctttcat tggaatcctg gatattgctg gatttgaaat ttttgagctg 1500 ET
036D, beegebbebb 4obebbobbe boqobebbbo bqbbepeepo 4E643.54 6E. obeebeebeb 098p ep54pubeo5 ubqe6bbPoo epeo6qope6 e6u6e6pi.-46 upbobbee64 Poo.66-2064e DPPoqbbut& qpq.boq4obe poobgebeuE, boupobbPoo qopeboe6pu 6643.6eb6pb of7LD, 6q3.6eoop2..5 beb.422?Bb2 b6qbbPobeo 5e6p4poo6b 6oPeepo4pe eeebqqoeub 08917 3p3445oePp eeebb6464e 64e6eeepoi. obe64Paqoo pbepb64p3p beobpboogo oz9f7 beobupoueb Pobbebe6q.q. 4.6ebbebbe.e. 3366e66.430 06ppb.626oq.
opobbboopb ocp, bqopo4.6403 obee2oopuP beephpbebe pobbeboobe pboobb.6pou bbbobebPpb oogr7 3064-eqp6pq. ob4pq.31.E.D6 PbeebebPe6 Po6p4q.bqp6 pope6qqqbe Pbpubeobep orn 5pp5eb544o 2Pooqopboq. 6bPoobobeo oeopeb6qop e5.64bboPoq. ooPboubfqo 08E17 bubbpobpob gooboopPbP epopbPPb-eb bq3pep3pb4 eq.5obb4peo bbeufiebbpb OZEfi 6qopbobepo Bp64opobbe 66063P6E,Pe bloqqobep6 ee6pepobpe bppbb4046u 09f, -226.44eppee 565 o532 b4ebeq.be2e bepbeepopq p.6406E4462 opoqbeobqo oon, oo6b4o646p pobeubp6bq popPbppbbp opEofiebbe66 e66e66e66p obpobebbuo OvVv.4434beoppb eebebbebee 55435eo55o oTebboqbpo Bubqooepeq Depubepobo 080 pop6ebbp6b po44044obe 6Bpae3pqp6 bppeqoppoq. 3q6p64434b pq.o6eo54e6 ija, 6-epq.D.6.444e eeq4e4bbbp pbeebebeob eubppbbqoq qpoppoD4pq. bgeeqebeqo 096E betqu'ubeob 4obeeq.5eep 52eebe5bob .640.6?bbi.bb beogobbpoe bobbeebgoi.
006E Dqbbeupobq epoqobebbe DoqbbeobDb DebDqDbeeb eebBebeeop Dbebqogbeb OD'8E qabbeepq.bb upbeobqopq bbeebqbbeb gbi.bobb4o5 ebbeepee4e beoebebbqo 08LE 3666p3bpe3 pe5eebp6eq oqueepbeee pqq65obepo obbeopp66-i obeobe6pog ozLE pqobebbebb qopobeopeo 50P325PPPO ubebqeoebb P304PPPD40 bepb4eopee oggE bee4Deee55 ebbebqq.o4D beeebeeb4o bebeobb4be ebeepeebqb oepeepe4bo oogE eqpeebbeob eDoobeobbo eoDeoebbqo boeppbbebb qabebeoppe ebqoqobeeb opgE b4peebbeb4 bebqqaebbb eeeebeobee eeboobbeep eubboupqqo bbeebebooi.
08yE pe64.443ebe eb6upqq.oup b4obqq.PePD po5eepu4o5 e5ebobqb44 bpue44poob HDT 4us6pp6pei. P00q0P0PPP .54P54Pb4bb pbepobbToe o5o5bbeob4 obebbebbeb 09EE beebepoobb qo5eob4obe eo4o6eb4e6 4qe5eD.6366. 2364o52beo boTebepopE, nc 5eo643Debo opboe5re666 6pubp4opep 26eeeeoo6.6 peee6.6qopu bbe3q.634o2 ot7zE beespbupbb ppbueeqq.ob peubP2.6eqg 4-2620.4o4p6 4P646ee5pu obeeqes56P
081E oq.epeepobb 44oppPeP5o b5eeee5PP6 fiebpebqobb qa5poqa4op 4464be.64ob OZTE 44po5oi.pbe e5b4uo4oue ebuueebeep 34e044bepo pq.q.peeepoe bbebo4o4qo 090E 6434gebe5b ebeebb4ebe e5eep4pEree 3066262062 oe54bbeeee b5q.obeo643 opos 5ue2e36.6pq o5556ep5be 6.6e5oe5pqo 5eopp6ee86 qoop66e044 egeopobeup op63 b4peepuee5 upeebqpeee poi.poTeeep 32225pp26e ebeebeebee b4q.bb5eqpi.
088z 5e554qoe5q Pppq.044P6u 5eu5eq.q.p.e6 bPobeupppq. 3.64obTi.oeb ueobbbp.64p 0z8z bebeebeobe eb436.4.44o4 o5ebi.oebe6 PO52P0P4OP eopebeo54q pogeqeebee coLz .6e6pbe44.1. qabeo6pooe obupb5o6e6 b4e6ebbubb 436ebeb5ee 6546bee5oe ooLz beobeebebb ep5455ee54 454o6ebee5 qebeeepobb epqqoeebeu bbubbepobo opgz 4opbqbepoe q34qobo3be ebi.bbeeeoe oqqoq.bebob bq5545uobb qopobboe44 ossz eueb4opeq5 o5oobq54De e5b35e3b.44 3465eeeq4o o5q5ee4ope obeobeobee Hgz beepob4440 obbeeebeop 55qooe445.5 e5eo5.4445o 05beopq4o4 404eqgeo4e 09D,z quboopp4pp pePTI.Te6e.6 epe5epb5e6 elloppeo65 qoq.q.bp654o bpbpagq.44-4 0017z eq.ebeeobub epeb544ee6 23e-454432e epope554g2 ebernobbb poqebqeebo opez eebgbgpobb eopee455qe 55qe444q5b upegooq4e4 ob4peepogo pegoo4e5eb qe4ebe5eoe beogqeebbe poqqq4bege eboopeqopo qqobbbepob D454o4eebo Hzz p4e555ee55 qooqb4bbqe eq.bqpbo440 buoqebeqop qbe4opupeo 34e55ggeee 091z a66436b5p6 eebeboepTe PPOD44POTe 4.64q.bol.4b4 qq.peeqopou popeoppebo ooTz Di.o4peeo5b lebi.abeeDD epqoqoqeeb eeeoeqoqop eo5b6-445oo eq.534q454e OPOZ obbbeubeeD 0peee4e4eD boogobbqqg 4obeoebe54 oebqugbbqo eogbeeogeb 0861 bqoqbbb45o qeqbopebbq bqebeeebbq qqDbebeobb qbqq.qebeoe beoquo45eo 0Z61 peobqqqq.Do pp3o6b4boe eoeb4eebqo DoDoebb42q. eebeebgebq o55qbeb4eb 098T eobbeul.eqo 2b6q.b6PP5b bPob4eql.eo PI.P4Teob44 1.1.4pb4o6pe e3ebeeep-1.4 0081 eepebo4ope eebeoqq4be e34peDD4 4b6eeobe5e 204.45b4pee e2e6-44544.4 0f7L1 00eeee4ebe 0e005eee40 po4j654D5i. ee6ee54e55 4441.3oo554 0e5455400 0891 q000eebobq Debebebeg pegooebDqe Dbqeopbeob q34ebbqpbb bpqq.q.ebpqe HgT oq4Deebbgb ebomeobbee 506052002; 8266268802 86eq.Doqe4q m542002080 ogsT Deep44bqob eobeoblobe 2525-42233e 0ei.3ee34e3 bqq43ee3ee b444334ope ETT
OE SZ OZ
eTV 1J 13,1, dse uTV UT zqj PTV cud use ziCI TI TPA eTV EuV dPV
ST OI , I
TA 91-Id nerl t1 &le nT9 cud cleV nTD neq ç1 1T4 51V Lyre PTV 49N
PS <0017>
suoTdes OWOH <ETZ>
Did <ZIZ>
9L6T <ITZ>
<OTZ>
6I9L eeb4b4epq ee4eebeeoe ee4eep4ope bebeeegeeb ebbgbapoep beeeeeebee 096L b443'844;61- 04054D0506 44qP4P5P42 44P044e444 Pee4Peoe6P P4b441-44eb 006L 4eeoebeqo4 44e4epoo44 e4b4404444 oqe4eeeobo Deb4opeoeb eapeopeb44 0D,17/. bqobbqop45 q3eebqu444 boboo44q4e b6m4o4ep66 q44bbb46q3 oqb44quebe 08EL ebbe44e44 eDeeq44abe eep44bbb44 44opueeoeo pepeb44ob4 b4eepb4o4o H-EL oqebqqooqe eeqoqq.eqq. bgbeoqpebq epoubqbeo4 qeoebepeqq. sqbbqbeeeD
09ZL 4be4D4o4D3 e4b4e34e4e p44Dbqb4oe b4q446Poq4 e4b422444e 2peeq.e4oqD
oN.L. obo4quoqpq eqeebqqbqe epebeel.peq beoeqpeoeb eqqopbqbee ebboeqqepe OIL b4oeeeobee 44beqbb4qb b444q4b400 4eobe443ep eeb4beoeq4 b4beoebb44 080L q000qq.000g oqqopqqqgq epqqopqoeb q..645bbqbeo obgeoebqqb 4peb4=q4o OZOL 4eopb4ebeD eebepoqopb ebb4e4q4bb eb4eeogb44 qbePoo44b4 4abbebDo46 0969 q644T4b5qq equebbbqee eeopobebqq. qobqobo3be oq4eeupbqq. poebq3bqeD
0069 40pobbboob eopbo4b4op 34p000bbee b64bb4obeb oDbpe4opoo ebbqbpobeo 0D'89 bueobubbeo 4booqooqo pobobboobq p4o5bqopbo peeb000qpq bbqebepoqq.
08L9 Debeqb4ep4 ebb4epobeo bb4bbeopoo bbeb4obp3b 4oupepobbq be4ebbb2eb 0n9 eqeobq64oq bbqobbbebo bbqqoa6b43 eebqbqeogo eqoqeoboop 4.bq6bqe6pq 0999 beboqoppob 4000.6.6b5bb P:2030004'20 34.64PDOP44 bba6444E00 OPOE'PObP2b 0099 bo4eb6qobb bqbbbbebbe qbebseebbq Tgobbbbeee bqbqoPeeob ebqbpoq4qe 0PS9 43.64euoqe6 4eequee344 00444P0404 0404b44oeo b4ouve4oqo pbbgbqopoo 08D,9 ebe4opqaqb PPO4PDED06 eoqopq.aebo poDobb4boe Dqqbqbqoqq. beqopeeqbb 0p9 e3ebeoe4uo 4b434343.54 eob4oqobog beogaeoqbp qbbqboobob eobbbbqqe4 09E9 qbbbqoboqb bbobqqbbqq. oopbbeooqo Peepeeepqq. qqqoppebee qbbTepeeee 00E9 424444epoe bebePo4upq bsqe4upp4q. 44e4o4eob4 qeo4uo444b 44ebupeP.4.
0fi9 Te4eqeoepe bbepeaeoPo ebeqeqeqe4 qq4qoppoqo bqqeepegbb eqq.De5eo4q.
0819 ob4poqe4b4 pe4pob4s4D obep4oqob bee44D4bqb qpeep4ebee eb4p344opq 0z19 qu555oe4o5 eeobbqqeee bboqqqabeo 64 04=566 booDeobqee b5e44beoeb 0909 bb4beopqee obbebbebeo obeebbeobq qbPue4bebe oqbeoppopo obeoboebeb 0009 opeambqebq 5epoebee4b eeebeoupeb qeboeboaqo qobubbgoop qqobebbeeb OMS 443peo64ob eopbobboob bqoqpboobe poqqa4344p beoqeopoob b4bb5bobbe OBBS bqobbDoeeb eebqopoeob eDqbbebobo obebqopbbb eboeepobbe bopeopbqeb pag 4ebb4pee6b bobeop4pee Pqbobboqpq eoboepoob4 boboebobee beebeebeob 09Lc ueb5ebb4ob eoobopeeqq. o5eobeeb4e'b6oqobpeep Dbbeebebbq ebeobebeee 00L; 4e4beDoeb5 obopoebogb obebgebbeb 44bbeob4eo q4ogeepbee eb4obeebee oD,9g be5y4Deobaq booqbeqqee speepoboob eobeboeebb eppobeebbe obe544obeo 080s bebbebbqob eabbbqqabe epobb.eb64o pobeo4oquo oepobbepoq qbee4o4beP
oqb4obqbbb ebogoeebbe obqobeeopb beebqpbebb eeopebppbb obebbqoeeo 09pg 6epobo2obq eeoebqbsbe ebeDoobDob obeobobebo obeobe4obe booboePbqo 00D,c eopoebbqbb epeqpqoepo ebueobooqi. o5o obebbq POPPDbebPD
op,Eg bebbubeebb gabebbebbe bb4Dbeoupb D4ebbo4obe pbb4D46obb obuebebqeb ogg bqobqobobo oqbeeob6q3 qoDbobpDpp opeDqpbebo pbbDbbqpbe bqubebubeb ozzg buobuboobo eDpboob000 bPbobeb4pq Po403644De ebbebbeobq queo4qop4e 09Ts upbpDbeebb 4Dqbebepbq geuebeeeeb qbebebeepo oqeeDq054-1, qqqebebqeb 00's ebepo4eob4 5D4obeebee 6e44pebgbo eepoe44ebb epb4ebeo4D bbeop4Dbee OVOS pbooqD6p6 euqqabqbbe bqubbbDqob eeeppebpbq DbbebogeuP oDDbepboqD
086v pubbueb43D ebuqebebbi, Pbueeepbpe Po4qobe4bq abggobobbb obeoPpubbe A

Lys Lys Leu Val Trp Ile Pro Ser Glu Arg His Gly Phe Glu Ala Ala Ser Ile Lys Glu Glu Arg Gly Asp Glu Val Met Val Glu Leu Ala Glu Asn Gly Lys Lys Ala Met Val Asn Lys Asp Asp Ile Gin Lys Met Asn Pro Pro Lys Phe Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Lys Asp Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Asn Leu Pro Ile Tyr Ser Glu Asn Ile Ile Glu Met Tyr Arg Gly Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Ser Glu Ser Ala Tyr Arg Cys Met Leu Gin Asp Arg Glu Asp Gin Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gin Tyr Leu Ala His Val Ala Ser Ser His Lys Gly Arg Lys Asp His Asn Ile Pro Gly Glu Leu Glu Arg Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ser Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser 225 230 235 . 240 Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Thr Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Val Arg Gin Ala Lys Asp Glu Arg Thr Phe His Ile Phe Tyr Gin Leu Leu Ser Gly Ala Gly Glu His Leu Lys Ser Asp Leu Leu Leu Glu Gly Phe Asn Asn Tyr Arg Phe Leu Ser Asn Gly Tyr Ile Pro Ile Pro Gly Gin Gin Asp Lys Asp Asn Phe Gin Glu Thr Met Glu Ala Met His Ile Met 325 330 . 335 Gly Phe Ser His Glu Glu Ile Leu Ser Met Leu Lys Val Val Ser Ser Val Leu Gln Phe Gly Asn Ile Ser Phe Lys Lys Glu Arg Asn Thr Asp .355 360 365 Gin Ala Ser Met Pro Glu Asn Thr Val Ala Gin Lys Leu Cys His Leu Leu Gly Met Asn Val Met Glu Phe Thr Arg Ala Ile Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Glu Gin 405 410 415 ' Ala Asp Phe Ala Val Glu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Leu Phe Arg Trp Leu Val His Arg Ile Asn Lys Ala Leu Asp Arg Thr Lys Arg Gin Gly Ala Ser Phe Ile Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Glu Leu Asn Ser Phe Glu Gin Leu Cys Ile Asn Tyr Thr Asn . :
Glu Lys Leu Gin Gin Leu Phe Asn His Thr Met Phe Ile Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Glu Trp Asn Phe Ile Asp Phe Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro Pro Gly Val Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Thr Phe Val Glu Lys Leu Val Gin Glu Gin Gly Ser His Ser Lys Phe Gin Lys Pro Arg Gin Leu Lys Asp Lys Ala Asp Phe Cys Ile Ile His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Asp Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val Ala Thr Leu Leu His Gin Ser Ser Asp Arg Phe Val Ala Glu Leu Trp Lys Asp Val Asp Arg Ile Val Gly Leu Asp Gin Val Thr Gly Met Thr Glu Thr Ala Phe Gly Ser Ala Tyr Lys Thr Lys Lys Gly Met Phe Arg Thr Val Gly Gin Leu 645. 650 655 Tyr Lys Glu Ser Leu Thr Lys Leu Met Ala Thr Leu Arg Asn Thr Asn Pro Asn Phe Val Arg Cys Ile Ile Pro Asn His Glu Lys Arg Ala Gly Lys Leu Asp Pro His Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Ile Val Phe Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile Pro Lys Gly Phe Met Asp Gly Lys Gin Ala Cys Glu Arg Met Ile Arg Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Ile Gly Gin Ser Lys Ile Phe Phe Arg Ala Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp Leu Lys Ile Thr Asp Ile Ile Ile Phe Phe Gin Ala Val Cys Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala Lys Lys Gin Gin Gin Leu Ser Ala Leu Lys Val Leu Gin Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg His Trp Gin Trp Trp Arg Val Phe Thr Lys Val Lys Pro Leu Leu Gin Val Thr Arg Gin Glu Glu Glu Leu Gin Ala Lys Asp Glu Glu Leu Leu Lys Val Lys Glu Lys Gin Thr Lys Val Glu Gly Glu Leu Glu Glu Met Glu Arg Lys His Gin Gin Leu Leu Glu Glu Lys Asn Ile Leu Ala Glu Gin Leu Gin Ala Glu Thr Glu Leu Phe Ala Glu Ala Glu Glu Met Arg Ala Arg Leu Ala Ala Lys Lys Gin Glu Leu Glu Glu Ile Leu His Asp Leu Glu Ser Arg Val Gila Glu Glu Glu Glu Arg Asn Gln Ile Leu Gln Asn Glu Lys Lys Lys Met Gln Ala His Ile Gln Asp Leu Glu Glu Gln Leu Asp Glu Glu Glu Gly Ala Arg Gln Lys Leu Gln Leu Glu Lys Val Thr Ala Glu Ala Lys Ile Lys Lys Met Glu Glu Glu Ile Leu Leu Leu Glu Asp Gln Asn Ser Lys She Ile Lys Glu Lys Lys Leu Met Glu Asp Arg Ile Ala Glu Cys Ser Ser Gln Leu Ala Glu Glu Glu Glu Lys Ala Lys Asn Leu Ala Lys Ile Arg Asn Lys Gln Glu Val Met Ile Ser Asp Leu Glu Glu Arg Leu Lys Lys Glu Glu Lys Thr Arg Gln Glu Leu Glu Lys Ala Lys Arg Lys Leu Asp Gly Glu Thr Thr Asp Leu Gln Asp Gln Ile Ala Glu Leu Gln Ala Gln Ile Asp Glu Leu Lys Leu Gln Leu Ala Lys Lys Glu Glu Glu Leu Gln Gly Ala Leu Ala Arg Gly Asp Asp Glu Thr Leu His Lys Asn Asn Ala Leu Lys Val Val Arg Glu Leu Gln Ala Gln Ile Ala Glu Leu Gln Glu Asp She Glu Ser Glu Lys Ala Ser Arg Asn Lys Ala Glu Lys Gln Lys Arg Asp Leu Ser Glu Glu Leu Glu Ala Leu Lys Thr Glu Leu Glu Asp Thr Leu Asp Thr Thr Ala Ala Gln Gln Glu Leu Arg Thr Lys Arg Glu Gln Glu Val Ala Glu Leu Lys Lys Ala Leu Glu Glu Glu Thr Lys Asn His Glu Ala Gln Ile Gln Asp Met Arg Gln Arg His Ala Thr Ala Leu Glu Glu Leu Ser Glu Gln Leu Glu Gln Ala Lys Arg Phe Lys Ala Asn Leu Glu Lys Asn Lys Gln Gly Leu Glu Thr Asp Asn Lys Glu Leu Ala Cys Glu Val Lys Val Leu Gln Gln Val Lys Ala Glu Ser Glu His Lys Arg Lys Lys Leu Asp Ala Gln Val Gln Glu Leu His Ala Lys Val Ser Glu Gly Asp Arg Leu Arg Val Glu Leu Ala Glu Lys Ala Ser Lys Leu Gln Asn Glu Leu Asp Asn Val Ser Thr Leu Leu Glu Glu Ala Glu Lys Lys Gly Ile Lys Phe Ala Lys Asp Ala Ala Ser Leu Glu Ser Gln Leu Gln Asp Thr Gln Glu Leu Leu Gln Glu Glu Thr Arg Gln Lys Leu Asn Leu Ser Ser Arg Ile Arg Gln Leu Glu Glu Glu Lys Asn Ser Leu Gln Glu Gln Gln Glu Glu Glu Glu Glu Ala Arg Lys Asn Leu Glu Lys Gln Val Leu Ala Leu Gln Ser Gln Leu Ala Asp Thr Lys Lys Lys Val Asp Asp Asp Leu Gly Thr Ile Glu Ser Leu Glu Glu Ala Lys Lys Lys Leu Leu Lys Asp Ala Glu Ala Leu Ser Gin Arg Leu Glu Glu Lys Ala Leu Ala Tyr Asp Lys Leu Glu Lys Thr Lys Asn Arg Leu Gin Gin Glu Leu Asp Asp Leu Thr Val Asp Leu Asp His Gin Arg Gin Val Ala Ser Asn Leu Glu Lys Lys Gin Lys Lys Phe Asp Gin Leu Leu Ala Glu Glu Lys Ser Ile Ser Ala Arg Tyr Ala Glu Glu Arg Asp Arg Ala Glu Ala Glu Ala Arg Glu Lys Glu Thr Lys Ala Leu Ser Leu Ala Arg Ala Leu Glu Glu Ala Leu Glu Ala Lys Glu Glu Phe Glu Arg Gin Asn Lys Gin Leu Arg Ala Asp Met Glu Asp Leu Met Ser Ser Lys Asp Asp Val Gly Lys Asn Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Gin Gin Val Glu Glu Met Arg Thr Gin Leu Glu Glu Leu Glu Asp Glu Leu Gin Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu Val Asn Met Gin Ala Met Lys Ala Gin Phe Glu Arg Asp Leu Gin Thr Arg Asp Glu Gin Asn Glu Glu Lys Lys Arg Leu Leu Ile Lys Gin Val Arg Glu Leu Glu Ala Glu Leu Glu Asp Glu Arg Lys Gin Arg Ala Leu Ala Val Ala Ser Lys Lys Lys Met Glu Ile Asp Leu Lys Asp Leu Glu Ala Gin Ile Glu Ala Ala Asn Lys Ala Arg Asp Glu Val lie Lys Gin Leu Arg Lys Leu Gin Ala Gin Met Lys Asp Tyr Gin Arg Glu Leu Glu Glu Ala Arg Ala Ser Arg Asp Glu Ile Phe Ala Gin Ser Lys Glu Ser Glu Lys Lys Leu Lys Ser Leu Glu Ala Glu Ile Leu Gin Leu Gin Glu Glu Leu Ala Ser Ser Glu Arg Ala Arg Arg His Ala Glu Gin Glu'Arg Asp Glu Leu Ala Asp Glu Ile Thr Asn Ser Ala Ser Gly Lys Ser Ala Leu Leu Asp Glu Lys Arg Arg Leu Glu Ala Arg Ile Ala Gin Leu Glu Glu Glu Leu Glu Glu Glu Gin Ser Asn Met Glu Leu Leu Asn Asp Arg Phe Arg Lys Thr Thr Leu Gin Val Asp Thr Leu Asn Ala Glu Leu Ala Ala Glu 1765 1770 1775 .
Arg Ser Ala Ala Gin Lys Ser Asp Asn Ala Arg Gin Gin Leu Glu Arg Gin Asn Lys Glu Leu Lys Ala Lys Leu Gin Glu Leu Glu Gly Ala Val Lys Ser Lys Phe Lys Ala Thr Ile Ser Ala Leu Glu Ala Lys Ile Gly =

Gin Leu Glu Glu Gin Leu Glu Gin Glu Ala Lys Glu Arg Ala Ala Ala Asn Lys Leu Val Arg Arg Thr Glu Lys Lys Leu Lys Glu Ile Phe Met Gin Val Glu Asp Glu Arg Arg His Ala Asp Gin Tyr Lys Glu Gin Met Glu Lys Ala Asn Ala Arg Met Lys Gin Leu Lys Arg Gin Leu Glu Glu Ala Glu Glu Glu Ala Thr Arg Ala Asn Ala Ser Arg Arg Lys Leu Gin Arg Glu Leu Asp Asp Ala Thr Glu Ala Asn Glu Gly Leu Ser Arg Glu Val Ser Thr Leu Lys Asn Arg Leu Arg Arg Gly Gly Pro Ile Ser Phe Ser Ser Ser Arg Ser Gly Arg Arg Gin Leu His Leu Glu Gly Ala Ser Leu Glu Leu Ser Asp Asp Asp Thr Glu Ser Lys Thr Ser Asp Val Asn Glu Thr Gin Pro Pro Gin Ser Glu <210> 55 <211> 6442 <212> DNA
<213> Mus musculus <400> 55 ccttttctgt ccaggccgag gcctctggac cgccctgggc gccgaccatg gctgcagtga 60 ccatgtccgt gtctgggagg aaggtagcct ccaggCcagg cccggtgcct gaggcagccc 120 aatcgttcct ctacgcgccc cggacgccaa atgtaggtgg ccctggaggg ccacaggtgg 180 agtggacagc ccggcgcatg gtgtgggtgc cctcggaact gcatgggttc gaggcagcag 240 ccctgcggga tgaaggggag gaggaggcag aagtggagct ggcggagagt gggcgccgcc 300 tgcggctgcc cagggaccag atccagcgca tgaacccacc caagttcagc aaggcagaag 360 atatggctga gctcacctgc ctcaacgagg cctcggtcct gcacaacctg cgagaacgct 420 actactccgg gctcatttat acctactctg gcctcttctg tgtggtcatt aacccataca 480 agcagctgcc catctacacg gaggccattg ttgaaatgta ccggggcaag aagcgccatg 540 aggtgccacc tcacgtgtat gctgtgacgg agggcgcgta ccgcagcatg cttcaggatc 600 gtgaggatca atccattctc tgcacgggag agtctggcgc tgggaagacg gagaacacca 660 agaaggtcat ccagtacctg gcccatgtgg catcatctcc aaagggcagg aaggagcctg 720 gtgtccctgc ctccgtcagc accatgtctt atggggagct agagcgtcag cttcttcaag 780 ccaaccccat cctagaggcc tttggcaatg ccaagacagt gaagaacgac aactcttccc 840 gatttggcaa attcatccgc atcaactttg atattgctgg ctacatcgtg ggagcaaaca 900 tcgagaccta tctgttggag aagtcccggg ccatcagaca ggccaaggat gaatgcagct 960 tccatatctt ctaccagctg ctagggggcg ctggggagca gctaaaagct gacctccttc 1020 tggagccctg ttcccattat cgcttcctga ccaatgggcc ctcatcgtcc ccgggccagg 1080 agcgtgagtt attccaggag accctggagt ccctgcgtgt gctgggcctc ctcccagaag 1140 agatcactgc catgctgcgc actgtctctg ctgtcctcca gtttggcaac attgtcctga 1200 agaaagagcg caatacggac caagccacca tgcctgacaa cacagctgcc cagaagcttt 1260 gccgcctctt gggactcgga gtgaccgact tctccagagc ccttctcaca ccccgcatca 1320 aagtgggccg agattatgtt cagaaagcac aaaccaagga gcaggctgac tttgcgctgg 1380 aggctctggc caaagctacc tatgagcgcc tgttccgctg gctggttctg cggctcaacc 1440 gtgccctgga cagaagcccg cggcagggtg cctccttcct gggcatcctg gacatcgcgg 1500 gctttgagat cttccagctg aactccttcg agcagctgtg catcaactac accaacgaga 1560 agctacagca gctattcaac cacaccatgt tcgtgctgga gcaggaggag taccagcgag 1620 agggcatccc ctggaccttc ctagacttcg ggttggacct gcaaccttgc atcgacctca 1680 ttgagcgtcc ggccaaccct ccaggtctcc tggccctgct ggacgaggag tgctggttcc 1740 og's bbeeo4obpe bepbpb4pee ebbbpobe54 oppeq4464e 6pbopboboo oqDBeq5o6o 00IS pbebbebeqb .6Pbbbobbqb qoerebbPPbq PbepoqbbeD bqp5eebeE5 4obpobePbq ovos bpobbPbPpb buPobbbeob bb4o6g3bqo 4e3ebe3bob beeb44bebb ebb4Deebb4 08617 obp.564Dbuu buuob000bq obb4e40.654 peobbbeb-eo buebboeubb pb4p6o6obs, oz617 6p456p6poE) oebe6Peqob Po6PPoobbq p6e3.66e66o 652bebbubq Moofyq.ebqp 09817 boboobbelpo bqoaeboboe PbTeoPPogo 65es,b4o4o5 6.20646q.a26 qft.pbbqopf, 008P 064D.5peopb qubb2buobo DbPoeb4obP .64ebb2bbqq. pubpD2b4bb Pouo.ebbobq OD'Lf7 00Pb3beopb pobbPaePbq obbob6Pegb opo6ubobe5 6-406.26peob 48opPbeep6 089t, bbqfippEq.pf, bePobpo6eb qpb4oPpEceP bbqobp64ob fibp6q34o64 booePbpobb OZ9P 2bebb4obeb bebbbppobb ebbeobebbe beebb4oDob bbppoebi.ob oqbqopobbb o9gf7 000bbpbebo beb6boo652 eboobbubeq. .ebbo-e-ely4.63 pubpebbqb4 obbboeqoqq.

00SD, beobqobbpp bebbebeobb qopqobpope bqqqeepbeo beDbeebeeb ebb4oppeob OT7171, P6433goeleo beebeobeob bb ebb elq.3epob4e6 Debb44bebb eobe3bqoeb 08Ef7 oobobb3pob ebobubbqoe bopPbpqb4o bbebqopb2.2 epbP365qop bobeopoub4 OZEfi 000e5ebeob bef&Ecoobe obgboobobb ogobbp6be6 Bbbqpbbebb qpb46boblo 09ZI7 bbebpubepb bpooboobob b3aq.pub4o gogobeoDb beoboeobeb eobi.obebbb 0HD, op&Eq.obbbo ee5bbeop6q. qbbqb5e.65e bebeo baboqqab 556o6bobbp ObTD. 50056p6u40 005q5064.64 Boop456fi5q. 4opE6qp6pu eobbbpooe6 e5be5beoqq.
08017 05gpeebbpo oppoebqeob 4obepoo4bp be3646eo5p 643Elebbepo bbb4obbeog OZO epobppuppq 62,6_605b-e.64 be.54opobeo spogblbo6e bpb443eebE0 06.6p000be6 096z pbpo54o5pe be54o6qo5b pbqoqbboqo 6b6pEce5f0p4 qpbqUepoqe 5DobEobepo3 006E 65ubbpoeqo beopo46-ebb qooboobobb ebpebpobeb qbbb.ebbeop bpboqoaebe 08E ofq.00beobe b4obubDobb p2bgDbaboo 464.5.62.6qob bubbqopoqe 4obbpqoPb2 onz ebubbbqbqb 455p2Po666 Bebboopb2p obEobqqbeo 5eboobb4p5 pbt0.456.4peo onz be.poobeqeo b6pbeop6pb qabebbpobq pooq.bqbbpb 4poopfq.bpo o4be5bpbep oggz ag.i.eobeee b2eb4obebe oe.64bb2bbe obebbbebee op4b.E,Db4ob pbbuobeopo 009E bopeopuppq qutb4o4oeo eabeboqofre bbbb.q.5oe4o pobbebb445 pbbE,boBbb.q.
of7cz oaebbboobo beobePbPE6 obbPupobbb poobeq.bbbo beN.Dbpebb qopebbebbu 08pz oqob6Pb4ob qq.pobEgobb upsobbebeb ob4o334bee 34ofq.46e3o obill000fq.b ozpz bqbbbpbpub bPbeoBb6Po 4D5qopoboo 5bpobgobeb 4ubbebbueo boobbbqp.62 ogzz oeDboqobqo peb5pbPoE6 bebPDBueb2 o5ebb4E6q2 be35-255204 qobebuoqob HEE e5pb5bboeb bqobeopflob ee6q3E.Pebe Bpqoppbbpo oboebbbepb pbbefifiepbp 2b4obbooeb epbb4PoubE p4ogeeoepo bepbqegeeu o4o5beb4o5 eeeoob 08TE PPPPOqbPPP bebppbficebe pbpo5Pobbe puo4Dogoqq 6.264365435 bobp5be5bq OZTE 36gobbpbbo bebbeeobpb gobpuooqq.0 ebeopebbpb bqop4obqpb gooebbpbbe 090E bqq.4eeebee b4ebeepobb ebeoPoo2bq Ebeebebbqo bepeqabepb eobb000bqb opoz bbebbpb4o5 epbbqopeoo 526p.bPqabe bbeDa4pTeo bpobeobi.ob bebpp6pp6E, OD'6Z b4butvo6qp bPobboobpo BqbebpPbee bbebo6fib4b pbapobbubb qobp5popbq 088Z 66456qobpb bgobebbeob eebb000bqo bfiqoebobob bbobDebebb eboobbebqo oz8z gobqogoEceb pobepbeobe bogqobuobe 54obb4po5o bopobobubb efthebeqobs, ogLz o236646pbo qUbsob4oe ubabbbqbee 51.5oi.ob3.5e beobeobeob qobpbbpoqq OOLZ bppebpD6qa bebbeopobp bobobbeobq ob4bbpbqpb bpobboeopb 4bbRobqpbq ugz oppobeeb4b bueo4poqq.b qobbPbbqbb gbeob6.43pe ayeo4o5e3 goop4opbqo oesz 546qopue5e 5eo64p6.4b5 525'43;35-46 PEopD6pobpo 5pobbop6p5 -200;4'40E66 OZcZ e4b000bbqo peqobbbbop obbobeobbe 3344404bqb Pqvp-TepEto opoqbePpbq 09DrZ opebbbobeb b2.5bebbgob eaoabbi.Doq. bb6beabbbp oqi.04404eb PP0.5PPPDa6 0017z b4qbgb3peq bqopeeopoo ebeqobebbq opobbepoqp b4u5eeEcebq bqopbbeoes, Of7Cz eobboebbqe 344Dbfibeep poggu4pEop pboopopo4D oqepebqeqo bobpDebooq.

04004eo6Do epopoo44ob 5eeppbo454 042pboeq.eq bbbebDqoo4 ozzz bbbboeeqbq qbooqoepoo ebbqobqbbq poboboobEt bqobeeebbq obbbpbeebe 09-CZ bg234223o3 gq5oqe3.6go'booqb41q4b eqooDeeope oeeobeoob DeDDbb4po4 00-Tz poboobpeclo poqep6Peyo eloqabeobb bb4b4oebbo p44bgeebbq 6Dobopoopb orioz opbbabbboo Eopobb4eb2 E0544pobob eeq.be2Db2b .5qobbabqbp qpobbbebbq 0861 5.4e65e-e5b4 oTetp64obe 3epi.34boqu 56peDbpb23 peaqqo5q4p oboobbqbqe 0F6T PoPbqeebqo popoe6b4v3 eebpebqe64 obbgbebgbu pabPepoe43 pEq.4bbpepb 0981 bpDb4e4p2o bqoD4bobeo 44oebpDbbe p4ebubDbqD 3226bepoop ba62334422 0081 POD0020052 obbb?Dbebb popoboqbbe pbebb45444 qoi.beepe.65 o23obbeepo ggctggaagc tgaggtgctg cgtctgcaag aggaacttgc tgcctcagac cgagcccgga 5220 ggcaggccca gcaagacaga gacgagatgg cagaggaggt ggccagtggc aatcttagca 5280 aggcagccac cctggaggaa aaacggcagc tggaggggcg actgagccag ttggaagagg 5340 agctggagga agaacagaac aactcggagc tgctcaagga ccattaccga aagctagtgc 5400 tacaggtcga gtccctcacc acagaactgt ctgccgaacg aagtttctca gccaaggccg 5460 agagtggacg gcagcagctg gagcggcaga tccaggaact gcgggcccgc ttgggtgaag 5520 aggatgctgg agcccgagcc aggcagaaaa tgctgatcgc tgctctggag tctaaactgg 5580 cccaggcaga ggagcagctg gagcaggaga gcagggagcg catcctctct ggcaagctgg 5640 tacgcagagc tgagaagcgg ctgaaggagg tagttcttca ggtggatgaa gagcgcaggg 5700 tggctgacca ggtccgggac cagctggaga aaagcaacct ccggctgaag cagctcaaga 5760 ggcagctgga ggaggcagag gaggaggcat ctcgggcaca ggctggtcgg aggcggctgc 5820 agcgggagct ggaggacgtc actgagtctg cagaatccat gaaccgggag gtgaccacgc 5880 tgaggaacag gctccggcgt ggcccactta cattcaccac acggactgtg cgccaggtgt 5940 tccggctgga agagggcgtg gcttctgacg aggaagaggc tgaaggagct gaacctggct 6000 ctgcaccagg ccaggagccg gaggctccgc cccctgccac accccaatga tccagtctgt 6060 cctagatgcc ccaaggacag agccctttcc agtgcccctc ctggtttgca ctttgaaatg 6120 gcactgtcct ctggcacttt ctggcattga tgaaccctcc tgggacccca ggacccctgc 6180 ccactggggg ccccaaacca aggagctggg tgggagggag gccatgatgg tctctcttgt 6240 tagagaaaca aaattgaacg tggatgtcaa gaatgtcctg tctgcaccta ttttcagcag 6300 gcctgtcccc tggagagggc aggcagggtg cttccatccc ctctcagtat cttgccctct 6360 tttttggggg gaagtggggt gtctgtgtgc tcatagggta atgctcatgg cccctcatgc 6420 tccagacact aaagaaataa aa 6442 <210> 56 <211> 2000 <212> PRT
<213> Mus musculus <400> 56 Met Ala Ala Val Thr Met Ser Val Ser Gly Arg Lys Val Ala Ser Arg Pro Gly Pro Val Pro, Glu Ala Ala Gln Ser Phe Leu Tyr Ala Pro Arg Thr Pro Asn Val Gly Gly Pro Gly Gly Pro Gin Val Glu Trp Thr Ala Arg Arg Met Val Trp Val Pro Ser Glu Leu His Gly Phe Glu Ala Ala Ala Leu Arg Asp Glu Gly Glu Glu Glu Ala Glu Val Glu Leu Ala Glu Ser Gly Arg Arg Leu Arg Leu Pro Arg Asp Gin Ile Gin Arg Met Asn Pro Pro Lys Phe Ser Lys Ala Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Arg Glu Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Gin Leu Pro Ile Tyr Thr Glu Ala Ile Val Glu Met Tyr Arg Gly Lys Lys Arg His Glu Val Pro Pro His Val Tyr Ala Val Thr Glu Gly Ala Tyr Arg Ser Met Leu Gin Asp Arg Glu Asp Gin Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gin Tyr Leu Ala His Val Ala Ser Ser Pro Lys Gly Arg Lys Glu Pro Gly Val Pro Ala Ser Val Ser Thr Met Ser Tyr Gly Glu Leu Glu Arg Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ala She Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Ile Ala Gly Tyr Ile Val.Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Ile Arg Gin Ala Lys Asp Glu Cys Ser Phe His Ile Phe Tyr Gin Leu Leu Gly Gly Ala Gly Glu Gin Leu Lys Ala Asp Leu Leu Leu Glu Pro Cys Ser His Tyr Arg Phe Leu Thr Asn Gly Pro Ser Ser Ser Pro Gly Gin Glu Arg Glu Leu Phe Gin Glu Thr Leu Glu Ser Leu Arg Val Leu Gly Leu Leu Pro Glu Glu Ile Thr Ala Met Leu Arg Thr Val Set Ala Val Leu Gin She Gly Asn Ile Val Leu Lys Lys Glu Arg Asn Thr Asp Gin Ala Thr Met Pro Asp Asn Thr Ala Ala Gin Lys Leu Cys Arg Leu Leu Gly Leu Gly Val Thr Asp She Ser Arg Ala Leu Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Glu Gin Ala Asp Phe Ala Leu Glu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Leu Phe Arg Trp Leu Val Leu Arg Leu Asn Arg Ala Leu Asp Arg Ser Pro Arg Gin Gly Ala Ser She Leu Gly Ile Leu Asp Ile Ala Gly She Glu Ile Phe Gin Leu Asn Ser She Glu Gin Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gin Gin Leu Phe Asn His Thr Met Phe Val Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Pro Trp Thr She Leu Asp She Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro Pro Gly Leu Leu Ala Leu Lou Asp Glu Glu Cys Trp She Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys Val Ala Gin Glu Gin Gly Ser His Pro Lys Phe Gin Arg Pro Arg Asn Leu Arg Asp Gin Ala Asp She Ser Val Leu His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Ser Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val Ala Ala Leu Leu His Gin Ser Thr Asp Arg Leu Thr Ala Glu Ile Trp Lys Asp Val Glu Gly Ile Val Gly Lou Glu Gin Val Ser Ser Leu Gly Asp Gly Pro Pro Gly Gly Arg Pro Arg Arg Gly Met Phe Arg Thr Val Gly Gin Leu Tyr Lys Glu Ser Leu Ser Arg Leu Met Ala Thr Leu Ser Asn Thr Asn Pro Ser Phe Val Arg Cys Ile Val Pro Asn His Glu Lys Arg Ala Gly Lys Leu Glu Pro Arg Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Ile Leu Phe Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile Pro Lys Gly Phe Met Asp Gly Lys Gin Ala Cys Glu Lys Met Ile Gin Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Val Gly Gin Ser Lys Ile Phe Phe Arg Ala Gly Val Leu Ala Gin Leu Glu Glu Glu Arg Asp Leu Lys Val Thr Asp Ile Ile Val Ser Phe Gin Ala Ala Ala Arg Gly Tyr Leu Ala Arg Arg Ala Phe Gin Arg Arg Gin Gin Gin Gin Ser Ala Leu Arg Val Met Gin Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg Asn Trp Gin Trp Trp Arg Leu Phe Ile Lys Val Lys Pro Leu Leu Gin Val Thr Arg Gin Asp Glu Val Leu Gin Ala Arg Ala Gin Glu Leu Gin Lys Val Gin Glu Leu Gin Gin Gin Ser Ala Arg Glu Val Gly Glu Leu Gin Gly Arg Val Ala Gin Leu Glu Glu Glu Arg Thr Arg Leu Ala Glu Gin Leu Arg Ala Glu Ala Glu Leu Cys Ser Glu Ala Glu Glu Thr Arg Ala Arg Leu Ala Ala Arg Lys Gin Glu Leu Glu Leu Val Val Thr Glu Leu Glu Ala Arg Val Gly Glu Glu Glu Glu Cys Ser Arg Gin Leu Gin Ser Glu Lys Lys Arg Leu Gin Gin His Ile Gin Glu Leu Glu Ser His Leu Glu Ala Glu Glu Gly Ala Arg Gin Lys Leu Gin Leu Glu Lys Val Thr Thr Glu Ala Lys Met Lys Lys Phe Glu Glu Asp Leu Leu Leu Leu Glu Asp Gin Asn Ser Lys Leu Ser Lys Glu Arg Arg Leu Leu Glu Glu Arg Leu Ala Glu Phe Ser Ser Gin Ala Ala Glu Glu Glu 1025 1030 1035 1040 .
Glu Lys Val Lys Ser Leu. Asn Lys Leu Arg Leu Lys Tyr Glu Ala Thr Ile Ser Asp Met Glu Asp Arg Leu Lys Lys Glu Glu Lys Gly Arg Gin Glu Leu Glu Lys Leu Lys Arg Arg Leu Asp Gly Glu Ser Ser Glu Leu Gin Glu Gin Met Val Glu Gin Lys Gin Arg Ala Glu Glu Leu Leu Ala Gln Leu Gly Arg Lys Glu Asp Glu Leu Gln Ala Ala Leu Leu Arg Ala Glu Glu Glu Gly Gly Ala Arg Ala Gln Leu Leu Lys Ser Leu Arg Glu Ala Gin Ala Gly Leu Ala Glu Ala Gln Glu Asp Leu Glu Ala Glu Arg Val Ala Arg Ala Lys Ala Glu Lys Gln Arg Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu Arg Gly Glu Leu Glu Asp Thr Leu Asp Ser Thr Asn Ala Gin Gln Glu Leu Arg Ser Lys Arg Glu Gln Glu Val Thr Glu Leu Lys Lys Ala Leu Glu Glu Glu Ser Arg Ala His Glu Val Ser Met Gln Glu Leu Arg Gln Arg His Ser Gln Ala Leu Val Glu Met Ala Glu Gln Leu Glu Gin Ala Arg Arg Gly Lys Gly Val Trp Glu Lys Thr Arg Leu Ser Leu Glu Ala Glu Val Ser Glu Leu Lys Ala Glu Leu Ser Ser Leu Gln Thr Ser Arg Gln Glu Gly Glu Gln Lys Arg Arg Arg Leu Glu Ser Gln Leu Gln Glu Val Gln Gly Arg Ser Ser Asp Ser Glu Arg Ala Arg Ser Glu Ala Ala Glu Lys Leu Gln Arg Ala Gln Ala Glu Leu Glu Ser Val Ser Thr Ala Leu Ser Glu Ala Glu Ser Lys Ala Ile Arg Leu Gly Lys Glu Leu Ser Ser Ala Glu Ser Gln Leu His Asp Thr Gln Glu Leu Leu Gln Glu Glu Thr Arg Ala Lys Leu Ala Leu Gly Ser Arg Val Arg Ala Leu Glu Ala Glu Ala Ala Gly Leu Arg Glu Gln Met Glu Glu Glu Val Val Ala Arg Glu Arg Ala Gly Arg Glu Leu Gln Ser Thr Gln Ala Gln Leu Ser Glu Trp Arg Arg Arg Gln Glu Glu Glu Ala Ala Val Leu Glu Ala Gly Glu Glu Ala Arg Arg Arg Ala Ala Arg Glu Ala Glu Thr Leu Thr Gln Arg Leu Ala Glu Lys Thr Glu Ala Val Glu Arg Leu Glu Arg Ala Arg Arg Arg Leu Gln Gin Glu Leu Asp Asp Ala Thr Val Asp Leu Gly Gln Gln Lys Gln Leu Leu Ser Thr Leu Glu Lys Lys Gln Arg Lys Phe Asp Gln Lou Leu Ala Glu Glu Lys Ala Ala Val Leu Arg Ala Val Glu Asp Arg Glu Arg Ile Glu Ala Glu Gly Arg Glu Arg Glu Ala 1490 1495 = 1500 Arg Ala Leu Ser Leu Thr Arg Ala Leu Glu Glu Glu Gln Glu Ala Arg Glu Glu Leu Glu Arg Gln Asn Arg Ala Leu Arg Ala Glu Leu Glu Ala Leu Leu Ser Ser Lys Asp Asp Val Gly Lys Asn Val His Glu Leu Glu 1540 1545 . 1550 Arg Ala Arg Lys Ala Ala Glu Gin Ala Ala Ser Asp Leu Arg Thr Gin Val Thr Glu Leu Glu Asp Glu Leu Thr Ala Ala Glu Asp Ala Lys Leu Arg Leu Glu Val Thr Val Gin Ala Leu Lys Ala Gin His Glu Arg Asp Leu Gin Gly Arg Asp Asp Ala Gly Glu Glu Arg Arg Arg Gin Leu Ala Lys Gin Leu Arg Asp Ala Glu Val Glu Arg Asp Glu Glu Arg Lys Gin 1620 1625= 1630 Arg Ala Leu Ala Met Ala Ala Arg Lys Lys Leu Glu Leu Glu Leu Glu Glu Leu Lys Ala Gin Thr Ser Ala Ala Gly Gin Gly Lys Glu Glu Ala Val Lys Gin Leu Lys Lys Met Gin Val Gin Met Lys Glu Leu Trp Arg Glu Val Glu Glu Thr Arg Ser Ser Arg Asp Glu Met Phe Thr Leu Ser Arg Glu Asn Glu Lys Lys Leu Lys Gly Leu Glu Ala Glu Val Leu Arg Leu Gin Glu Glu Leu Ala Ala Ser Asp Arg Ala Arg Arg Gin Ala Gin Gin Asp Arg Asp Glu Met Ala Glu Glu Val Ala Ser Gly Asn Leu Ser Lys Ala Ala Thr Leu Clu Glu Lys Arg Gin Leu Glu Gly Arg Leu Ser Gin Leu Glu Glu Glu Leu Glu Glu Glu Gin Asn Asn Ser Glu Leu Leu Lys Asp His Tyr Arg Lys Leu Val Leu Gin Val Glu Ser Leu Thr Thr Glu Leu Ser Ala Glu Arg Ser Phe Ser Ala Lys Ala Glu Ser Gly Arg Gin Gin Leu Glu Arg Gin Ile Gin Glu Leu Arg Ala Arg Leu Gly Glu = Glu Asp Ala Gly Ala Arg Ala Arg Gin Lys Met Leu Ile Ala Ala Leu Glu Ser Lys Leu Ala Gin Ala Glu Glu Gin Leu Glu Gin Glu Ser Arg Glu Arg Ile Leu Ser Gly Lys Leu Val Arg Arg Ala Glu Lys Arg Leu Lys Glu Val Val Leu Gin Val Asp Glu Glu Arg Arg Val Ala Asp Gin Val Arg Asp Gin Leu Glu Lys Ser Asn Leu Arg Lou Lys Gln Leu Lys Arg Gin Leu Glu Giu Ala Glu Glu Glu Ala Ser Arg Ala Gin Ala Gly Arg Arg Arg Leu Gin Arg Glu Leu Glu Asp Val Thr Glu Ser Ala Glu Ser Met Asn Arg Glu Val Thr Thr Leu Arg Asn Arg Leu Arg Arg Gly Pro Leu Thr Phe Thr Thr Arg Thr Val Arg Gin Val Phe Arg Leu Glu Glu Gly Val Ala Ser Asp Glu Glu Glu Ala Glu Gly Ala Glu Pro Gly Ser Ala Pro Gly Gin Glu Pro Glu Ala Pro Pro Pro Ala Thr Pro Gin SZT
ogoE bubf?qobqob bebbabebbp so5E,b4obpp pol.Teebpoo e,f)ebbqopq. 05405qoppb 00H bpbbe6qqqe ee5ee5q.P.62 Poo.66e5eae ope5.46bee6 ebbqobpoeq obpeapobbo OMZ opbqbbbebb ebqobeebbq opeoo6Pbeb Pqobubbpoo 4Pqeobpobe obqDbbebpP
088Z beebebi.beb eabqpbeobb pobeo.64beb ePbe2bb-ebo bbbqixebopo bbpbb4Dbeb ozgz eopbqbbqbb qp6ub540.6e 5bpobpp650 Dob4obbqop bobobbbobo ebpb6p6Do6 09L obeboobpu bPobebo.1.4o bpobpbqobb goobobopob obebbpbbPb OOL e4062Deobb qbeboq.bae ob4peebbbb .54beebqbpq D5pbebeobe abeobl.obeb Z
opgz beoqq.bppeb pobqp.butbp popE,Dbobob bpob4o5455 ebTe.65up56 opopEq.bbuo 08gZ b4obqoppob ee6.1.bbeepq Poqqbgobbr. bbqbbqbeob bqoupb6eaq. obeepqopeq ozsz 33bqob1b.1.3 eppbebeobq ebqbbbebqo 4obi.bpbe3b eabeabeobb oebebeopi.4 09Z 4pbbbpqboo obbqopeqpb .5553p3bbob eob5eopqq4 040.46Pquo4 eopboaeoqb oopz eepb4poeb5 bobebbebbe ffq.obpopob Egool.bbbbe oftheopqq.34 qompErepobp 017E3 ppoobb4#14 booeqbqope ppowebego bebb43O3bb epo42b4ebe eiyebqbqopb ogzz boeprobbo e554234-4Db 66PPoopl1.e qabouebow peoqoaquep bqpqobobeo 03 P5poqq6p.56 p331.434opq P0600P2300 oqqobbeeop boqbqoqeob peqeqbbbeb 091z D403;566.63 upqb4gboo4 peepoebbqo Eqbbqopbon oobebbqobp ephbgobbbe ooTz b?ebeb4sog peopogq.504 eobqp6oDqb qq4.46eq.3op ePOOPOPPO5 eoloboppob ofioz 6-4p04po5D3 6e6qopoqee Beppoe.qoqo 5p065ELT5q. 3vb5ooqq64 ppfifiqboobo 0861 33o3b3D5bP bbbooPpoob b4P6Pbbq4o o6eobeeq6e pobpb6qob6 bfq.bogeobb 061 Babb.4.642bb pebb4o4e6u 64obepeogo .463gebbopo bpbeo3pDT4 o.5.4.4oDboob 09BT 5.45qppop64 eubqoe3oDe Bbqeoeebee fq.-264ob6q5 p64.6poobee uoeqoe54q5 0081 beeobboofq. pqopob4opq babeo44oeb pobopoqebp bobgooppbb pooppeobpo ObLT oqq2.pepoop eop&eobbbe obpbbepoob al.fibeEtebb qb4q4404be epubboupob 0891 6ETopoo4q6 Eq.D54.6P65-e bD2Bbqo6qo po6.54poqpq 5bepo4oDou epobbooqbo 0Z91 bebg4poq.op eboqeob4go oeeoN.opeb bqq.bbboggo ebuqop4goo ebbqoppogE, 09ST obbbebebob eapegbebbe bbeobebbqo fq.b543 DPOPDOPPD4 4P4a523bP0 00s1 p4o6sebu5o PPOOPOP4OU poqepeq.bgo 5eob2boq.qo ogoep64o6u poqqoqebeb 0D'f71 q4gob5b3b3 qeoubbgoog eobbbqopqg pogoobgbbb pobbobopob epbp3e5643 HET pob4.6ope2o qobbob4044 bb43b643bo 044bq33bp6 ebi.e4opeqo beeepobbqo ozET qobbebbqob ofq.qqopf)qo bbpoficebbse DOPPEO20bP pp6eoqq5q2 qq.e5p600b6 ogz.T bqbppeoqeo booppepeoq oqq.Doobebe Doqoqq.oe6o opfiqb.ebboq.
op.E65.1.qoqo 00ZT ob33f44qo6 pebpooa6qo bepepeepeb qoab4eopeo ob2eopebbo 2q2eobobeb opTT esebEebqop 45.4qeoppab fq.44.5Poogo oqb.q.Dfq.ogo 4bqopobo64 obTepobqop 0801 oq.u.E?e.bu2b2 opoqopqopb bb43.5q5q.EQ 6i.pooqbe5b qopoebp5be opqq.pqqbp6 oug q.53.6pbbeop bbboopoqbp Teoqwobbb Tepoopfq.po qq.3.6p4p4qe opoqq.64opo 06 bebbqoqq.Do 4ope54o5ee Peqpb-eoba6 65.6gobobbb bbegob4D.Ere oppqoqqoqp 006 Tepoqq.obuo frTeebqubbu epobbeaebe pqapo.55630 pq.beebeffq. gbqoqeqoae opg beba4.2opee obpbb5.4.6og yoeqobblob qq.eqpfq.4.40 peoqpobooq po44epeobb 08L qq.q.eboopq.4 D4OPP02532 Pbeefq.bpoe Beupabgepo bbqq400bbe buqop42pop OZL peuopbppoq. 434436eoqb obebeqobeE, b6bgoopqb4 5640 62E6p p562056be2 ogg pooqomeoqe obb-4.6q-epoo bbqoaeqbeo obb5ePOOPOPPE,R bba2.52-eb5b 009 43.63bbi.o46 ebebbboepb 4p4o4q.upoi. ee342bbe54 fm.ebbeojq. obTeobepho ops opqboBobbb ebboe54.64o .54Pgbq6o?D qDoeopbqbb ebqppobobe p52uobb6bo ogp Deqbqeep64 q64.i.poD5be bboep-eqoqe opobqobpof, PEOPqPOODP eqq.poqbbqb op .1.6qpqi.oqop 664ogoei.po 24empo43 bbboal.peqo eq.Dboeebeb obqopeepeo 09c b4poqbboqo obbubopepq o3.64=2340 bpbqabbi.eq. Pbeebuofibe eabeoqqbee QQ oppeopopeb geobobewq ebe3oPbb5,2 poobqp6bD5 qopboabobb bqbebuabob OVZ bqpbabb4bu pfippe,fie6b2 bbpbbbbeeb .426E63.6403 obeobeobbe 604qbbbqeo 081 bqope6bo4o optq.56bqbq bbTeo53bbo pobPoebb4b pbbqbbeoeo ob6be66qoo D.5645.5eq6q peeooboebb 3opobo6oPq oqopqq.63Te Poopbeobbe bqpoSq6bDo og obbepobbpo o400bpq6be ebbebbbl.pq bi.booqbqep oebqbeab4o belq.epoeboo LS <OOP>
snTnosnm snw <ET>
VNG <ZIZ>
LL9 <ITZ>
LS <OTZ>

Peueqee 26PPP4OPOP
09E9 beopq3b4e3 qappobb4e3 qabqueqbbb P4e340b4bq bqoqbqbbbb qbeebbbbbb 00E9 4444440400 ob44oTegbE. oi.D4opoo4P oa4gobqbbb eobbeobbbe 6ebb4oppog 0f79 bqpabbeobe al.q.q.q.eqope abqoqbqopq. bqeebeep4b 4ebbqbpeeb q4PPepOPPP
0819 bebegq.b1.43 4Dial.bbqeb 4epobbu665 ebbbqbbbqa bebbeeppee epopabbbbb H19 qoppoobqop poebbeopoo ebb5qop4o3 pue64.54qe obb4344qop obbqogooqb 0909 40Pabbqeee b4q4peob44 4bb1opqap3 ob4bp30444 poobeftoeb beep3ppb4e 0009 beqop4b4pg bpopqebgee ooppepeopb goo3poboo4 abbabboabe bbeopbbeop 0t76S eob-laqabbq ooeebqobeb beebqabbeb eebbeboebq al.qobb4b35 bbebeebb4D
088S bbo3q4b4bb ep3b3bqbqa ebboeoepoe 34423e4q.pe o3ob64bobb op4obbepee 08q bbebqoboeo oebqbbebbb opeebgpopq eubeobqoqb ebgpeo4boe bbe5b4obeb 09LS bbobeobqab Lobbpbboqb blabbepeob bboqoleobb ebbebbebeo bb-ebbebbqa OOLS 5P3b5Pbppo gobeDbepbq 0553pgDope obpePpbebb gobpoop55.5 ooqbbpoopb Of79g q06546.55eD bobefippbqp 6b4bbeoq40 q;beqbbebb eeb4obbDbe ebebqabebe 08gg Dbae4bb 40 b eeobb4343q poqeobobeb bbeDbebebb epbebb4obe 3bebbeb23b (Dss fyeDDobbqop ?e4o45p6b4 o40.64o6o4p b4o64eeepb pob5poo6e5 poobp.654a6 09VS q?bbebeebq bbfq.qpboop bb63.643u5 Eceo34ube3b bofipbb4obp 36pobbop6b 00t7g 45ebaboobb eepobeogoq 44beeboeeb 3obqoqb4oe pbepeoppoq oop4beboqb ODTS 5Poeq.Dbgbe qobppebope qqpoopbbpP oq3b4Dbeb5 oqoeeps,rbe DeebePbbpb 08Zg biabebbebe ebbi.q.beo3b eb4De5obbb bebbiabeob baeeeeebbe bbiaapepob OZZS eobbpuo5ei. qaqupob64b upabbgbbpb bu6eobb4e5 eboebebpoe beeobpDoob 091s beabbebboo obebooebeo qopbqpb4-4.3 eebbebeepb 43q.bobqabq bbablabeeb 00-Es 543556.6peo go62P5PPEce Egeeee5b6P obebqopopq gq.b4ebpbop boboopqobu ObOS gbobopbebb Pb2gbbe5bb obbgbqobeb beeb4ebeop 455eobTebp e6pebqpbeo 086D' beebqbeobb ebeebbeepb bbeobbbgob iabiaq.epeb e3bobbeeb4 4bebbebbqa 0Z6 eebbgobebb gobeebPeob poobqabbqp gobbgpeobb bebeobeebb opebbebgeb 099p obobebeqbb ebeaboebeb ee4abeobep opbbqabpab bebbobbebe bbebgbboob 008' 4ebTebo600 bbbeob4poe boboeeb4eo epogobbpeb 4ogobbeobq bqoeb4bbeb OPLP bgpobobqab pepobqpbbe beoboobeae 6.435eb4p5b e6544up6eo e64bbecepe 08917 bbobqapebq bepobeobbe pepbqobbob beeqboopbe bobebb4obe boeob4boee beeobbbqbo pbqebbepob Pobebqobqo pobeebbqob pbqobbbebq oqob4booue 09s, beobbebebb qabpbbebbb poobbebbpo bebbebeebb 4poobbboop eb4obolbqa 00sp 3obb60035b ebebobebbb pobbeuboob beLeqebboe ebi.booebee bbgbqabbbo 017D,t, eqpi.q.be354 obbpebebbe beobbqopqa beoppb444e eebbobpobe e5eebpbb40 08E17 Poeobeb-lao qabeobeebe obeobbbbqo gebb4b4opo 3b4eb3ebbq qbebbeobeo 0zE bgoeboobob booabebobe bb4Deboeub eq.biabbebq oebPeeebeo bbqoabobeD
opeb400peb ebeabbebbb opobeobqbo obobboqabb ebbebbbbqo bbeb5qob4b 00 boboobbebe ebeebbeopb oibobbobbq eebqpiaiab epoobbeDbo eobebeobia 0t7ifi bebbboobbq obbboeebbb e3pb44b5g5 bpbbebeebb gebeobebbb oqqabbbbob 090p bobbeboobb ebeq.paabqb 3b4b.l.booaq 6bbb4qopbb qabeeeobbb epoebebbeb 0z0, beo4gabgoe ebbeopoppe bTeab4obeo opqbebuob4 beobeb4obe bbpeobbb4o 096E bbeogeoobe eeopqbebba bbebqbebqo opbepeopqb qbabebebqq. opebbobbeo 006E 00bebe6e35 qabeebebia bgobbebiag 5bo4obbbob ebbo41.e.bgb epoqebpobb =
0f79E SepogbbPbb poeqabepoo qbebb4pobo obabbubsub pabpb4555re b5poe5e5ai.
08LE apebeobqop beobebqobe boobbPebqa beboa4.64bb ebqobbpbbq opoqe4obbo OZLE goebpebpbb bgb4b45bee eabbbbpbbo oobeepbubb 4g5eoheboo b5qubpbb4b 099E 5432obbeop 5e4Po55eEce. o5p6;D5s1) 6sob4upoq5 qbbeb4Poop 6463pp-4625 009E be5eebb4ge obeeebeeb4 abebeaebqb bebbeobebb befreepoqbb abqobebbeo 0p,sE beppoboeep oppoqq.ebbq pgaeoeb5p6 ogobe5b6bq 6324opobbe 554g5ebbeb 0,E 3bbb4DDe5b, boDbDbeobe ebebbobbep Dobbbeopbe qbbbobebqo bepbb4Doeb ofiE bebbeol.obb e54ob44Dpb Sgobb2Deob 5eb26obqop ogbee34ofq. 4.5eDapbgbp 09E 306q5.545.6.6 E.62eb5e5P3 bbbeoqobqo poboobbeob 43.5.25426E1e 55peo63o5b 00E.E. bqobppeabo -436qoPpbbe buobbbebeo bpubPobpbb 4ft.geb23be b5poqqabe6 017z eaq.Dbpbebb bboebbqpbb Debobupbqo bepbebeqoe pbbeopboeb bbpebebbeb 08ft beebee.54b 5oDebee.55.4 upebeDqDqe eoeopbepbq pqepeo4Db5 Pfq.DE,PPDPP
0z1 3.4345eeee3 qbeeebebee Mebeebeob eobbepeo43 p4o44beb4D b54ob5pbeb <210> 58 <211> 1992 <212> PRT
<213> Mus musculus <400> 58 Met Ala Ala Val Thr Met Ser Val Ser Gly Arg Lys Val Ala Ser Arg Pro Gly Pro Val Pro Glu Ala Ala Gln Ser Phe Leu Tyr Ala Pro Arg Thr Pro Asn Val Gly Gly Pro Gly Gly Pro Gln Val Glu Trp Thr Ala Arg Arg Met Val Trp Val Pro Ser Glu Leu His Gly Phe Glu Ala Ala Ala Leu Arg Asp Glu Gly Glu Glu Glu Ala Glu Val Glu Leu Ala Glu Ser Gly Arg Arg Leu Arg Leu Pro Arg Asp Gln Ile Gln Arg Met Asn Pro Pro Lys Phe Ser Lys Ala Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Arg Glu Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Gln Leu Pro Ile Tyr Thr Glu Ala Ile Val Glu Met Tyr Arg Gly Lys Lys Arg His Glu Val Pro Pro His Val Tyr Ala Val Thr Glu Gly 165 170 175 .
Ala Tyr Arg Ser Met Leu Gin Asp Arg Glu Asp Gln Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gln Tyr Leu Ala His Val Ala Ser Ser Pro Lys Gly Arg Lys Glu Pro Gly Val Pro Gly Glu Leu Glu Arg Gln Leu Leu Gln Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Ile Ala Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Her Arg Ala Ile Arg Gln Ala Lys Asp Glu Cys Ser Phe His Ile Phe Tyr Gln Leu Leu Gly Gly Ala Gly Glu Gln Leu Lys Ala Asp Leu Leu Leu Glu Pro Cys =

Ser His Tyr Arg Phe Leu Thr Asn Gly Pro Ser Ser Ser Pro Gly Gln Glu Arg Glu Leu Phe Gln Glu Thr Leu Glu Ser Leu Arg Val Leu Gly Leu Leu Pro Glu Glu Ile Thr Ala Met Leu Arg Thr Val Ser Ala Val Leu Gln Phe Gly Asn Ile Val Leu Lys Lys Glu Arg Asn Thr Asp Gln Ala Thr Met Pro Asp Asn Thr Ala Ala Gln Lys Leu Cys Arg Leu Leu Gly Leu Gly Val Thr Asp Phe Ser Arg Ala Leu Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Glu Gin Ala Asp Phe Ala Leu Glu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Leu Phe Arg Trp Leu Val Leu Arg Leu Asn Arg Ala Leu Asp Arg Ser Pro Arg Gin Giy Ala Ser Phe Leu Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Gin Leu Asn Ser Phe Glu Gin Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gin Gin Leu Phe Asn His Thr Met Phe Val Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Pro Trp Thr Phe Leu Asp Phe Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro Pro Gly Leu Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys Val Ala Gin Glu Gin Gly Ser His Pro Lys Phe Gin Arg Pro Arg Asn Leu Arg Asp Gin Ala Asp Phe Ser Val Leu His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Ser Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val Ala Ala Leu Leu His Gin Ser Thr Asp Arg Leu Thr Ala Glu Ile Trp Lys Asp Val Glu Gly Ile Val Gly Leu Glu Gin Val Ser Ser Leu Gly Asp Gly Pro Pro Gly Gly Arg Pro Arg Arg Gly Met Phe Arg Thr Val Gly Gin Leu Tyr Lys Glu Ser Leu Ser Arg Leu Met Ala Thr Leu Ser Asn Thr Asn Pro Ser Phe Val Arg Cys Ile Val Pro Asn His Glu Lys Arg Ala Gly Lys Leu Glu Pro Arg Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Ile Leu Phe Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile Pro Lys Sly Phe Met Asp Gly Lys Gin Ala Cys Glu Lys Met Ile Gin Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Val Gly Gin Ser Lys Ile Phe Phe Arg Ala Gly Val Leu Ala Gin Leu Glu Glu Glu Arg Asp Leu Lys Val Thr Asp Ile Ile Val Ser Phe Gin Ala Ala Ala Arg Gly Tyr Leu Ala Arg Arg Ala Phe Gin Arg Arg Gin Gin Gin Gin Ser Ala Leu Arg Val Met Gin Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg Asn Trp Gin Trp Trp Arg Leu Phe Ile Lys Val Lys Pro Leu Leu Gin Val Thr Arg Gin Asp Glu Val Leu Gin Ala Arg Ala Gin Glu Leu Gin Lys Val Gin Giu Leu Gin Gin Gin Ser Ala Arg Glu Val Gly Glu Leu Gin Gly Arg Val Ala Gin Leu Glu Glu Glu Arg Thr Arg Leu Ala Glu Gin Leu Arg Ala Glu Ala Glu Leu Cys Ser Glu Ala Glu Giu Thr Arg Ala Arg Leu Ala Ala Arg Lys Gin Glu Leu Glu Leu Val Val Thr Glu Leu Glu Ala Arg Val Gly Glu Glu Glu Glu Cys Ser Arg Gin Leu Gin Ser Glu Lys Lys Arg Leu Gin Gin His Ile Gin Glu Leu Glu Ser His Leu Glu Ala Glu Glu Gly Ala Arg Gin Lys Leu Gin Leu Glu Lys Val Thr Thr Glu Ala Lys Met Lys Lys Phe Glu Glu Asp Leu Leu Leu Leu Glu Asp Gin Asn Ser Lys Leu Ser Lys Glu Arg Arg Leu Leu Glu Glu Arg Leu Ala Glu Phe Ser Ser Gin Ala Ala .Glu Glu Glu Glu Lys Val Lys Ser Leu Asn Lys Leu Arg Leu Lys Tyr Glu Ala Thr Ile Ser Asp Met Glu Asp Arg Leu Lys Lys Glu Glu Lys Gly Arg Gin Glu Leu Glu Lys Leu-Lys Arg Arg Leu Asp Gly Glu Ser Ser Glu Leu Gin Glu Gin Met Val Glu Gin Lys Gin Arg Ala Glu Glu Leu Leu Ala Gin Leu Gly Arg Lys Glu Asp Glu Leu Gin Ala Ala Leu Leu Arg Ala Glu Glu Glu Gly Gly Ala Arg Ala Gin Leu Leu Lys Ser Leu Arg Giu Ala Gin Ala Gly Leu Ala Giu Ala Gin Glu Asp Leu Glu Ala Glu Arg Val Ala Arg Ala Lys Ala Glu Lys Gin Arg Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu Arg Gly Glu Leu Glu Asp Thr Leu Asp Ser Thr Asn Ala Gin Gin Giu Leu Arg Ser Lys Arg Giu Gin Glu Val Thr Glu Leu Lys Lys Ala Leu Glu Glu Glu Ser.

Arg Ala His Glu Val Ser Met Gin Glu Leu Arg Gin Arg His Ser Gin Ala Leu Val Glu Met Ala Glu Gin Leu Glu Gin Ala Arg Arg Gly Lys Gly Val Trp Glu Lys Thr Arg Leu Ser Leu Glu Ala Glu Val Ser Glu Leu Lys Ala Glu Leu Ser Ser Leu Gin Thr Ser Arg Gin Glu Gly Glu Gin Lys Arg Arg Arg Leu Glu Ser Gin Leu Gin Glu Val Gin Gly Arg Ser Ser Asp Ser Glu Arg Ala Arg Ser Glu Ala Ala Glu Lys Leu Gin Arg Ala Gin Ala Glu Leu Glu Ser Val Ser Thr Ala Leu Ser Glu Ala Glu Ser Lys Ala Ile Arg Leu Gly Lys Glu Leu Ser Ser Ala Glu Ser Gln Leu His Asp Thr Gln Glu Leu Leu Gln Glu Glu Thr Arg Ala Lys Leu Ala Leu Gly Ser Arg Val Arg Ala Leu Glu Ala Glu Ala Ala Gly Leu Arg Glu Gln Met Glu Glu Glu Val Val Ala Arg Glu Arg Ala Gly Arg Glu Leu Gln Ser Thr Gin Ala Gln Leu Ser Glu Trp Arg Arg Arg Gln Glu Glu Glu Ala Ala Val Leu Glu Ala Gly Glu Glu Ala Arg Arg Arg Ala Ala Arg Glu Ala Glu Thr Leu Thr Gln Arg Leu Ala Glu Lys Thr Glu Ala Val Glu Arg Leu Glu Arg Ala Arg Arg Arg Leu Gln Gln 1425 1430 1.435 1440 Glu Leu Asp Asp Ala Thr Val Asp Leu Gly Gln Gln Lys Gln Leu Leu Ser Thr Leu Glu Lys Lys Gln Arg Lys Phe Asp Gln Leu Leu Ala Glu Glu Lys Ala Ala Val Leu Arg Ala Val Glu Asp Arg Glu Arg Ile Glu Ala Glu Gly Arg Glu Arg Glu Ala Arg Ala Leu Ser Leu Thr Arg Ala Leu Glu Glu Glu Gln Glu Ala Arg Glu Glu Leu Glu Arg Gln Asn Arg Ala Leu Arg Ala Glu Leu Glu Ala Leu Leu Ser Ser Lys Asp Asp Val Gly Lys Asn Val His Glu Leu Glu Arg Ala Arg Lys Ala Ala Glu Gln Ala Ala Ser Asp Leu Arg Thr Gln Val Thr Glu Leu Glu Asp Glu Leu Thr Ala Ala Glu Asp Ala Lys Leu Arg Leu Glu Val Thr Val Gln Ala Leu Lys Ala Gln His Glu Arg Asp Leu Gln Gly Arg Asp Asp Ala Gly Glu Glu Arg Arg Arg Gln Leu Ala Lys Gln Leu Arg Asp Ala Glu Val 1605 1610 1615 .
Glu Arg Asp Glu Glu Arg Lys Gln Arg Ala Leu Ala Met Ala Ala Arg Lys Lys Leu Glu Leu Glu Leu Glu Glu Leu Lys Ala Gln Thr Ser Ala Ala Gly Gln Gly Lys Glu Glu Ala Val Lys Gln Leu Lys Lys Met Gln Val Gln Met Lys Glu Leu Trp Arg Glu Val Glu Glu Thr Arg Ser Ser Arg Asp Glu Met Phe Thr Leu Ser Arg Glu Asn Glu Lys Lys Leu Lys Gly Leu Glu Ala Glu Val Leu Arg Leu Gln Glu Glu Leu Ala Ala Ser Asp Arg Ala Arg Arg Gln Ala Gln Gln Asp Arg Asp Glu Met Ala Glu Glu Val Ala Ser Gly Asn Leu Ser Lys Ala Ala Thr Leu Glu Glu Lys Arg Gin Leu Glu Gly Arg Leu Ser Gin Leu Glu Glu Glu Leu Glu Glu Glu Gin Asn Asn Ser Glu Leu Leu Lys Asp His Tyr Arg Lys Leu Val Leu Gin Val Glu Ser Leu Thr Thr Glu Leu Ser Ala Glu Arg Ser Phe Ser Ala Lys Ala Glu Ser Gly Arg Gin Gin Leu Glu Arg Gin Ile Gin Glu Leu Arg Ala Arg Leu Gly Glu Glu Asp Ala Gly Ala Arg Ala Arg Gin Lys Met Leu Ile Ala Ala Leu Glu'Ser Lys Leu Ala Gln Ala Glu Glu Gin Leu Glu Gin Glu Ser Arg Glu Arg Ile Leu Ser Gly Lys Leu Val Arg Arg Ala Glu Lys Arg Leu Lys Glu Val Val Leu Gin Val Asp Glu Glu Arg Arg Val Ala Asp Gin Val Arg Asp Gin Leu Glu Lys Ser Asn Leu Arg Leu Lys Gin Leu Lys Arg Gin Leu Glu Glu Ala Glu Glu Glu Ala Ser Arg Ala Gin Ala Gly Arg Arg Arg Leu Gin Arg Glu Leu Glu Asp Val Thr Glu Ser Ala Glu Ser Met Asn Arg Glu Val Thr Thr Leu Arg Asn Arg Leu Arg Arg Gly Pro Leu Thr Phe Thr Thr Arg Thr Val Arg Gin Val Phe Arg Leu Glu Glu Gly Val Ala Ser Asp Glu Glu Glu Ala Glu Gly Ala Glu Pro Gly Ser Ala Pro Gly Gin Glu Pro Glu Ala Pro Pro Pro Ala Thr Pro Gin <210> 59 <211> 6786 <212> DNA
<213> Homo sapiens <400> 59 ctctttctcc ccaggccgaa gcctcgggac ggccctggaa gccgaccatg gcagccgtga 60 ccatgtcggt gcccgggcgg aaggcgcccc ccaggccggg cccagtgccc gaggcggccc 120 agccgttcct gttcacgccc cgcgggccca gcgcgggtgg 'cgggcctggc tcgggcacct 180 ccccgcaggt ggagtggacg gcccggcgtc tcgtgtgggt gccttcggag cttcacgggt 240 tcgaggcggc ggcgctgcgg gacgaaggcg aggaggaggc ggaggtggag ctggcggaga 300 gcgggaggcg gctgcgactg ccgcgggacc agatccagcg catgaacccg cccaagttca 360 gcaaggccga ggacatggcc gagctgacct gcctcaacga ggcctcggtc ctgcacaacc 420 tccgggagcg gtactactcc ggcctcatct acacgtactc cggccttttc tgtgtggtca 480 tcaacccgta caagcagctt cccatctaca cagaagccat tgtggagatg taccggggca 540 agaagcgcca cgaggtgcca ccccacgtgt acgcagtgac cgagggggcc tatcggagca 600 tgctgcagga tcgtgaggac cagtccattc tctgcactgg agagtctgga gctgggaaga 660 cggaaaacac caagaaggtc atccagtacc tcgcccacgt ggcatcgtct ccaaagggca 720 ggaaggagcc gggtgtcccc ggtgagctgg agcggcagct gcttcaggcc aaccccatcc 780 tagaggcctt tggcaatgcc aagacagtga agaatgacaa ctcctcccga ttcggcaaat 840 tcatccgcat caactttgat gttgccgggt acatcgtggg cgccaacatt gagacctacc 900 tgctggagaa gtcgcgggcc atccgccagg ccaaggacga gtgcagcttc cacatcttct 960 accagctgct ggggggcgct ggagagcagc tcaaagccga cctcctcctc gagccctgct 1020 ZET
ebebbqoppe obe5.4.54qob eabbobeobe obe65-4Doeb b4pooepo53 ebopb64obe 08ED, .bbebeobq.o bboobooboo 5655o6u55q p6.5a4Pbb46 opebutpop5 Pepubeobbq 006obpoope Bqpoobbe6D obbeb6Eopo Elpobbboobo ElbopobbPbb ebbbbpobbp 09ZI7 bb4peobbElb eabbebbebb ebbepobobb obbobbl.beb paq.443beo3 3b5epopb4D
pozt, ebeobqoepb gboobbbobb boPebBbeop 5-435eobbv.b bebbebbqob eo6pbqbobq 017T17 obbboobPo6 5ub4o66ebb Tepo5e5354 bb5oop466b bqqoo.66q4e pubobbErepo 080P Pbebbpbbpo 540.6-4.0E,PE6 uppobqpboe ob4obpoop6 ep6p3e3bp3 butgabubbu OZOP. eobei.1.046o 04POOPPPED oq.bp5gob5e boeeb4abob b.E64D4Eqb4 eebpbb4opp 096E bqobbpoopb ebobPpEcq.ob PeEcebgobqo bbbbobebD 23.5bbpbebb bbqe.bqb64o 006E 86603655eo bmbbubbeob qobppegq.be bbqopboobo arebbobeob efq.bbbebbe 08E 3qb3eob4De beobqopbeo butqopPfileo bfflobqobeb po4.64bbebo obbebbqoop 08LE aq.obboope bepbubbbge ob4b5Peepb bffyebb000b bpobutb4ob 206pbbob6.4 ozLE obpb6566q3 pobbeopbbo Poo6o5p365 -26-436-256e3 .645pobb3.56 pbob 099E oqopbpbbpb bp6bqoqopb pe.6peb4obp bbopbqbbeb beopebbbeb ppoolelbooq 009E obebbeobeo e3.632e3Dep Di.oebb4o6o uoebbebbqo Bebobbbbob gobobb26b4 0T7sE ofyebbpbobb bqoopbbboo 5obeo6pv5p 5bobbeu3oe bbeo35.6q54 bo5p.b4pq5e 08pE bbqopubbab beoopbbpbo obb4opp6eo bepoqobbeb 5bobqoDD4p pabqp5q.35e ozr7E poobbboopb bbo4b.6bub3 ebeebeobbb epob54opob 4ofibeob4ob ebbebbefibe 09a Ebboobbbqo beopobbbob 4obebbubeo bbbobppeep Beobpbbqbb qpbeobeffye 00u obqobebeoq p6e5u6b6b4 Pbbqoelbubb p.5e254D6pp 6v5bqobe5b poobo4655e opu eb-ebbp5bee bboPqopboo Pb6E,Pbb4e3 pbpobaq.eeD eoobbebleq epepqobboe 081E 4Dbeeqeep4 oDbebeep4b bueLebb2bb ebbbqobeo bbeopp42pq pi.452bDobb ozH 4D-q.boqp.62.2 Bbqobqobue bbobebPeob eb4ob2popq Teeb2DDP6P PE543040b4 090E obqpopbbpb Pe.6.444PePb pebqeeeePo bbebeaeboe bq.5.6e?bebb qDbeofq.obe 000E Pbeobbpbob 4bbbebbpbri. obb.ebT4Doe opobbebpqo beftheopTeo PabuobPopq 06 obbebeebeu bebooePeob geePo4boob eobqbebbpb bebbebobbb 4.bobD43bbe 088Z 564052bPO4 5465456,405 Pbb4obPb5p obppoboDob Pobbqo55Pb BbbbobaeLp 5bpboobbp6 e35.454.6qop pbeobbefipo butobqqepo npbppabgpo boopbobobu 09/2 elbpbppbbqo Bepeobb4be boofibbeopq obebbbb44b eeboboopbo bebeobeobe onz oeqpbebbso 64.6pepbeob go5p5beopo bbbopobbpo Eq.o.636.6ebq e.66pobbobo ov9z efq.5.5eob4o BqouppEceub qbbeeppe4q 454055 654 56.45pobbqo popbefi4o5p 08g po4opeqoab bobabqopPb bobeobqebq bb6pbqopob obebeobpob pobpoobo6u OZGZ ebeop44pob bbeobo4obb 4ope4ebbbb opobqobeob 62poq4poqp 4bo4upg2oP
09T7Z boopo4bfyee bqoapbPbo6 EMPbeebbq obpopobb4o ogbbbbqobb booggoggo4 0oD. pbsp.ofyebpo ebbbqboboo eqpqoappoo Doebbqpepb Egobobbeop 4ebgebpe2e OVEZ 5.464pobbeo bupbbbqebb qeo4qobbbp Poopo4epob qpeoppeoPb qopqebeboe 08ZZ Tebobeobbp oqqbebElpoo q4o4opqeob opeupopoq4 obbhupobo4 b4o4Pobooq.
. ozzz eobbbeb64o p46.6.6boepo 543634435e oD2b5qobqb 5405.6opoob ebb4o6pebb 09TZ boo5bbebee beboeopPeo poogfiggE,Db qbbpogbqqg gbepoopeep peopppbeog OOTZ Deoepobb4e al_poboobeb 4opoi.bebbe epe4D4oneo ebatqbeoeb booqqbqe4b opoz bbboq.boopo o5oobb4bbe ooepoobbo2 6065E14036u obpb45.Erepe ebbqDbbbbq 0861 5oqp05.66e6 6g5opb2Pub 54o4ebebpo 55pe64Db8o pe6Popo6p6 pDpeop4o5q.
OZ6T 400bpoboqb opeopEgeeb gogoopubb4 ppeeepp.64p bqobb4bebo pepobbaeou 0981 4Deboqb5ee obbbobouqo ppo434qb4b epg4oeboob beo4ebbbob 4popobbubo 008T obbobepogq. bPpooppeop BbobbbeobP 552poob2qb 5uebeElb4.64 Ti.boqbupou OD'LT 5pop.po6bee boopq46.5qo bq5p6bebe 5b4DbqDoob .6q.Doqop65q. 00300OPPOO
0891 5boobbobeb oqpoqopebo quobqopobp ob4oppb343 obbqqqoebo gooqqoppbb 0Z91 4oppoq2abb beb4bob2po eq52bbebb2 obebb4a64.5 p4;642oop3 200ePo4404 09G1 o6eob2ob4o Bepbaboeep aeopqoP2pq 2obqo4Db2D beboqqDoqo peb435.2004 00gT qp4Pb2bqq.q obbbo5Dgeo ebbqopqeob bbqopqqopq DobobbeepD boDoppbeob 01717T poebbgi.pob bbopepal.po bobqoqqbbq obb4oboD44 oqopbobebo e4oppoobbe 08E1 2Dp5b4Doo6 .52.554obo63 qqoebqobbp peebb2243e beoDobe2eb 2o5454eqo2 ozET 6253p5bq4b eeeDgpobo4 poopeo4354 4po5e5oD34 0qqqe5bo25 4E6b6bq0eb 097T bbDqoDbo Dbqpqobepb Poepbqobeo popeoebqoD bqeopeoDbe poqpboDepe 00ZI ebbpeebebe beeb1.4o054 ge0e2obb4q 4beaDq344b epbeo434bb Tebbab4ob4 0171T eoo43.4e3qp EabbubDeo3 5eo44e5554 D34b55D5qo 63.4.5ebbqob Debebbeopq 0801 4D4D2Pbbbo 5,255200550 ooqDqpoqeD Ilbo30bboep D3ebgooqqb booeqoepoo EET

AID sTH naq n19 IeS old TEA daI TEA naq bay bay PTV 114.1, dcL TD
St7 017 SE
TPA UT D old l@S lIIL AID 19S AID cud AID AID AID PTV 39S cud AID
OE SZ OZ
bay 03d 3U aqd n9q cad uTD PTV PTV nTD old TEA old AT Old ST OT
bay old Old ETV sic,' bay AID old TPA 1@S 4W -NI TPA PTV PTV 49W
09 <00f7>
suaTdes owoH <ETZ>
<ZTZ>
0661 <TTZ>
09 <OTZ>
98L9 oeBbqo 08L9 eb000epooq OPPPq.PUP.6P ob6q34obbe 004005P000 4000P44403 qbqbebbEEE
0ZL9 4Debb6q3q3 opagobebbo .1.4bbbeb-404 obqq.bblo44 333433 6;o 4obqe3p3bi..
0999 ob4obq3o1.o P34040303E bbbbeeoebb eabbbbeeeo b4400peeb4 4o3be3peo3 0099 qoobbeoppo buEbeoebob Eb43o4oeEb 4000pE3o4b ob40444E0o opoqqop4o4 op,09 oe3obe45oe 4o4oi.oepq3 4o6o4o4eeb be444qqoqe ofq.64o4o4o 4b65e6qoqo ogp9 qoobb44o4-4 -404Eopeo4o 43o3eq3poq 4poqoq0004 opoqoqoqoq ogoqoqoqoq 0z179 oqoq.q.obgaq. poogqeopop Eobqbeopbe 04004'200P3 oqooqobbou befigbebbbe 09E9 EbbEqquaeb e4eq3q.E544 E4q534op34 qoqqqoaq.00 46qo3oqobe oTeooqqq5q.
009 b43bee3b54 qbeoeqbbbq oEbbbbbqqb -443fqqopeq obubbqoebb ueobbEbbbe 0f7z9 obbtobfibbo Beb5PbPOPO PPP40000P6 Tebbeepoqe opoqoppEob qopooqbbbq ogT9 opeoopoopo qeqq4E3bbq oqoEobeob4 bbqeeebbqq. q000b4-43.44 oeb4o4000b 0Z19 opooeEbbuo ooqbqopoob bboe0000eb 643334334g op000bepoo bbbb4ebeoe 0909 eg3e6b4ebe opoo4b4000 E43p3eb4be op000epoob eopeopoo4b bbbeb4005e 0009 bboopoqeop bbbqoqb5b4 oobeoeobEE b5EbEobbEb beboeboo4E obbqbobbbE
03,6g bbebeqoebo oq.q.D4bbE33 b3b4bb3uo.5 003P3OPD44 30P0400000 5b353eb044 oggg 0bb33EE5bE 543p3P3oe5 4beEbqbo3e ubqeooqbeb 3p5boqbE5E opoqbqebEE
ozgg bb4obEbgb3 bE3b4o65e5 8 053065g bbeoqobbbo 00.4E365E65 EDBEEcobbE
09L0 bbebbqobeo 5Do6ee6q3.5 e3bEE04.5E5 oqqopEEEbb bEe5e5bqo6 eopEbbbooq.
on; obeopebqob 545bbE653b e5bE55E5bq b5Epoq3bq6 64bbebEEEq. lobbobeebE
(,9g bqobebeobo Erl.b.bqobeee 6b4oqpi_ooq eabobebEbe opEbEbEeob EbeqobEobe 08SS bbebqobbeo oobbqqbEE-4 oqbEbqqopo b4o6qqeoop b4Ebeeopoo b000bgb000 OZSS bbbbgobqeb bebbebqbbb gooboEbbbb oE43bebbeo ogEbeobboe ebbgobeobe 09170 obbobbbobe bebeobbeeo obe3434qq5 eobobebqob e34bq3bebe oeooebqoeo 0017; Mbebegbbeo bi.00qobqob eeobooegob 33E54e-234o 64obebeogo eeobEbEobE
op,gg bbebbebbqo bebEEbbebb q4bE355bbq opbobbbbEb bqobeo4bob EEbEbbebb4 ogzg oqqeoobeob bEeobeqqop epqbbTeEpo bEc4e,b2b4E5 eo65qube64 Ebbbooebbe ozzg obeopobbeo bbobbo4obq booEbboqop boo5bq3pE6 bEbbeobqob bobqobqbbe ogIg .64obbebbqo ob65uE343o bobEEEE54.5 eeEb65ogee bEopoqoqqo qpbebSebbb 0010 033.430E35o p3ebeb0e65 45bE6b6obb Teqo6Ebbee bqubeopobb eobqebeEpb oog oqqobEobee bqbbobbebb Ebbeeobbbe pob5oobgo4 pobbqebEoq obbeEbqobE
086f7 5bebbqpbe5 ebbbebbqob Eebeeob000 bqobbqboob bqoqopobob eobEebbobe 0z6f7 bbebqebbbo bebbqbbebe ob4ebEbeb4 obEobEepob b4o5Eobbvb bobbebebEE
098P 6qbb4obbub qebgboobbb e36433eb4b obeb4eo6eo 4oEbee3l.o4 obbe3b4b43 008 Pb4bbEbb40 gbobi.obeeo obgebbeboo b535eoe543 bEbgebbebb goEebeoebq bbeopobebo bq34ebgEe3 ob2ob52o2e be352q.bbb3 ob4o3beb3e 25b436a642 089 obqbabebep obbolbDeb ebbpPobeDb eb43b43236 bebbqobpbq abbbobqo3o 0z9D, bbboouebeo 6b3bebbqb ebbpbqboeo 6ftebbe3beb bubbebbq.De 35E63e3pb4 090f, 3u34643D3b 55343bbeb4 5D5.25.66oD5 650bea6be6 op655obebq 53eeb5e554 000 Eceobbboqqo e45qp6eo5b ee5256,2523 55qoqq36p3 opbqqqbpeo bobeobeebe Phe Glu Ala Ala Ala Leu Arg Asp Glu Gly Glu Glu Glu Ala Glu Val Glu Leu Ala Glu Ser Gly Arg Arg Leu Arg Leu Pro Arg Asp Gin Ile Gin Arg Met Asn Pro Pro Lys Phe Ser Lys Ala Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu Arg Glu Arg Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys Gin Leu Pro Ile Tyr Thr Glu Ala Ile Val Glu Met Tyr Arg Gly Lys Lys Arg His Glu Val Pro Pro His Val Tyr Ala Val Thr Glu Gly Ala Tyr Arg Ser Met Leu Gin Asp Arg Glu Asp Gin Ser Ile Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gin Tyr Leu Ala His Val Ala Ser Ser Pro Lys Gly Arg Lys Glu Pro Gly Val Pro Gly Glu Leu Glu Arg Gin Leu Leu Gin Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Ala Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Ile Arg Gin Ala Lys Asp Glu Cys Ser Phe His Ile Phe Tyr Gin Leu Leu Gly Gly Ala Gly Glu Gin Leu Lys Ala Asp Leu Leu Leu Glu Pro Cys Ser His Tyr Arg Phe Leu Thr Asn Gly Pro Ser Ser Ser Pro Gly Gin Glu Arg Glu Leu She Gin Glu Thr Leu Glu Ser Leu Arg Val Leu Gly Phe Ser His Glu Glu Ile Ile Ser Met Leu Arg Met Val Ser Ala Val Leu Gin Phe Gly Asn Ile Ala Leu Lys Arg Glu Arg Asn Thr Asp Gin Ala Thr Met Pro Asp Asn Thr Ala Ala Gin Lys Leu Cys Arg Leu Leu Gly Leu Gly Val Thr Asp She Ser Arg Ala Leu Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gin Lys Ala Gin Thr Lys Glu Gin Ala Asp Phe Ala Leu Glu Ala Leu Ala Lys Ala Thr Tyr 435 , 440 445 Glu Arg Leu Phe Arg Trp Leu Val Leu Arg Leu Asn Arg Ala Leu Asp Arg Ser Pro Arg Gin Gly Ala Ser She Leu Gly Ile Leu Asp Ile Ala 465 470 475 . 480 Gly Phe Glu Ile Phe Gin Leu Asn Ser Phe Glu Gin Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gin Gin Leu She Asn His Thr Met She Val Leu Glu Gin Glu Glu Tyr Gin Arg Glu Gly Ile Pro Trp Thr Phe Leu Asp Phe Gly Leu Asp Leu Gin Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro Pro Giy Leu Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys Val Ala Gin Glu Gin Gly Gly His Pro Lys Phe Gin Arg Pro Arg His Leu Arg Asp Gin Ala Asp Phe Ser Val Leu His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Asn Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val Ala Ala Leu Leu His Gin Ser Thr Asp Arg Leu Thr Ala Glu Ile Trp Lys Asp Val Glu Gly Ile Val Gly Leu Glu Gin Val Ser Ser Leu Gly Asp Gly Pro Pro Gly Gly Arg Pro Arg Arg Gly Met Phe Arg Thr Val Gly Gin .

Leu Tyr Lys Glu Ser Leu Ser Arg Leu Met Ala Thr Leu Ser Asn Thr Asn Pro Ser Phe Val Arg Cys Ile Val Pro Asn His Glu Lys Arg Ala Gly Lys Leu Glu Pro Arg Leu Val Leu Asp Gin Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gin Gly Phe Pro Asn Arg Ile Leu Phe Gin Glu Phe Arg Gin Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile Pro Lys Gly Phe Met Asp Gly Lys Gin Ala Cys Glu Lys Met Ile Gin Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Val Gly Gin Ser Lys Ile Phe Phe Arg Ala Gly Val Leu Ala Gin Leu Glu Glu Glu Arg Asp Leu Lys Val Thr Asp Ile Ile Val Ser Phe Gin Ala Ala Ala Arg Gly Tyr Leu Ala Arg Arg Ala Phe Gin Lys Arg Gin Gin Gin Gin Ser Ala Leu Arg Val Met Gin Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg His Trp Gin Trp Trp Arg Leu Phe Thr Lys Val Lys Pro Leu Leu Gin Val Thr Arg Gin Asp Glu Val Leu Gin Ala Arg Ala Gin Glu Leu Gin Lys Val Gin Glu Leu Gin Gin Gin Ser Ala Arg Glu Val Gly Glu Leu Gin Gly Arg Val Ala Gin Leu Glu Glu Glu Arg Ala Arg Leu Ala Glu Gin Leu Arg Ala Glu Ala Glu Leu Cys Ala Glu Ala Glu Glu Thr Arg Gly Arg Leu Ala Ala Arg Lys Gin Glu Leu Glu Leu Val Val Ser Glu Leu Glu Ala Arg Val Gly Glu Glu Glu Glu Cys Ser Arg Gin Met Gin Thr Glu Lys Lys Arg Leu Gin Gin His Ile Gin Glu Leu Glu Ala His Leu Glu Ala Glu Glu Gly Ala Arg Gin Lys Leu Gin Leu Glu Lys Val Thr Thr Glu Ala Lys Met Lys Lys Phe Glu Glu Asp Leu Leu Leu Leu Glu Asp Gin Asn Ser Lys Leu Ser Lys Ser Gly Ser Cys Trp Lys Ile Val Trp Pro Ser Ser His Pro Arg Gin Leu Arg Arg Arg Arg Arg Ser Arg Ala Ser Ile Ser Tyr Gly Ser Asn Met Arg Pro Gin Ser Gin Thr Trp Arg Asp Arg Leu Arg Lys Glu Glu Lys Gly Arg Gin Glu Leu Glu Lys 1060 1065, 1070 Leu Lys Arg Arg Leu Asp Gly Glu Ser Ser Glu Leu Gin Glu Gin Met Val Glu Gin Gin Gin Arg Ala Glu Glu Leu Arg Ala Gin Leu Gly Arg Lys Giu Glu Glu Leu Gin Ala Ala Leu Ala Arg Ala Glu Asp Glu Gly Gly Ala Arg Ala Gin Leu Leu Lys Ser Leu Arg Glu Ala Gin Ala Ala Leu Ala Glu Ala Gin Glu Asp Leu Glu Ser Glu Arg Val Ala Arg Thr Lys Ala Glu Lys Gin Arg Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu 1155 1160 1165 .
Arg GlY Glu Leu Giu Asp Thr Leu Asp Ser Thr Asn Ala Gin Gin Giu Leu Arg Ser Lys Arg Glu Gin Glu Val Thr Glu Leu Lys Lys Thr Leu Glu Glu Glu Thr Arg Ile His Glu Ala Ala Val Gin Glu Leu Arg Gin Arg His Gly Gin Ala Leu Gly Glu Leu Ala Glu Gin Leu Glu Gin Ala Arg Arg Gly Lys Gly Ala Trp Glu Lys Thr Arg Leu Ala Leu Glu Ala =

Giu Val Ser Glu Leu Arg Ale Glu Leu Ser Ser Leu Gin Thr Ala Arg Gin Glu Gly Glu Gin Arg Arg Arg Arg Leu Glu Leu Gln Leu Gin Glu Val Gin Gly Arg Ala Gly Asp Gly Glu Arg Ala Arg Ala Glu Ala Ala Glu Lys Leu Gin Arg Ala Gin Ala Giu Leu Glu Asn Val Ser Gly Ala Lou Asn Glu Ala Glu Ser Lys Thr Ile Arg Leu Ser Lys Glu Leu Ser Ser Thr Glu Ala Gin Leu His Asp Ala Gin Giu Leu Leu Gin Glu Glu Thr Arg Ala Lys Leu Ala Leu Gly Ser Arg Val Arg Ala Met Glu Ala Glu Ala Ala Gly Leu Arg Glu Gin Leu Glu Glu Glu Ala Ala Ala Arg Glu Arg Ala Gly Arg Glu Leu Gin Thr Ala Gin Ala Gin Leu Ser Glu Trp Arg Arg Arg Gin Glu Glu Glu Ala Gly Ala Leu Glu Ala Gly Glu Glu Ala Arg Arg Arg Ala Ala Arg Glu Ala Glu Ala Leu Thr Gln Arg Leu Ala Glu Lys Thr Glu Thr Val Asp Arg Leu Glu Arg Gly Arg Arg Arg Leu Gln Gln Glu Leu Asp Asp Ala Thr Met Asp Leu Glu Gln Gln Arg Gln Leu Val Ser Thr Leu Glu Lys Lys Gln Arg Lys Phe Asp Gln Leu Leu Ala Glu Glu Lys Ala Ala Val Leu Arg Ala Val Glu Glu Arg Glu Arg Ala Glu Ala Glu Gly Arg Glu Arg Glu Ala Arg Ala Leu Ser Leu Thr Arg Ala Leu Glu Glu Glu Gln Glu Ala Arg Glu Glu Leu Glu Arg Gln Asn Arg Ala Leu Arg Ala Glu Leu Glu Ala Leu Leu Ser Ser Lys Asp Asp Val Gly Lys Ser Val His Glu Leu Glu Arg Ala Cys Arg Val Ala Glu Gln Ala Ala Asn Asp Leu Arg Ala Gln Val Thr Glu Leu Glu Asp Glu Leu Thr Ala Ala Glu Asp Ala Lys Leu Arg Leu Glu Val Thr Val Gln Ala Leu Lys Thr Gln His Glu Arg Asp Leu Gln Gly Arg Asp Glu Ala Gly Glu Glu Arg Arg Arg Gln Leu Ala Lys Gln Leu Arg Asp Ala Glu Val Glu Arg Asp Glu Glu Arg Lys Gin Arg Thr Leu Ala Val Ala Ala Arg Lys Lys Leu Glu Gly Glu Leu Glu Glu Leu Lys Ala Gln Met Ala Ser Ala Gly Gln Gly Lys Glu Glu Ala Val Lys Gln Leu Arg Lys Met Gln Ala Gln Met Lys Glu Leu Trp Arg Glu Val Glu Glu Thr Arg Thr Ser Arg Glu Glu Ile Phe Ser Gln Asn Arg Glu Ser Glu Lys Arg Leu Lys Gly Leu Glu Ala Glu Val Leu Arg Leu Gln Glu Glu Leu Ala Ala Ser Asp Arg Ala Arg Arg Gln Ala Gln Gln Asp Arg Asp Glu Met Ala Asp Glu Val Ala Asn Gly Asn Leu Ser Lys Ala Ala Ile Leu Glu Glu Lys Arg Gln Leu Glu Gly Arg Leu Gly Gln Leu Glu Glu 1745 1750, 1755 1760 Glu Leu Glu Glu Glu Gln Ser Asn Ser Glu Leu Leu Asn Asp Arg Tyr Arg Lys Leu Leu Leu Gln Val Glu Ser Leu Thr Thr Glu Leu Ser Ala Glu Arg Ser Phe Ser Ala Lys Ala Glu Ser Gly Arg Gln Gln Leu Glu Arg Gln Ile Gin Glu Leu Arg Gly Arg Leu Gly Glu Glu Asp Ala Gly Ala Arg Ala Arg His Lys Met Thr Ile Ala Ala Leu Glu Ser Lys Leu Ala Gln Ala Glu Glu Gln Leu Glu Gln Glu Thr Arg Glu Arg Ile Leu Ser Gly Lys Leu Val Arg Arg Ala Glu Lys Arg Leu Lys Glu Val Val Leu Gin Val Glu Glu Glu Arg Arg Val Ala Asp Gin Leu Arg Asp Gin Leu Glu Lys Gly Asn Leu Arg Val Lys Gin Leu Lys Arg Gin Leu Glu Glu Ala Glu Glu Glu Ala Ser Arg Ala Gin Ala Gly Arg Arg Arg Leu Gin Arg Glu Leu Glu Asp Val Thr Glu Ser Ala Glu Ser Met Asn Arg Glu Val Thr Thr Leu Arg Asn Arg Leu Arg Arg Gly Pro Leu Thr Phe Thr Thr Arg Thr Val Arg Gin Val Phe Arg Leu Glu Glu Gly Val Ala Ser Asp Glu Glu Ala Glu Glu Ala Gin Pro Gly Ser Gly Pro Ser Pro 1970 1975 1980 , Glu Pro Glu Gly Ser Pro Pro Ala His Pro Gin <210> 61 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 61 Ala Cys Gly Met Pro Tyr Val Arg Ile Pro Thr Ala <210> 62 <211> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic peptide <400> 62 Ala Gly Cys Met Pro Tyr Val Arg Ile Pro Thr Ala <210> 63 <211> 11 <212> PRT
<213> Homo sapiens <400> 63 Leu Met Lys Asn Met Asp Pro Leu Asn Asp Ile <210> 64 <211> 12 <212> PRT
<213> Homo sapiens <400> 64 Leu Met Lys Asn Net Asp Pro Leu Asn Asp Asn Val <210> 65 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Synthetic linker peptide <400> 65 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

Claims (17)

CLAIMS:

1. An inhibitor of natural IgM antibodies, wherein the inhibitor is an isolated antibody or antigen-binding fragment thereof that binds to a self-antigen, inhibits binding of a natural IgM antibody to the self-antigen, and blocks complement activation, wherein the amino acid sequence of the self-antigen is SEQ ID NO: 38.

2. The inhibitor of claim 1 wherein the natural IgM antibody is a pathogenic antibody.

3. The inhibitor of claim 1 or 2, wherein the antibody inhibits the binding of natural IgM antibody IgM to the amino acid sequence of SEQ ID NO: 38.

4. The inhibitor of any one of claims 1 to 3, wherein the antibody is a monoclonal antibody.

5. The inhibitor of claim 4, wherein the antibody is selected from the group consisting of chimeric and CDR grafted antibodies.

6. The inhibitor of any one of claims 1 to 5, wherein the inhibitor is an antigen-binding fragment.

7. The inhibitor of claim 6, wherein the antigen-binding fragment is a Fab fragment, a F(ab')2 fragment or scFv fragment.

8. The use of an inhibitor of any one of claims 1 to 7 for the preparation of a medicament for treating a complement-dependent inflammatory condition triggered by binding of natural IgM antibodies.

9. The use of claim 8, wherein the inflammatory condition is selected from the group consisting of reperfusion injury, ischemia injury, stroke, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, rheumatoid arthritis, celiac disease, hyper-IgM
immunodeficiency, arteriosclerosis, coronary artery disease, sepsis, myocarditis, encephalitis, transplant rejection, hepatitis, thyroiditis, polymyositis, dermatomyositis, Type I diabetes, gout, dermatitis, alopecia areata, systemic lupus erythematosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, pelvic inflammatory disease, periodontal disease, juvenile chronic arthritis, psoriasis, nephropathy in diabetes mellitus, asthma, chronic inflammatory liver disease, chronic inflammatory lung disease, lung fibrosis, liver fibrosis, Crohn's disease, and burn injury.

10. The use of claim 9, wherein the inflammatory condition is reperfusion injury or ischemia injury.

11. The use of claim 10, wherein the reperfusion or ischemic injury follows a naturally occurring episode.

12. The use of claim 11, wherein the naturally occurring episode is stroke or myocardial infarction.

13. The use of claim 11, wherein the reperfusion or ischemic injury follows a surgical procedure.

14. The use of claim 13, wherein the surgical procedure is selected from the group consisting of angioplasty, stenting procedure, atherectomy and bypass surgery.

15. The use of claim 10, wherein the reperfusion or ischemic injury occurs in a cardiovascular tissue.

16. The inhibitor of claim 1 or 2, wherein the antibody or antigen-binding fragment is an IgG.

17. A pharmaceutical composition comprising the inhibitor of any one of claims 1 to 7, and a pharmaceutically acceptable excipient.